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CHAPTER I 
General introduction and outline of the thesis 

The development of diabetic nephropathy is the most important factor determining the 
morbidity and mortality of patients with insulin dependent diabetes mellitus In the 
Netherlands, like in other countries, diabetic nephropathy is a leading cause of end-stage 
renal disease and diabetic patients account for approximately 12% of all patients on renal 
replacement therapy Apart from end-stage renal disease, cardiovascular disease is a 
major cause of the high morbidity and mortality in these patients In recent years, our 
insight in the pathophysiology ot diabetic nephropathy has greatly increased (reviewed in 
chapter II) From studies in humans, prognostic factors which can identify patients at nsk 
for the development of diabetic nephropathy and treatment modalities for patients with 
established nephropathy have emerged (chapter II) 
In the present thesis we descnbe the results of our studies that have focussed on diabetic 
nephropathy We have evaluated methods aimed at diagnosing patients at risk for the 
development of diabetic nephropathy To this end we have developed a laser ïmmu-
nonephelometric method for the measurement of small amounts of albumin in the unne 
(chapter III) In chapter IV we descnbe the effects of a standardized exercise test on the 
urinary excretion of albumin and IgG Specifically we have evaluated if this test could 
identify patients at nsk for the development of diabetic nephropathy The usefulness of 
erythrocyte sodium-lithium countertransport as a potential risk marker for diabetic ne-
phropathy is evaluated in chapter V 
In the second part of this thesis we focus on the therapeutic effects of antihypertensive 
drugs in patients with diabetic nephropathy In chapter VI a controlled, double blind, 
cross-over trial is presented which was performed to compare the antihypertensive 
efficacy of Captopril and atenolol in hypertensive type 1 and type 2 diabetic patients The 
acute effects of Captopril on albuminuria and renal hemodynamics in normotensive 
diabetic patients with persistent proteinuria are described in chapter VII The effects of 
two years treatment with either captopnl or atenolol on the progression of diabetic 
nephropathy m type 1 diabetic patients are described in chapter VIII In this same group 
of patients the effect of this treatment on the progression of retinopathy was studied, the 
results are given in chapter IX In Chapter X we review the current opinion on antihyper-
tensive treatment in patients with diabetic nephropathy Finally, a summary of the thesis 
is given m chapter XI 
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CHAPTER II 
Diabetic nephropathy 

Introduction 
The classical histological picture of diabetic glomerulosclerosis was first described in 
1936 by Kimmelstiel and Wilson'. They noticed the characteristic intercapillary, nodular 
thickening of mesangial regions in the glomeruli of patients with a history of diabetes 
accompanied by severe proteinuria, hypertension and loss of renal function. In 1951 it 
was first suggested by Wilson et al.2 to use the term "diabetic nephropathy" for patients 
with a clinical syndrome of "a renal disease of mixed etiology seen only among patients 
with diabetes, and although occurring at all ages, most frequently seen among young 
patients in their thirties and forties with severe poorly controlled diabetes of long 
duration". 
The clinical syndrome of diabetic nephropathy, consisting of proteinuria, hypertension and 
a decline in renal function, ultimately develops in about 30% of all patients with insulin 
dependent diabetes mellitus, with a peak incidence after 15 years of diabetes duration. 
Especially during the past 20 years our knowledge about the pathogenesis of diabetic 
nephropathy has greatly increased. 
Epidemiology 
In a large Danish cohort of 1475 patients, in whom diabetes was diagnosed before 1953, 
25 years after onset of diabetes the cumulative incidence of diabetic nephropathy was 
40%3. In an American cohort of 292 patients with insulin dependent diabetes mellitus a 
35 % cumulative incidence was found4. More recent data indicate a decline in the 
incidence of diabetic nephropathy. The Steno-group, which reported the above mentioned 
figure of 40%, found an incidence of 27% after 25 years of duration in patients who 
developed diabetes between 1953 and 19625. This figure corresponds well with the 28% 
cumulative incidence after 20 years noticed by Bojestig et al. in patients with onset of 
diabetes between 1961 and 19656. This latter study6 reported an even further decline to 
5.8% in patients with an onset of diabetes between 1971 and 1975. This decline is 
probably due to a better metabolic control. 
An uniform finding in the studies on epidemiology of diabetic nephropathy is that diabetic 
nephropathy is more frequently seen in men and in patients with age at onset of diabetes 
15 
below 20 years3·5. The explanation for the latter association is unknown, but may be 
related to the worse metabolic control so often seen in children and adolescents. The rate 
of development of end-stage renal disease seems to differ between patients with onset of 
diabetes before or after puberty4. The former group reaches a cumulative incidence of 
end-stage renal disease of 35 % after 40 years of diabetes while the latter reaches the same 
cumulative incidence already after 25 years. In this study4 age at diagnosis of diabetes 
was the most important factor for the rate of progression to renal failure. This observation 
was confirmed in a group of 29 diabetic patients who received a kidney transplant in our 
hospital7. We also found a significant correlation between the age at onset of diabetes and 
the interval between onset of diabetes and the development of end-stage renal disease. 
The mortality rate of diabetic patients (of either sex) with persistent proteinuria is about 
40 times higher than that of patients not developing persistent proteinuria8, while the 
mortality among the latter group is about two fold higher than in a reference population. 
The relative mortality rate of the diabetic patient with diabetic nephropathy is therefore 
80-110 times higher than that of the non-diabetic population. About 66% of the patients 
die from causes directly related to uremia and about 20% from cardiovascular diseases. 
Relative mortality from cardiovascular disease is 8 times higher in patients with nephro-
pathy9. This suggests a relation between micro- and macroangiopathy. 
The renal and patient survival of patients with diabetic nephropathy has greatly improved 
during the past decade. The cumulative mortality 7-10 years after onset of persistent 
proteinuria has previously been reported as 50-70%3·4, but was recently estimated to be 
13-18%10·11. The initiation of early antihypertensive treatment is probably the main cause 
for this improvement. 
Stages in the natural course of diabetic nephropathy 
The development of methods to measure small increases in urinary albumin excretion, 
below the detection level of test strips for albuminuria (albustix), has given more insight 
into the course of diabetic nephropathy as a progressive disease in which five stages can 
be defined12. 
Stage 1. At onset of insulin-dependent diabetes mellitus glomerular hyperfunction and 
hypertrophy are present. The kidneys are enlarged and an increased glomerular filtration 
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rate (GFR) and albuminuria can be measured while blood pressure is normal. Insulin 
therapy can correct these abnormalities. In periods with bad metabolic control hyper-
filtration and an increased albumin excretion can occur again. In this stage of nephropathy 
renal biopsies are in general normal. 
Stage 2. The silent stage which is detectable about 2 years after onset of diabetes. 
Albuminuria is normal but structural lesions, such as increased basement membrane 
thickening and mesangial expansion, are present. Blood pressure is normal, while GFR 
may be normal or increased. Albumin excretion in these patients can increase during bad 
metabolic control and strenuous exercise. 
Stage 3. Incipient nephropathy, the stage of persistent microalbuminuria, which mainly 
develops after 10-15 years. This microalbuminuric phase is characterized by an urinary 
albumin excretion between 30-300 mg/24 h (or 20-200 ^g/min). In the beginning GFR is 
elevated or normal but starts to decline when albumin excretion rises above 80 mg/24 h. 
Blood pressure is increased when compared to normoalbuminuric patients or to healthy 
subjects, but may still be in the normal range. Progressive structural abnormalities, 
including nodular and diffuse forms of glomerulosclerosis can be found. 
Stage 4. Overt diabetic nephropathy after 15-20 years of diabetes, is considered present 
when albuminuria is persistently above 300 mg/24 h (200 ¿tg/min). Blood pressure 
increases almost invariably to hypertensive levels with a concomitant further decrease in 
GFR. Structural findings are more pronounced with a greater percentage of sclerosed 
glomeruli and arteriolar hyalinosis. 
Stage 5. End-stage renal failure presents with the clinical symptoms of uremia and a 
decline of GFR to levels less than 10 ml/min. Hypertension can be a serious problem and 
difficult to treat. Structurally a generalized glomerulosclerosis is present. 
Structural abnormalities 
Thickening of the basement membrane of glomerular capillaries and mesangial expansion 
are the hallmarks of diabetic glomerulosclerosis. Basement membrane thickening is seen 
in virtually all diabetic patients a few years after onset of their disease13. With longer 
duration of diabetes almost all patients will develop more histological abnormalities. Even 
in normoalbuminuric patients without clinical evidence of renal dysfunction glomerular 
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structure differs significantly from that in normal controls About 50% of normoalbumin-
unc patients show the same lesions as patients with high levels of microalbuminuria. With 
increasing albuminuria structural lesions become more advanced14. However, severe 
glomerular lesions have been seen in normoalbuminunc patients with low GFR and 
hypertension, remarkably all these patients were women1' 
In addition to basement membrane thickening the following lesions can be seen in the 
glomeruli mesangial expansion, leading to either nodular or diffuse forms of glomeru­
losclerosis, the capsular drop lesion and the fibrin cap lesion Besides these glomerular 
abnormalities, often afferent and efferent arteriolar hyahnosis is present The typical 
nodular lesions which were initially described by Kimmelstiel and Wilson1 are less 
frequently seen than the diffuse form of glomerulosclerosis. Approximately 80% of 
patients with clinical nephropathy have few or no nodular lesions16. Glomerular basement 
membrane thickness was not found to be related to functional parameters of diabetic 
nephropathy, ι e hypertension, proteinuria and decrease in renal function13 The mesan­
gial expansion seems to be the structural lesion with the closest relation to functional 
abnormalities The volume fraction of the mesangium is highly inversely correlated to the 
capillary filtration surface area per glomerulus, the latter correlating well with GFR. 
Nearly all patients with overt nephropathy have a mesangial volume fraction exceeding 
30% of the volume of the glomerulus11, while normally the mesangium (matrix and cells) 
occupies about 15% of the glomerular volume in humans 
So, despite the fact that almost all diabetic patients will have histological abnormalities 
consistent with diabetic glomerulosclerosis, only about 30-40% will develop the clinical 
symptoms of diabetic nephropathy which eventually leads to end-stage renal disease. Until 
now it is therefore not possible to predict the development of overt diabetic nephropathy 
on the basis of renal biopsies 
Pathogenesis 
Although the pathogenesis of diabetic nephropathy is not well understood, it is evident 
that the diabetic state is a prerequisite because diabetic nephropathy develops in normal 
kidneys after transplantation into diabetic patients17. The diabetic state seems to induce 
hemodynamic and biochemical changes, which ultimately lead to the clinical symptoms It 
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remains to be elucidated which changes are of primary importance, but most likely they 
act in concert. Furthermore, evidence arises that also genetic factors are of importance. 
1. Hemodynamic changes 
An increase of GFR and of effective renal plasma flow (ERPF) have been reported in 
insulin-dependent diabetic patients before morphological changes occur'8'20. GFR is 
increased to a higher degree than ERPF resulting in an increased filtration fraction (FF) 
suggesting an increase in glomerular intracapillary pressure. This initial hyperfiltration 
does not seem to predict development of nephropathy, but persisting hyperfiltration during 
treatment with insulin seems to be associated with a higher chance to develop nephropa-
thy21, although this is not a uniform finding22. Micropuncture studies in rats with 
untreated diabetes have revealed an increased intraglomerular pressure and single nephron 
GFR, secondary to a decrease in the tone of the afferent arteriole. This permits a direct 
transmission of the systemic blood pressure to the glomerulus. It has been shown that this 
hyperfiltration can induce glomerulosclerosis2324. In diabetic rats the development of 
glomerulosclerosis is markedly accelerated by uninephrectomy25 and in the undipped 
kidney in the two-kidney, Goldblatt hypertension model26. In a diabetic patient with 
unilateral renal artery stenosis only the contralateral non-stenosed kidney shows signs of 
diabetic glomerulosclerosis27. These findings suggest an important role for increased 
intraglomerular pressure in the pathogenesis of diabetic nephropathy. The mechanisms 
underlying hyperfiltration remain to be elucidated28,29. Moderate increments in blood 
glucose can induce a slight increase in GFR30, as can increases in other factors linked to 
the diabetic state, such as glucagon" 32 or growth hormone33. However, plasma levels of 
both hormones are elevated to the same extent in type 1 diabetic patients with a normal or 
an elevated GFR34. Insulin by itself apparently has no influence on GFR in patients with 
diabetes. Ketone bodies are known to increase GFR35. Other factors that may influence 
the renal hemodynamics include changes in the glomerulo-tubular feedback mecha-
nism36·37, elevated atrial natriuretic peptide levels38 or an increased production of en-
dothelium derived relaxing factor (EDRF, nitric oxide)39. Since the typical structural 
lesion of diabetes cannot be reproduced in other states with hyperfiltration (i.e. acrome-
galy, uninephrectomy in non-diabetic patients) hemodynamic factors alone cannot be held 
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responsible for the development of diabetic nephropathy 
2 Biochemical change!, 
Albuminuria, the key-feature of diabetic nephropathy, is the result of an abnormal 
glomerular filtration The glomerular ultrafiltration is regulated by hemodynamic 
(glomerular plasma flow and hydrostatic pressure) and oncotic factors (mainly the protein 
concentration of the plasma) and by the intrinsic properties of the glomerular capillary 
wall. The glomerular filtration barrier consists of three layers, the capillary endothelium, 
glomerular basement membrane (GBM) and the epithelial cells. The GBM acts as a semi-
permeable layer allowing free passage of water and small molecules With increasing size 
of a molecule, permeation through the GBM decreases. This is called the size-selective 
permeability. During progression of diabetic nephropathy the number of large pores 
increases40. Although the albumin molecule is small enough to pass the normal pores, this 
will nearly not occur due to the negative charge of the GBM. This so-called charge-
selective permeability is due to anionic sites present in the GBM During the early stages 
of nephropathy (microalbuminuria < 100 mg/24 h), a preferential loss of anionic proteins 
(i.e. IgG4 and albumin) indicates a loss of anionic charge of the GBM"1. The anionic sites 
within the GBM are mainly composed of heparan sulfate (HS) since incubation of kidney 
sections with hepantinase removes almost all anionic sites from the lamina rara externa 
and interna of the GBM42. HS is the negatively charged glycosaminoglycan side chain of 
HS-proteoglycan (HSPG) and located in the extracellular matrix, in the basement 
membranes or at the cell surface. The loss or neutralization of HS acutely induces 
proteinuria43. In kidney biopsies of patients with diabetic nephropathy the amount of HS 
in the GBM was decreased and inversely correlated with the level of proteinuria44. Apart 
from maintaining the negative charge in the glomerular basement membrane HSPG has an 
important role in maintaining the structural integrity of basement membranes, it has 
antithrombogenic and antilipemic properties and plays a role in the regulation of mesang-
ìal cell growth. 
The decrease in HS may be partly due to the effect of non-enzymatic glycation of the 
basement membrane components lammin and collagen, both leading to reduced binding of 
HS45. Also some evidence regarding a genetic defect in the regulation of the biosynthesis 
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of HS has been presented46. Besides changes in HSPG and/or HS also other changes in 
extracellular matrix components occur in diabetic nephropathy. Predominantly there is an 
accumulation of collagen type IV and laminin both in the mesangium and in the GBM. 
This is not only due to an increased synthesis as revealed by increased mRNA levels for 
these components, but also to a decreased degradation partly caused by non-enzymatic 
glycation of these components47. Since patients with diabetic nephropathy also experience 
a higher cardiovascular morbidity and mortality one can argue that in these patients 
proteinuria is not only a marker for nephropathy but also a marker for a generalized 
vasculopathy. In patients with microalbuminuria an increased nonrenal transcapillary 
escape rate of albumin has been found48 indicating an overall increased capillary per-
meability. The hypothesis put forward by Decken, as the Steno hypothesis states that a 
decreased concentration of HS in the extracellular matrix explains the simultaneous 
occurrence of albuminuria and premature atherosclerosis in insulin dependent diabetes 
mellitus49. Already in 1954 Lundbiek suggested to regard all anomalies in long standing 
diabetes mellitus as the various manifestations of one generalized specific vascular 
disorder which he called diabetic angiopathy50. 
3. Genetic predisposition 
Although the initial glomerular hyperfiltration is found in almost all diabetic patients it 
remains unsolved why 30-40% of these patients ultimately develop diabetic nephropathy. 
It has therefore been suggested that other factors, apart from the diabetic state, may be 
important for the susceptibility to develop nephropathy. Genetic factors may be important 
in this respect. Seaquist et al. demonstrated that about 80% of diabetic siblings of patients 
with diabetic nephropathy about 80% also had diabetic nephropathy, while only 20% of 
the siblings of diabetic patients without nephropathy had nephropathy51. Apart from a 
possible genetic defect in the sulfatation of HS, as discussed above, a linkage between the 
susceptibility for nephropathy and essential hypertension has been suggested. A higher 
blood pressure has been found among parents of diabetic patients with nephropathy52. This 
was however not confirmed in a more recent study from the same group53 nor in a large 
Danish study54. Also a higher prevalence of parental cardiovascular disease has been 
found in patients with diabetic nephropathy and cardiovascular disease55. An elevated 
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erythrocyte sodium-lithium countertransport is thought to be a genetic marker for essential 
hypertension56 An increased erythrocyte sodium-lithium countertransport in patients with 
diabetic nephropathy as well as in patients at risk for the development of diabetic 
nephropathy has been reported""40 
Risk factors predicting the development of diabetic nephropathy 
Microalbuminuria is until now the only parameter known to predict the development of 
overt nephropathy In view of the high mortality of diabetic nephropathy it would be a 
great advantage to be able to identify, at an early stage, diabetic patients who have a great 
risk for the development of diabetic nephropathy This would allow identification of 
patients who may particularly benefit from early interventions and would thereby have 
important prognostic implications Identification of risk factors would also give more 
insight into the pathogenesis of the disease Apart from microalbuminuria, possible 
alternative predictors for nephropathy are poor metabolic control, hyperfiltration and an 
increased blood pressure 
1 Microalbuminuria 
Keen and Chlouverakis61 were the first in 1963, who employed a radioimmunoassay to 
detect small amounts of albumin in the unne They found higher levels of albuminuria in 
diabetic patients compared to controls Later this slight increase in albuminuria was called 
microalbuminuria The definition of microalbuminuria is still a matter of debate and it 
largely depends on the method employed for collection of the unne Generally the lower 
limit is set at 30 mg/24 h or 20 μg/mln and the upper limit at 300 mg/24 h or 200 
μg/mln. Many factors can influence unnary albumin excretion e g posture and exercise 
Therefore unnary albumin excretion has a day-to-day vanabihty of up to 40-50 % 6 2 6 3 For 
this reason it is necessary to measure at least 3 unne samples and to use a standardized 
method of unne collection Several methods of unne collection can be applied The 24-
hour unne collection, thought to be the golden standard, is troublesome and bears the 
problem of incomplete collection More easy to perform are the ovemight-timed unne 
collection, a first morning unne sample or a short-term collection over a few hours in the 
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clinic These methods probably underestimate the albumin excretion Overnight albumin 
excretion rate is on average about 25% lower than albumin excretion calculated from a 
24-hour unne collection64. It has therefore been recommended to use only 24-hour urine 
collections65 However for screening purposes a more convenient method will probably 
yield better compliance. 
Before considering the diagnosis of incipient nephropathy other causes of microal-
buminuria must be excluded, such as: urinary tract infection, fever, poor metabolic 
control, recent onset of diabetes, essential hypertension, physical exercise or non-diabetic 
renal disease. 
In the early 1980's four studies were published addressing the predictive value of 
microalbuminuria for the development of nephropathy2166~68 The results are summarized 
in Table 1. These data indicate that microalbuminuria will identify about 80% of the 
patients who will develop overt nephropathy within 10 years. The initial cohort studied by 
Viberti66 was again studied after 23 years of follow-up69 These latest data indicate that 
patients with microalbuminuria have a relative risk of 9 3 for developing overt diabetic 
nephropathy Interestingly, cardiovascular mortality was more than two times higher in 
the initial microalbuminunc patients After adjusting for age and duration of diabetes 
microalbuminuria appeared to be an independent predictor for cardiovascular mortality 
In patients with a long duration of diabetes microalbuminuria may not be as predictive for 
nephropathy, as was demonstrated by Forsblom et al.70 They found that only 5 of 18 
patients with microalbuminuria developed macroalbuminuna after 10 years. The initial 
median diabetes duration m these patients was 26 years (range 16-36) 
In three of the studies mentioned in Table 1, elevated blood pressure may have been an 
important confounder71, since especially in patients with microalbuminuria blood pressure, 
either systolic67, or both systolic and diastolic21 M was elevated. One might therefore argue 
that microalbuminuria is not a predictor but more an indicator of diabetic nephropathy71. 
Recently Almdal et al n reported the results of 10 years follow-up of 118 patients with 
microalbuminuria. Only 22 (19%) developed overt nephropathy and 39 (33%) showed a 
regression to normoalbuminuna The mean duration of diabetes in this study was 20 
years. An interesting finding was that calculating the annual rate of progression of 
microalbuminuria appeared to be more specific in identifying patients at risk for the 
development of persistent proteinuria than the absolute value A progression rate of more 
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than 5% per year identified patients at risk for persistent proteinuria, and was associated 
with a higher blood pressure, higher HbAlc and a higher incidence of proliferative 
retinopathy. 
2. Poor metabolic control 
A prerequisite for the development of diabetic nephropathy is hyperglycemia. Interesting 
in this respect is the report of two non-diabetic patients who received a kidney transplant 
from a diabetic donor. The lesions of diabetic nephropathy present in the donor kidneys 
regressed after transplantation73. Disappointing however, is the fact that in diabetic 
patients who received a pancreas transplantation the diabetic glomerular lesions did not 
show any regression after 5 years of normoglycemia74. 
The degree of blood glucose control can not reliably predict the development of nephropa-
thy, since there are patients with poor control who never develop nephropathy, while 
some with good control do. But a correlation between the prevalence of diabetic compli-
cations and degree of metabolic control has been demonstrated in several studies3,4,75. In 
patients with incipient nephropathy it has been demonstrated that strict metabolic control 
can decrease urinary albumin excretion and may prevent the development of clinical 
nephropathy76"79. The Diabetes Control and Complications Trial (DCCT)79 has unequivo-
cally demonstrated that improvement of metabolic control has a positive effect on the 
development of diabetic complications. The occurrence of microalbuminuria and albumi-
nuria in this study was reduced by 39% and 54% respectively in patients receiving 
intensive therapy. The mean difference in HbAlc between intensified and regular treatment 
was 1.5-1.7% throughout the study. Bangstad et al. found a close relationship between the 
level of mean blood glucose and the progression of glomerular morphological changes in 
patients with early diabetic nephropathy78. They studied young diabetic patients on regular 
or intensified treatment. The mean difference in HbAlc was 1.2%. All patients underwent 
repeated kidney biopsies. In patients on intensified treatment progression of structural 
changes was clearly attenuated. In the studies mentioned above, HbA,c levels in the 
patients treated with intensified insulin treatment ranged between 7-8 %7 6 ·7 9 , 8 0 . An HbAu 
level greater than 8.5% was associated with the development of clinical nephropathy80. 
Krolewski et al. recently showed that a HbAlc above 8.1% is accompanied by a steep 
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increase in the occurrence of microalbuminuria and diabetic retinopathy81. To prevent 
diabetic nephropathy and at the same time minimize the risk of hypoglycemia it may 
therefore be reasonable to strive for an HbAlc level between 7 and 8%8283. 
3. Glomerular hyperfiltration 
A high GFR and an increased kidney size are seen in almost all diabetic patients at onset 
of diabetes. These abnormalities are reversible after treatment with insulin for some 
months18. The initial hyperfiltration does not seem to be predictive for future development 
of nephropathy. Mogensen21 found that all diabetic patients with a diabetes duration of 
more than 3 years and a GFR of more than 150 ml/min later developed diabetic nephro-
pathy. Rudberg et al 84 demonstrated in an 8-year prospective study that an initial GFR of 
less than 125 ml/min had a negative predictive value for nephropathy of 95%, while the 
positive predictive value of a GFR ol more than 125 ml/min was 53% So, the GFR of 
the patients who later develop nephropathy and those who do not shows a wide overlap, 
making it impossible to use a high GFR as the sole predictor for the development of 
diabetic nephropathy. In two studies by Lervang et al228' no relation between high GFR 
early during the course of diabetes and later development of nephropathy could be found. 
4. Elevated blood pressure 
Hypertension is a major symptom of diabetic nephropathy. Systemic blood pressure is 
elevated early during the course of diabetic nephropathy and eventually virtually all 
patients develop hypertension It can be found in about 80% of the patients with overt 
diabetic nephropathy and in about 25% of the patients with microalbuminuria86. Patients 
with uncomplicated diabetes of more than 40 years duration almost always have a low 
systemic blood pressure87. Blood pressure is an important determinant for the course of 
nephropathy, especially in the advanced stages88. Several studies have indicated that 
antihypertensive therapy slows the rate of decline of GFR and improved survival in 
patients with diabetic nephropathy10118990. It is not clear however, whether hypertension 
which is seen in 80% of the patient with overt nephropathy is a cause or a consequence of 
diabetic nephropathy. Recent studies suggest that blood pressure increases above baseline 
26 
before the onset of microalbuminuria9192. The initial albumin excretion, mean blood 
pressure and smoking were significant determinants of progression to microalbuminuria". 
Conclusion 
It can be summarized that diabetic nephropathy probably results from hyperglycemia 
leading to hemodynamic and biochemical changes in a genetically susceptible diabetic 
patient. Yearly measurements of urinary albumin excretion and blood pressure will allow 
early identification of patients at risk for the development of nephropathy. Treatment 
should be aimed at optimal control of blood glucose and blood pressure. 
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Screening for Microalbuminuria in Patients with Diabetes Mellitus: Frozen Storage of Unne 
Samples Decreases Their Albumin Content 
L D. Elvlng, J A. J M Bakkeren,1 M J H Jansen,' С M de Kat Angelino,1 E. de Nobel, and Ρ J J. van Munster1 
The influence of storage on urinary albumin concentration 
was prospectively studied with use of overnight unne speci­
mens (Albustix negative) from 73 diabetic patients From 
each urine sample four aliquote were taken One was stored 
at 4 °C and assayed within two weeks, the other three were 
stored at -20 °C and assayed within two weeks and after two 
and six months Albumin concentration was measured with 
laser immunonephelometry The detection limit, 1 mg/L, 
suffices for the screening of diabetic patients for microalbu­
minuria After storage for two and six months at - 2 0 "C, 
significantly lower albumin concentrations were found The 
difference was mainly caused by lower concentrations found 
in unne samples in which a precipitate had formed, which 
was the case in 22 and 25 samples respectively Thus, 
freezing of unne samples for determination of low concentra­
tions of albumin may yield falsely low results Unne samples 
are best stored at 4 °C and assayed within two weeks 
Additional Keyphraaes diabetic nephropathy laser immuno­
nephelometry 
About 30% to 40% of all patients with type 1 (insulin 
dependent) diabetes mellitus will develop the clinical syn­
drome of diabetic nephropathy, characterized by persistent 
proteinuria (г0 3 g/24 h), hypertension, and deterioration of 
renal function It invariably leads to end-stage renal failure 
(1) Manifest diabetic nephropathy is preceded by a phase in 
which albuminuria is abnormally increased but not yet 
detectable with routine methods This microalbuminuria 
(20-200 fig/nun, ι e , 30-300 mg/24 h) is highly predictive of 
future development of manifest diabetic nephropathy (2) In 
patients with microalbuminuria, strict metabolic control 
can retard the progression toward mamfeBt diabetic 
nephropathy (3) Screening of diabetic patients for microal­
buminuria therefore has become part of routine diabetes 
care This screening concerns large groups of patients, so a 
simple, sensitive, and inexpensive method should be avail­
able for measuring low concentrations of urinary albumin 
Here we describe a laser immunonephelometnc method that 
meets these requirements 
Little is known about the effect of storage on urinary 
albumin concentrations Unne samples often are stored at 
- 20 °C for long penods before being analyzed Thus we have 
performed a prospective study to evaluate the effects of 
freezing unne samples for longer penods on measured 
albumin concentration 
Materials and Methods 
Samples Overnight unne specimens were collected from 
73 nonproteinunc (Albustix negative) diabetic patients, 
Department of Medicine, Division of General Internal Medicine, 
University Hospital, Geert Grooteplein Zuid 8,6500 HB Numegen, 
The Netherlands 
1
 Department of Pediatrics, Laboratory for Immunochemistry, 
University Hospital, Numegen, The Netherlands 
Received August 24, 1988, accepted November 16, 1988 
consecutively attending the outpatient diabetes clinic The 
specimens were centnfuged (1500 χ g, 15 mm) and the 
supernate was divided into four 2-mL aliquota and stored at 
4 X for determination within two weeks and at -20 °C for 
determination within two weeks and after two and six 
months, respectively Before assay, all samples were exam­
ined for the presence of a precipitate and again centnfuged 
(1500 x g, 15 mm) In 33 unne samples the albumin 
concentration was also measured within two days after 
collection The pH of 59 unne samples was measured 
Apparatus Urinary albumin concentrations were mea­
sured with the Disc 120 Nephelometer (Hyland, Nivelles, 
Belgium) 
Standards and controls A pool of serum from 500 donore 
was stored at 4 °C for two weeks It then was centnfuged 
(60 000 x g, 1 h) and precipitates and lipids were removed 
The supernate was filtered consecutively through 0 45-μτη 
and 0 22-μιη pore-size filters (Milhpore Corp, Bedford, MA), 
quick-frozen m 0 7-mL portions by use of a solid CCVace-
tone mixture, and stored in sealed ampules at -70 °C Two 
control unnes, one with high and one with low albumin 
concentration, were prepared and stored m an identical way 
Antiserum Antiserum was raised in New Zealand White 
rabbits as follows For immunization we used 0 5 mg of 
human serum albumin (Behnngwerke, Frankfurt, F R.G ) 
and complete Freund's adjuvant After three and six weeks, 
booster injections were given, consisting of 0 5 mg of albu­
min ш incomplete Freund's adjuvant When the optimal 
antibody titer was reached, the rabbit was bled Antibody 
specificity was checked by Ouchterlony double immunodif­
fusion and by Immunoelectrophoresis Titer and avidity 
were estimated by laser immunonephelometry The serum, 
stored at -20 °C, was diluted 300-fold in diluent (see below) 
immediately before use This dilution factor was chosen to 
get high sensitivity without getting into the range of 
antigen excess After 1 h at room temperature the diluted 
antiserum was filtered through a 0 22-μπι filter to minimise 
antiserum blanks 
Diluent The diluent was phosphate-buffered isotonic sa­
lme (phosphate 5 mmol/L, pH 7 4) containing, per liter, 20 g 
of polyethylene glycol 4000 (Merck, München, F R G ) and 
20 g of polyethylene glycol 2000 (Merck), plus 0 25 g of 
NaN3 as preservative This diluent gave low light scatter in 
blanks m combination with high sensitivity Before use it 
was filtered through 0 22-μτη filters It is stable at room 
temperature 
Assay procedure The standard was first diluted 100- and 
1000-fold with isotonic salme Subsequently, dilutions from 
five- to 80-fold were made to get six-point standard curves 
The concentrations were 5 5,11, 22,44, 65, and 87 mg/L for 
the high range and 0 6,11,2 2,4 4,6 5, and 8 7 mg/L for the 
low range At the beginning and end of each run, both sets of 
standards were assayed For the high range, the signal was 
measured at gain 11, for the low range, at gain 12 The 
detection limit was 1 0 mg/L All samples were first tested 
with Albustix (Ames Miles, Pans, France) For samples 
with high concentrations of albumin, 10 /iL of undiluted or 
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of twofold diluted unne was mixed with 1000 μ ι of diluted 
antiserum (or diluent), and for the lower concentrations a 
100-uL unne sample was used Incubation was for exactly 1 
h The relative light scatter from all samples was then 
measured nephelometncally 
Calibraban and standard serum The standard pool was 
calibrated nephelometncally for albumin vs purified serum 
albumin (Behnngwerke) There was consistent parallelism 
between the six-point calibration curves, the standard pool, 
and the unne samples, respectively 
Statistical analysis Results are presented as mean and 
standard deviation (SD), or median and range Albumin 
concentrations m samples stored for two weeks or for two or 
an months at -20 °C were compared with those m samples 
stored for two weeks at 4 °C by use of Wilcoxon's signed rank 
test for paired data We also applied Bonferrom's adjust­
ment for multiple comparisons 
Results 
Analytical Variables 
Precision Albumin m unne samples was determined in 
duplicate Table 1 shows the between-run variation, mea­
sured over a one-year period, for the high- and the low-
concentration control unne samples Both samples re­
mained free of precipitate The intra-run CV was 1 8% for 
two unne samples, one m the high and one in the low range 
Analytical recovery Recovery was determined after add­
ing diluted standard serum to unne samples containing 10-
22 or 1 5—6 6 mg of albumin per liter Albumin concentra-
faons were measured before and after addition of the stan­
dard serum (albumin content 20 6 or 41 2 mg/L, or 2 2 or 4 4 
mg/L, respectively) The mean (and SD) recovery was 96 7% 
(3 0%) (n = 8) and 103 2% (9 0%) (n = 7) for the high and low 
ranges, respectively 
Effects of Storage Conditions 
Thirty-three unne samples, stored at 4 °C, were analyzed 
for albumin concentration within two days and within two 
weeks after collection No significant difference in albumin 
concentration was found (14 1 ± 20 4 vs 14 3 ± 19 9 mg/L) 
Subsequently, after different penods of storage, we tested for 
albumin concentration in unne samples from 73 diabetic 
patients without proteinuria (Albusfax negative), using the 
values for samples stored at 4 °C for two weeks as the 
reference value The mean urinary albumin concentration 
of these 73 samples, stored at 4 °C for two weeks, was 17 9 ± 
28 4 mg/L Storage for two weeks at 20 °C produced no 
significant change in results, although the albumin concen­
tration was clearly decreased m two samples After two and 
sui months of storage at -20 °C, significant differences in 
albumin content were evident (Table 2) 
As shown m Figure 1, the albumin concentration de­
creased, especially m samples in which a precipitate had 
formed during storage After two and six months, a precipi­
tate had formed m 22 and 26 of the urines, respectively The 
Table 1. Interaasay Variation of Laser 
Immunonephelometrlc Determination of Albumin 
Concentration (mg/L) in Control Urines 
Hlghconcn Low сопел 
Mean 70 7 5 3 
SO 2 1 0 6 
CV, % 3 10 
η 32 23 
Table 2. Albumin Concentrations In Urine Samples 
after Storage for Various Periods 
Albumin, mg/L 
Stone· condition· 
< 2 weeks 4°C 
< 2 weeks, - 2 0 °C 
2 months, - 2 0 °C 
6 months, - 2 0 "C 
Maan (and SD) 
17 9 ( 2 8 4) 
17 8 ( 2 8 5) 
15 5 ( 2 3 9)* 
14 8 ( 2 3 1)* 
Rang· (and median) 
2-172(9) 
1-174(9) 
1-112(7) 
1-107 (7) 
Significantly different from results after <2 weeks at 4 eC 'P <0 03 
<0 005 
pH was not measured in all urines, but the mean pH of 20 
urines with a precipitate and of 39 urines without precipi­
tate was not significantly different 5 7 ± 0 5 and 6 0 ± 0 6, 
respectively Microscopic examination of the precipitate 
showed that it consisted almost entirely of urates, both 
amorphous and crystalline 
Discussion 
In this study we used a rapid, sensitive method for 
measuring low concentrations of albumin, a modification of 
a method previously described (4) The intra- and interassay 
tlbunw,«лів/1)я1 «««Its al 4 »С 
Fig 1 Albumin concentrations of 7 3 unne samples measured within 
two weeks {bottom), after two months (rradd/e) and after s a months 
(top) of storage at - 2 0 °C compared with albumm concentrations found 
witrun two weeks of storage at 4 °C 
Logantfvnlc acale Feed dots represent samples in which a precplata had 
formed Because many concentrators were equal some dots represent two or 
more samples 
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CVs for the laser immunonephelometry—2% and 10%, 
respectively—compare well with those for techniques such 
as radioimmunoassay, enzyme-linked immunoassay, radial 
immunodiffusion, and immunoturbidimetry (5-7) The de­
tection limit of 1 mg/L suffices for the screening of diabetic 
patients for microalbuminuria Automatization of the meth­
od facilitated analysis of large runs of samples Smaller 
runs, however, can also be handled easily and do not make 
the method more expensive The low cost of the method is 
mainly due to the easy production of large amounts of 
antiserum, which need not be punned, and to the need for 
only small volumes of antiserum in the assay Laser immu­
nonephelometry costs about $30 per 100 samples, in dupli­
cate, which can be performed in one 8-h working day 
Analysis of the same number of samples measured by 
radioimmunoassay would cost about $500 
Unne is often stored for long periods at —20 °C, particu­
larly m research programs We found albumin concentra­
tions to be decreased in frozen unne samples, especially in 
those in which precipitates (mainly urates) had formed 
Presumably, albumin is entrapped in the precipitates, how­
ever, heating five precipitate-containing samples for 1-12 h 
at 37 and 56 °C did not restore the albumin concentration to 
its original value 
It has also been suggested that urinary pH is important m 
the formation of precipitate leading to decreased albumin 
concentrations in unne samples (8), but we found no rela­
tion between pH and precipitate formation 
We found no loss of urinary albumin when samples were 
analyzed within two weeks and stored at 4 °C Because 
important conclusions are sometimes drawn from rather 
small variations m albuminuria, one must be aware that 
storage at - 2 0 °C can influence albumin concentration In a 
concurrent study, Ennan et al (9) found a decrease in 
urinary albumin concentration after even as little as one 
week of storage at - 2 0 °C We confirm that albumin concen­
trations are underestimated m frozen samples Two of our 
samples stored at - 2 0 °C for two weeks showed substantial 
loss of albumin, but greater differences were seen after two 
and six months of frozen storage 
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Abstract 
To evaluate whether patients at risk for the development of diabetic nephropathy can be 
identified before the development of microalbuminuria we have performed a standardized 
exercise test in 24 patients with insulin-dependent diabetes mellitus (IDDM) with a normal 
urinary albumin excretion The results were compared to those obtained in 13 healthy 
controls After a follow-up of 5 years the patients were screened for the presence of 
microalbuminuria Each subject exercised on a bicycle at a workload that was 60% of his 
maximal level Patients were considered to have a positive test when albuminuria after 
exercise exceeded the maximal value obtained in the normal controls In this way we 
could identify 8 patients with a positive test. In these 8 patients urinary excretion of both 
albumin and IgG increased after exercise. However, the ratio between urinary IgG and 
urinary albumin excretion decreased when compared to controls or patients with a 
negative test. No difference in blood pressures was found This suggest that the increase 
in urinary albumin excretion is the result of glomerular permeability changes rather than 
of hemodynamic changes. The patients with a positive test did not differ from the patients 
with a negative test after a follow-up of 5 years. Only one patient has become microalbu-
minunc. In conclusion 30% of normoalbuminunc IDDM patients show an abnormal 
increase of urinary albumin excretion after a standardized exercise test. This test however 
could not predict the future development of microalbuminuria, after 5 years of follow-up. 
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Introduction 
Diabetic nephropathy ultimately develops in about 30% of all IDDM patients'. The phase 
of overt diabetic nephropathy, defined by the presence of persistent proteinuria in the 
absence of other renal disease, is always preceded by a period of incipient nephropathy 
characterized by microalbuminuria2. Almost 20 years ago studies about exercise-induced 
albuminuria suggested that with an exercise-test patients at risk for the development of 
diabetic nephropathy34 could be detected. It was found that after exercise some IDDM 
patients showed an exaggerated increase of albuminuria when compared to normal 
controls. This was especially seen in patients who showed already in rest levels of 
albuminuria above normal, i.e microalbuminuria5. Since it became clear that this 
microalbuminuria68 is predictive for future development of overt diabetic nephropathy, 
the cumbersome test for exercise-induced albuminuria seemed to be obsolete. However, in 
some of the former studies also patients with normal albumin excretion at rest showed 
increased levels of albuminuria after exercise. It is not clear whether this is of any 
importance, but one might argue that in these patients an exercise test can disclose certain 
abnormalities in the renal handling of albumin which could be indicative of renal damage. 
The exact pathophysiologic mechanism for albuminuria in diabetic nephropathy is not 
completely elucidated but in the initial phase it probably results from losses of negative 
charges in the glomerular basement membrane together with an increased intraglomerular 
pressure secondary to dilatation of the afferent arteriole'l0. Exercise induces an increase 
in intraglomerular pressure as is reflected by an increase in filtration fraction511. In our 
present study we analyzed whether abnormalities in renal albumin handling can be 
detected during an exercise test in patients with IDDM without any sign of nephropathy. 
Unlike other studies, all our subjects exercised at an individually determined work load of 
60% of their measured maximal working capacity. To test whether size or charge defects 
of the glomerular basement membrane are of importance we measured the influence of 
exercise on excretion of both albumin and IgG After a follow-up period of 4-5 years the 
patients were studied for the presence of microalbuminuria or hypertension. 
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Patients and methods 
Patients 
All patients were attending the outpatient diabetic clinic of the University Hospital 
Nijmegen. IDDM had to be present for at least 5 years and was defined as age of onset of 
diabetes before 30 yr and start of insulin treatment within one year after diagnosis. 
Further selection criteria were: a normal renal function (serum creatinine level < 100 
μπιο1/1), a normal albumin excretion rate (AER: <20 ^g/min in at least two timed 
overnight urine collections) and a normal blood pressure (< 140/90 mmHg). The test was 
also performed in 13 healthy volunteers, mainly medical students and staff members. 
The protocol was approved by the local ethical committee and all patients and volunteers 
gave informed consent. 
Methods 
To determine exercise-induced albuminuria, a standardized isotonic exercise test was 
performed with a Lode electric bicycle ergometer (Lode's Instruments B.V., Groningen, 
The Netherlands). The used pedal rate was 60 rpm in all tests and the height of the saddle 
and handle bar was adjusted for each subject. In all subjects a pretest was carried out to 
determine the individual's maximal working capacity (W-max). In this pretest exercise 
was started at 20 Watt and increased every 2 min with 20 Watt until a heart rate of about 
110 beats per min was reached. This workload was then maintained for 3 min and 
thereafter increased in the same way until a heart rate of about 130 beats per min was 
reached, which again was stabilized for 3 min. The same procedure was carried out to 
achieve a heart rate of about 150 beats per min. This way each individual exercised at 3 
incremental work loads. The mean heart rate was plotted against the corresponding work 
loads. The line through these 3 points can be extrapolated to the, for that individual's age 
expected maximal heart rate, as derived from a table published by the American Heart 
Association12. This results in an extrapolated W-max. A pilot study in 20 healthy 
volunteers learned that this submaximal exercise test compared to a maximal exercise test 
yielded a calculated W-max which was 10% lower than the true W-max. Therefore for all 
subjects the W-max was estimated to be the extrapolated W-max + 10%13. Exercise-
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induced albuminuria was measured after 20 min exercise at 60% of that individual's 
calculated W-max. 
On the day of the exercise-test the subjects came to the outpatient clinic at 8.30 a.m. A 
breakfast was permitted. The patients took their normal dose of insulin or an adjusted 
dose. In the 12 hours before the test the subjects were not allowed to smoke or drink 
coffee. During the entire test the subjects remained in the sitting position except for 
voiding. A water diuresis was maintained by drinking 1000 ml of water at 8.30 a.m. 
followed by 250 ml every 30 min. After 90 min when a stable water diuresis was 
achieved two 30-min urine samples were collected (period 1 and 2). Thereafter the 20 
min exercise at 60% of the calculated W-max was carried out followed after 10 min by 
an urine collection (period 3). Subsequently, two 30-min urine specimens were collected 
(period 4 and 5). Each urine sample was analyzed for albumin, IgG and creatinine 
concentration. Bovine serum albumin was added to the urine samples to prevent ab-
sorption of proteins to the plastic tubes. The samples were stored at -70 °C until analysis. 
In the pre- and post-exercise period blood samples were taken for measurement of glucose 
and creatinine. HbA,c was measured before exercise and analyzed by HPLC (normal 
value <6.2%). Albumin and IgG concentrations of the test urine samples were measured 
by ELISA (detection limit 0.05 mg/1). Albumin concentration in the overnight urine 
collections was measured by laser-immunonephelometry (detection limit 1 mg/1)'4. During 
the pre- and post-exercise periods blood pressure and heart rate were measured 2 times 
with a standard sphygmomanometer. Blood pressure and heart rate during the exercise 
were recorded with an automatic exercise blood pressure monitor (Criticón 1165). This 
non-invasive device reliably measures systolic blood pressure by ECG-assisted auscul-
tation15. 
After 4-5 years all patients were asked to collect two overnight urine samples for 
measurement of albumin. They were seen at the outpatient clinic where supine and 
standing blood pressure were measured, in duplicate, after 5 min rest, with a standard 
sphygmomanometer. A blood sample for HbA,c and creatinine was taken. 
Statistical analysis 
The means of the values measured in period 1 and 2 are taken as pre-exercise value. The 
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post-test values are the means of period 3, 4 and 5. All values are given as means and 
standard deviations or as medians and range in case of skewed distribution. The Kruskall-
Wallis test is used for comparison between the groups. The Mann-Whitney U test is 
applied for comparison of pre- and post-test results within one group. A ρ value of less 
than 0.05 is considered significant. Correlation coefficients are calculated as Spearman's 
correlation coefficient. 
Results 
The exercise test was performed in 24 IDDM patients and in 13 healthy volunteers. The 
workload of 60% of the calculated W-max did not differ between the controls and 
diabetic patients (140+17 vs. 131+23 Watt). The maximal heart rate during exercise was 
144+10 beats/min in the control group and 145±19 in the diabetic patients, which is not 
significantly different. The highest level of post-test AER measured in healthy controls 
was 13.5 /ig/min. Hence a positive exercise test was defined as post-exercise AER above 
this level. Of the 24 IDDM patients 8 had a positive test. The clinical data of the patients 
with a positive and negative exercise test and controls are shown in Table 1. There is no 
significant difference for any of the clinical parameters between any of the groups. 
Table 1. Clinical data of the diabetic patients with a positive and negative exercise test 
and controls. 
N 
Age (yr) 
Duration od diabetes (yr) 
HbA,
c
 (%) 
Proliferative retinopathy (n) 
Serum creatinine (дтоі/і) 
BMI (kg/m2) 
Overnight AER (/ig/min) 
Diabetic 
Positive test 
8 
31±6 
16±9 
8.6±1.2 
2 
85±8 
24.2±3.1 
7 (4-16) 
patients 
Negative test 
16 
34±6 
13±8 
8.8+1.0 
1 
85±8 
22.8 + 2.5 
6 (3-13) 
Controls 
13 
27+4 
71+9 
22.2±1.9 
5 (3-8) 
Data are presented as means ± SD or median (range) 
BMI = body mass index, AER = albumin excretion rate 
A positive test is defined as a mean post-exercise AER above 13.5 i^g/min (see results). 
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In Table 2 the results of the parameters obtained during the exercise test are presented. 
The pre-test AER in the patients with a positive test is significantly higher than the pre-
test AER in patients with a negative test. After exercise, IgG-excretion in the patients 
with a positive test increased, although to a lesser degree than albumin. Hence, the ratio 
between IgG and albumin excretion decreased in the patients with a positive test. 
Table 2. Results of exercise test in normoalbuminuric diabetic patients with a positive 
and negative exercise test and in controls. 
N 
Workload (W) 
AER (/ig/min) 
(pre-test) 
AER Oig/min) 
(post-test) 
IgGER 0*g/mm) 
(pre-lest) 
IgGER ÍMg/mín) 
(post-lesi) 
IgG/Alb pre-test 
IgG/Alb post-tesi 
Glucose (mmol/1) 
(pre-test) 
Glucose (mmol/1) 
(post-lest) 
Systolic BP (mmHg) 
pre-test 
during exercise 
post-test 
Diastolic BP (mmHg) 
pre-test 
post-test 
HR (beats/min) 
pre-lest 
during exercise 
post-tesi 
Diabetic 
Positive lest 
8 
12б±І6 
8 6 (4 4-13 0) 
23 0(14 4 57 7)' 
3 7 (2 8-4 3) 
5 5 (4 3-10 I)* 
0 39 (0 32-0 54) 
0 26 (0 17-0 38)* 
7 2 ( 3 5-14 2) 
4 5 (3 9-13 1) 
119±12 
17S±36 
115±11 
79±11 
76+9 
66±9 
157±12 
76±8 
patients 
Negative lest 
16 
134±24 
5 3 (3 3-8 8) 
7 1 (3 8-12 4)' 
2 7(1 5-6 5) 
3 8 (1 4-6 9) 
0 51 (0 17-1 47) 
0 55 (0 23-1 34) 
9 0 (2 6-18 0) 
6 5 (4 4-16 1) 
114±10 
172±17 
114±11 
76±8 
77±8 
61±9 
141±19 
68±11 
Controls 
13 
140±17 
6 1 (3 7-8 6) 
6 7 ( 4 5-13 5) 
1 7 (0 7-3 3) 
2 0 (0 6-7 4) 
0 25 (0 14-0 50) 
0 28 (0 12-0 71) 
120±11 
161 ±17 
116±11 
78 ±7 
76±9 
65±1І 
144+10 
70±8 
Р* 
N S 
< 0 05 
< 0 05 
< 0 05 
< 0 05 
< 0 05 
< 0 05 
N S 
N S 
N S 
N S 
N S 
Dala are presented as means ±SD or median (range) 
AER = albumin excretion rale, IgGER = IgG excretion rate 
A positive test is defined as a post exercise AER above 13 5 /ig/min (see results) 
* ρ value for comparison between Ihe three groups (Kruskall Wallis test) 
* p < 0 05 vs pretest 
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Blood glucose levels, also shown in Table 2, do not differ before and after exercise 
between the two groups. Blood pressure and maximal heart rate during exercise are the 
same in the three groups. 
Post-test AER was not correlated with the workload, blood pressure or heart rate 
achieved during the test. Neither was there a correlation with duration of diabetes and the 
level of metabolic control as measured by HbAlc. 
Of the 24 patients 19 patients were studied after 5 years. Four had moved out of the area 
and another one could not be traced. The data obtained after 5 year follow-up are shown 
in Table 3. One patient with a positive test has developed microalbuminuria after 5 years. 
All others have remained normoalbuminuric. The individual results are shown in Fig.l. 
No correlation was found between AER at follow-up and post-test AER. 
Table 3. Data of the patients with a positive and negative exercise test obtained after a 
follow-up of 4-5 years. 
Positive test Negative test 
N 8 11 
HbA lc(%) 8.8± 1.3 9 0 + 0.7 
Overnight AER (Mg/min) 6 (3-42) 5 (2-16) 
Blood pressure (mmHg) 132 ± 8/77 ± 7 125 + 11 /74 ± 8 
Serum creatinine /imol/l 93±12 89±7 
Data are presented as means ± SD or median (range) 
AER = albumin excretion rate. 
A positive test is defined as a post-exercise AER above 13.S μg/mln (see results) 
Discussion 
Previous studies have shown that moderate to heavy exercise can induce an increase in 
albumin excretion in diabetic patients. This appeared especially to be the case in microal-
buminuric patients416. However several studies have also shown an increase in albuminu­
ria after exercise in normoalbuminuric patients31722. The results from these studies may 
have been influenced by the fact that in these studies, except two (2I and23), all patients 
exercised at the same level. Our results show that when exercise is performed at a level, 
standardized for physical training and age, a third (33%) of the IDDM patients with a 
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Fig 1. Initial urinary albumin excretion rate (AER) and AER after a follow-up of 5 years 
in diabetic patients with a positive exercise test (upper panel) or with a negative 
exercise test (lower panel). A positive exercise test was defined as a post-exercise 
AER > 13.5 μg/min. 
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normal albumin excretion rate at baseline show an abnormal albumin excretion after 
exercise Contrary to other studies we could not demonstrate a relation with metabolic 
control"21 The patients with a positive test are also distinguished by a significant 
increase in the excretion of IgG, while in the patients with a negative test IgG-excretion 
remains unchanged. Since the blood pressure achieved during exercise was not different 
between the two groups during exercise this could mean that the diabetic patients with a 
positive test react differently to an exercise load. Viberti et al.3 showed, by simultaneous 
measurement of (^-microglobulin and albumin during exercise, that the elevated albumin 
excretion after exercise was not accompanied by a rise in ß2-microglobuhn excretion This 
suggests that the albuminuria induced by exercise is due to increased transglomerular 
passage of albumin and not to diminished tubular albumin reabsorption Since the albumin 
and IgG excretion both increased it can be argued that this is due to an increased 
intraglomerular capillary pressure or either an increased transglomerular passage of 
proteins due to changes in the glomerular permeability These changes could result from 
increase in pore size or loss of negative charge of the glomerular basement membrane 
The latter would induce a preferential loss of albumin. In our patients with a positive 
exercise test the ratio between the urinary excretion of IgG and albumin decreased We 
suggest that these results are in accordance with a loss of negative charge of the glomeru-
lar basement membrane in patients with IDDM. 
Only one of the patients with a positive test showed microalbuminuria at a follow-up of 5 
years. At present our data thus do not allow to draw definitive conclusions regarding the 
usefulness of the exercise test in identifying patients at nsk for the development of 
diabetic nephropathy If more patients become microalbuminunc as follow-up continues, 
than a relationship between the exercise test and the development of microalbuminuria can 
be defined In retrospect, we probably have included to many patients with longstanding 
diabetes, who as we now know have a low risk for the development of diabetic nephro-
pathy24. The relationship between exercise-induced microalbuminuria and the development 
of microalbuminuria was also studied by Bognetti et al22 These authors have studied 66 
IDDM patients, who were followed-up for 6 years after performing an exercise-test. In 
this study no relationship between post-exercise albuminuria and the development of 
microalbuminuria was found 
We conclude that approximately 30% of normoalbuminunc diabetic patients show an 
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increased urinary albumin excretion rate after moderate exercise. Since the increase in 
urinary albumin excretion is accompanied by a lesser increase in IgG excretion, the data 
suggest that in these patients exercise discloses a change in glomerular permeability, 
based on the reduction of the negative charge of the glomerular basement membrane. A 
positive test was however not predictive for the development of microalbuminuria after 5 
years. 
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Is increased erythrocyte sodium-lithium counlertransport a useful 
marker for diabetic nephropathy? Genetic predisposition to essential 
hypertension has been proposed as a nsk factor for the development of 
diabetic nephropathy in type 1 (insulin dependent) diabetes mellitus 
An increased sodium-lithium counlertransport activity (NaLiCT) has 
been suggested as a genetic marker for essential hypertension We 
therefore evaluated NaLiCT in diabetic patients with (N ~ 39) or 
without (rV = 23) diabetic nephropathy (DNP), patients with non 
diabetic renal diseases (N = 42) and in healthy controls (N = 24) The 
NaLiCT was elevated in both diabetic patient groups compared to 
healthy controls (median 244, range 134 to 390 μπιοΙ liter 
cells ' hr '), but was not different in patients with DNP (median 314, 
range 162 to 676) without DNP (median 325 range 189 to 627) and 
patients with non-diabetic renal disease (median 300, range 142 to 655) 
The genetic predisposition to DNP is illustrated by the fact that diabetic 
sibs of probands with DNP showed a higher occurrence of DNP than 
diabetic sibs of patients without DNP We analyzed whether familial 
DNP clustered with an increased NaLiCT The NaLiCT in sibs con 
cordant for the presence of DNP (N = 10, median 307, range 217 to 428 
umol liter cells ' hr ') was not significantly different from that in 
sibs concordant for absence of DNP ( N = 1 5 median 279, range 189 to 
442) We conclude that erythrocyte sodium lithium countertransport 
activity cannot be used as a marker to identify patients at nsk for the 
development of diabetic nephropathy 
Approximately one third of the patients with type 1 (insulin-
dependent) diabetes mellitus develop the clinical syndrome of 
diabetic nephropathy (DNP), mostly 15 to 20 years after the 
onset of diabetes [1] The development of DNP is heralded by 
microalbuminuria and a nse in blood pressure [2] At present 
there are no explanations why some patients develop DNP and 
others do not [1, 3] The susceptibility to DNP cannot solely be 
explained by differences in glycémie control [4], which suggests 
that other factors are involved Even at the early stages, DNP 
is accompanied by a nse in blood pressure [5], and some 
authors have already observed such a nse before any impair-
ment of kidney function was detectable [2,6] Others, however, 
argue that the nse in blood pressure is rather the consequence 
of DNP than a causative factor [7] 
Recently, Viberti, Keen and Wiseman have found that non-
diabetic parents of patients with DNP had higher blood pressure 
levels, suggesting that a familial predisposition to hypertension 
is a nsk factor for the development of DNP [8] This contention 
was corroborated by findings of two independent groups of 
© 1992 by the International Society of Nephrology 
investigators, who showed that erythrocyte sodium-lithium coun-
tertransport activity (NaLiCT), a genetic marker for essential 
hypertension in non-diabetic patients [91, ts increased in patients 
with overt DNP compared to diabetics without DNP [10, 11] and 
patients with non-diabetic renal disease [11] Subsequently, an 
increased NaLiCT was also found in patients with microalbumin-
uria [12], who are at high nsk for progression to overt DNP [6] 
Finally, an increased NaLiCT in type 1 diabetic patients with 
normoalburmnuna and nonmotension appeared to be associated 
with an increased glomerular filtration rate and filtration fraction 
[13] Since hyperfiltration is regarded as one of the possible 
pathophysiological mechanisms in the development of DNP, these 
findings suggest that patients who are at nsk for the development 
of DNP can be identified by an increased NaLiCT Based on these 
observations, the concept was formulated that the susceptibility to 
DNP in type 1 diabetes may be associated with a genetic predis-
position to essential hypertension, and that an increased NaLiCT 
could be used as a marker to identify patients at nsk for DNP We 
measured NaLiCT in patients with type 1 diabetes with and 
without DNP, patients with various non-diabetic renal diseases 
and normal healthy control subjects Furthermore, a second study 
was undertaken in which we analyzed NaLiCT in familial diabetes 
mellitus It has been reported that development of DNP is clus-
tered in families, since diabetic sibs of patients with DNP show a 
higher frequency of DNP than diabetic sibs of patients without 
DNP [14], which supports the hypothesis that genetic factors are 
involved in the susceptibility to DNP We investigated whether 
familial DNP clustered with an increased NaLiCT by measunng 
NaLiCT in diabetic sibs concordant for the presence or absence of 
DNP 
Our results [IS, 16] appeared to be at variance with those 
mentioned earlier [10, 11], but were similar to those reported 
recently by Jensen et al [17] Like Jensen we used LiHC03 to 
load erythrocytes with lithium, while Krolewski et al [10] and 
Mangili et al [11] used LiCl To exclude that this discrepancy in 
NaLiCT activity in DNP was due to differences m methodol-
ogy, we measured NaLiCT after both loading conditions 
(L1HCO3 and LiCl) in healthy controls and in diabetic patients 
with and without DNP 
Methods 
Patients 
Study I To study the relation between NaLiCT and DNP, 
patients with and without diabetic nephropathy were recruited 
53 
from the diabelology outpatient clinic All patients had type 1 
(insulin-dependent) diabetes mellitus Duration of diabetes in 
the patients without diabetic nephropathy had to be at least 15 
years NaLiCT was also measured in a group of patients with 
various non-diabetic renal diseases who were recruited from the 
nephrology outpatient clinic The original renal disease in these 
patients was respectively chronic pyelonephritis (/V = 5), adult 
polycystic kidney disease (N = 6), interstitial nephritis (/V = 3), 
hypertensive glomerulosclerosis (N = 2), chronic glomerulone­
phritis (N = 3), focal glomerulonephritis (N = 7), Alport's 
disease (N = 1), membranous glomerulonephritis (N = 5). IgA 
nephropathy (N = 5), and focal and segmental glomeruloscle­
rosis (N = 5) A control group of 24 healthy subjects was also 
studied The control subjects all had a normal blood pressure, 
normal renal function and no proteinuria All studied patients 
and controls were Caucasians The results of this study have 
partly been published elsewhere [15] In this report 11 diabetic 
patients were additionally studied 
Study II To analyze whether familial DNP clusters with an 
increased Nal.iCT, patients with type 1 diabetes mellitus ot at 
least 15 years duration who also had a living sib with type I 
diabetes for at least 15 years were identified and enrolled in this 
study The results of the NaLiCT measurements in these 
patients are included in study I 
Methods 
Diabetic nephropathy is defined as the presence of an albu­
min excretion rate (AER) > 20 μβ/min in each of two timed, 
overnight, stenle, non-ketotic urine collections Incipient 
nephropathy is defined as an AER between 20 and 200 μg/mln 
and overt nephropathy as an AER > 200 μ^πιιη The albumin 
concentration was measured by laser immunonephelomelry as 
described previously [18J [interassay coefficient of variation 
3% for high (>70 μg/ml) and 10% for low albumin concentra­
tions] Other kidney or urinary tract diseases were excluded by 
clinical or laboratory parameters In the patients with non-
diabetic renal disease, proteinuria was assessed by measure­
ment of the protein/creatinine ratio (g/mmol of creatinine χ 10) 
in a fresh morning sample [19], protein concentration was 
measured with the biuret method and creatinine with the Jaffe 
method Blood pressure was measured after five minutes of 
recumbency with a standard mercury sphygmomanometer 
Hypertension was defined as a mean arterial pressure (MAP) > 
110 mm Hg or the use of antihypertensive drugs MAP was 
calculated as diastolic blood pressure plus one third of the pulse 
pressure In all patients NaLiCT, blood pressure, HbAk, albu 
mm excretion rate (AER), serum creatinine and body weight 
were measured In the diabetic patients serum cholesterol was 
also measured HbAk was analyzed by HPLC (normal value 4 3 
to 6 3%) 
Measurement of sodium-lithium countertransport 
Venous blood was drawn between 08 00 and 10 00 a m and 
all measurements were performed on the day of the blood 
collection The blood was collected in two 10 ml hepann-coated 
tubes for duplicate measurement of NaLiCT 
Measurement of NaLiCT after loading и ith lithium bicarbon­
ate NaLiCT was measured according to the method described 
by Ibsen et al [20] All steps were performed in duplicate The 
whole assay was earned out on ice with cooled (4°C) media. 
except for the efflux measurements, which were performed in a 
water bath at 37°C From the blood samples plasma and buffy 
coat were removed and the erythrocytes were washed three 
times in a magnesium chloride medium (75 тм magnesium 
chlonde, 85 тм sucrose, 10 тм glucose, 10 тм Tris-MOPS, 
pH 7 4) and after centnfugation (5 mm 1500 g at 4°C) resus-
pended in the lithium loading medium (150 тм lithium bicar­
bonate, S тм potassium chloride, 10 тм glucose) to a hema­
tocrit of 20% 1 he medium was made from lithium carbonate 
and titrated with C0 2 to pH 7 4 The erythrocytes were 
incubated in this medium during 20 minutes at 37°C After 
loading, the cells were washed five times in a potassium 
chlonde medium (150 тм potassium chloride, 10 тм glucose, 
0 1 тм ouabain, 10 тм Tns-MOPS, pH 7 4) After each wash 
step the cells were centnfuged three minutes at 1500 g at 4°C 
After washing a 35% erythrocyte suspension was made in the 
potassium medium A sample was taken for measurement of the 
intracellular lithium concentration and for the measurement of 
hemoglobin concentration and mean cell hemoglobin concen­
tration (Technicon HI) For the lithium efflux measurements 0 5 
ml of the erythrocyte suspension was incubated at 37°C in 
parallel in either 3 5 ml sodium chlonde medium (150 тм 
sodium chlonde, 10 тм glucose, 0 I тм ouabain, 10 тм 
Tns-MOPS) or in 3 5 ml of the above-mentioned potassium 
chlonde medium 1 he hematocrit at which the countertransporl 
measurement took place was therefore 4% After 30, 60 and 90 
minutes, incubation in either medium was stopped by placing the 
tubes on ice for two minutes and subsequent centnfugation at 
1500 g for three minutes at 4°C Lithium concentration in the 
supernatant was measured by atomic absorption spectropho­
tometry (Perkin Elmer 5000) The standard solutions contained 
0 25 to 2 5 тм lithium 
For the calculation of the NaLiCT, it is assumed that a linear 
relation exists between the sodium-simulated lithium efflux over 
time We measured three time points (30, 60 and 90 mm) to 
improve accuracy The slope of this line (ALi/At) can be 
calculated by linear regression analysis That our approach 
yielded linear kinetics can be derived from the observation that 
the mean r value of the separate measurements was 0 9995 ± 
00006 
The lithium efflux rale (/xmol/hter cells/hr) -
(ALi/At) x (MCHC/Hb) x df x к 
where df = dilution factor = 8/21 and 
к = constant - 60 IO1 min/hr 
Sodium-lithium counlertransport was calculated from the dif­
ference between the lithium efflux rate in the sodium chlonde 
medium and in the potassium chloride medium The intra-assay 
vanation of our assay is 5%, while the inter-assay vanation was 
13% This inter-assay variation, representing both inter-test 
variability as well as biological variability, was measured by 
performing 4 to 6 measurements during a six week period in six 
individuals These figures arc comparable to those reported in 
the literature [21, 22] 
Measurement of NaLiCT after loading nith lithium chloride 
This method was carried out by a procedure identical to that 
described above except for the loading conditions Erythro­
cytes were suspended in lithium chlonde medium (150 тм 
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Fig. 2. Change (Δ) in intracellular bicarbonate concentration of eryth­
rocytes loaded with LiHCO, (O) or LiCl (U) 
lithium chloride, 10 т м glucose, 10 т м Tns-MOPS) and 
incubated for three hours Thereafter the cells were washed and 
efflux measurements were performed in the same way as 
mentioned above In 17 subjects NaLiCT measurements ob­
tained with both methods were compared In three subjects the 
change in intracellular bicarbonate concentration was measured 
after loading with LiHCO-, or LiCl and the complete washing 
cycle 
Statistical analysis 
All results are expressed as mean ± SD or as median (range) 
when the data were not normally distributed Wilcoxon's rank 
sum test for unpaired data was applied for comparison of the 
groups With Bonferroni adjustment for multiple comparisons 
the significance level was set at Ρ < 0 01 Correlations were 
measured as Spearman's correlation coefficients in all cases 
Comparison of the two methods for measurement of Nal iCT 
was performed according to the linear regression analysis of 
Passing and Bablok which was developed to compare analytical 
procedures [23] 
Results 
Validation of NaLtCT measurement 
Before measurement of the sodium stimulated lithium efflux 
an intracellular lithium concentration should be reached of at 
least 5 mmol/liter, since at that concentration the countertrans­
port is saturated [20] After loading of erythroctyes with 
LiHCO, or with LiCl, we analyzed the intracellular concentra­
tions obtained with both methods The lithium-influx as a 
function of the incubation time is shown in Figure I From this 
figure it is clear that the critical intracellular lithium concentra­
tion of 5 mmol/liter was reached much faster by loading with 
LiHCO, than by LiCl (20 vs 180 mm) During incubation with 
LiHCOj, Li+ is transported into the cell as LiCOJ' in exchange 
for Cl~ via the anion exchanger [24], but under these condi­
tions, HCO^" is also exchanged for CI" To evaluate this change 
we measured the change in the intracellular HCOJ concentra­
tion after loading with LiHCO, or LiCl As can be seen in 
Figure 2, there was indeed an increase in the intracellular 
HCO7 concentration after loading with HCO¡\ but during the 
wash cycles with KCl this was corrected via the same anion 
exchange At the moment the actual countertransport measure-
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Fig. Э. Lithium-efflux in sodium chloride medium (ШІШ) and potassium 
chloride medium (Ώ/Ο) of erythrocytes loaded in LiHCO; (Φ/Ο) or m 
LiCl (ΜΙΏ) as a function of time (mean of 6 measurements) 
ment began, the intracellular HC07 concentration was again 
identical to that of cells loaded with LiCl Also, the intracellular 
Cl~ concentration was identical after the washing procedure in 
cells either loaded with LiHCO, or LiCl (data not shown) 
Measurements of the Li efflux m a KCl medium (spontaneous 
lithium leakage) or in a NaCI medium (spontaneous leakage and 
sodium-lithium exchange) after loading with LiHCO, or LiCl 
were completely identical (Fig 3) To further substantiate this, 
we measured NaLiCT with both loading procedures in healthy 
subjects and in diabetic patients with and without DNP As can 
be seen in Table 1 the magnitude of the NaLiCT was identical 
for both methods If we compared NaLiCT activities obtained 
with the two different loading conditions according to the linear 
regression model of Passing and Bablok [23], we found an R2 of 
0 97 (Fig 4), indicating that the two loading procedures yielded 
identical results 
NaLiCT and diabetic nephropathy 
The clinical and laboratory data of the patients in study I are 
shown in Table 2 No difference was found in age or duration of 
diabetes in the diabetic patients with or without nephropathy 
There was a male preponderance in the renal disease groups 
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ТаЫе I Sodium lithium countertransport [median (range)] after 
loading of the red cells with LiHCCs or LiCI in patients with 
(DNP+) or without (DNP-) diabetic nephropathy and normal 
healthy controls 
LiHCO, LiCI 
Number μ/nol liter celh~' hr~' Ρ 
DNP+ 6 276(240-601) 280(248-608) NS 
DNP- 5 277 (221-360) 304 (232-350) NS 
Controls 6 254 (166-355) 255 (187-160) NS 
NS is not significant 
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Fig 4. Comparison of NaLtCT after loading of the erythrocytes и uh 
LiHCOj or LiCI Given are the regression line and the line of identity 
(dotted line) 
(DNP+ and RD) This is in line with the observations that male 
sex is prevalent in patients with either diabetic or non diabetic 
renal disease [25] By definition the patients with DNP had a 
higher AER and, as expected higher serum creatinine levels 
and blood pressure readings Cholesterol levels were equal in 
both diabetic groups From the patients with DNP, 15 patients 
had incipient diabetic nephropathy (median AER 72, range 27 to 
159 /xg/min) and 24 patients had overt diabetic nephropathy 
with a median AER of 432 (range 219 to 2846) pg/min In 
patients with DNP, the MAP was significantly higher than in 
diabetic patients without DNP (P < 0 001) Of the 24 patients 
with overt DNP, 15 had hypertension, and one of the patients 
with incipient DNP had hypertension None of the diabetic 
patients without DNP had hypertension Of the patients with 
non-diabetic renal disease (RD), 26 had renal disease which was 
glomerular in origin and 16 non-glomerular These two groups 
only differed for the magnitude of the proteinuria [median 3 8 
(0 1 to 19 7) vs 0 8 (0 1 to 5 8) g/mmol creatinine, Ρ < 0 01] 
Hypertension was present to the same extent in patients with 
glomerular RD (21/26, 81%) and in the patients with non-
glomerular RD (13/16, 81%) The blood pressure level was 
higher in the non-glomerular group (MAP 112 ± 13 vs 104 ± 9 
mm Hg, Ρ < 0 02) The serum creatinine was significantly 
higher in the RD patients than in either group of diabetic 
patients In normal controls the median NaLiCT was 244, range 
134 to 390 pmol liter cells" 1 hr"1 NaLiCT was elevated in 
all patient groups compared lo normal controls This increase 
Table 2. Clinical characteristics and metabolic parameters of patients 
with diabetes mellitus without (DNP-) or wiih nephropathy (DNP+) 
patients with non-diabetic renal diseases (RD) and of healthy controls 
Number 
M/F 
Age vears 
Diabetes duration 
years (range) 
НЬА
Ь :
% 
AER ng/mm 
Creatinine μ/nollliler 
Protein/creatimnc ratio 
glmmol x 10 
MAP mm Hg 
Prevalence of 
hypertension % 
Serum cholesterol 
mmoUUter 
Insulin dose 
D N P -
23 
10/13 
43 ± 9 
26 ± 8 
(18-44) 
8 8 ± I I 
7 
(3-19) 
83 ± 12 
ND 
93 ± 5 " 
0 
5 8 ± 0 8 
0 66 + 0 17 
DNP+ 
39 
24/15 
38 ± 12 
24 ± 7 
(10-37) 
9 1 ± 1 1 
258b 
(27-2846) 
103 ± 38 
ND 
101 ± 10 
41 
5 9 + 1 2 
0 72 + 0 22 
RD 
42 
26/16 
4 4 + 1 5 
NR 
NR 
N D 
399 + 286c 
2 6 
(0 1-19 7) 
107 ± 1I e 
81 
N D 
NR 
Controls 
24 
9/15 
31 ± 8 * 
NR 
NR 
ND 
81 ± 12 
0 
85 + 8 f 
0 
ND 
NR 
Data are given as mean + SD or as median and (range) Abbreviations 
are ND not determined NR not relevant AbR albumin excretion 
rate MAP mean arterial blood pressure 
" Ρ < 0 01 compared to DNP- and RD 
b
 Ρ < 0 01 compared to DNP-
' Ρ < 0 001 compared to DNP+ and DNP-
d
 Ρ < 0 001 compared lo DNP+ and RD 
• Ρ < 0 001 compared to DNP+ 
' Ρ < 0 01 compared to DNP-
was only significant for both the diabetic patient groups (P < 
0 01) NaLiCT in patients with DNP (median 314 range 162 to 
676) was not different from that in patients without DNP 
(median 325, range 189 to 627) or RD (median 300, range 142 to 
655 Fig 5) NaLiCT in patients with overt DNP (median 326, 
range 162 to 676) was not different from that of patients with 
incipient DNP (median 284, range 217 to 649) Also in patients 
with glomerular (median 321, range 142 to 614) or non-glomer­
ular renal disease (median 291, range 142 to 655) NaLiCT was 
not different In the two patients with renal disease secondary 
to hypertension, NaLiCT was respectively 211 and 271 
ujnol liter cells" ' hr ' No correlations were found between 
NaLiCT and age, HbA,t, creatinine, AER, body weight, MAP 
and total cholesterol (measured only in the diabetic patients) 
Of the 16 patients with DNP and hypertension, three (19%) had 
a NaLiCT > 400 μπιοί liter cells"1 hr"1 (the upper normal 
limit), whereas 8 of 23 (35%) of the patients with DNP without 
hypertension had a NaLiCT above this limit This indicates that 
hypertension in patients with DNP is not associated with an 
increased NaLiCT Of the 50 patients with hypertension, 47 
were receiving antihypertensive therapy Monotherapy was 
used in 23 patients (ACE inhibitors in 7, 0-blockers in 10, 
diuretics in 3 and calcium entry blockers in 3) A two drug 
regimen was used in 20 patients (ACE inhibitors or 0-blockers 
combined with a diuretic in 2 and 15 patients, respectively, and 
a 0-blocker combined with a calcium entry blocker in 3 pa­
tients) Triple therapy was used by four patients The type of 
antihypertensive drug or the combination used had no influence 
on NaLiCT Antihypertensive treatment was not discontinued 
before the NaLiCT measurement 
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Table 3. Clinical characteristics and metabolic parameters of 
probands and sibs concordant (DNP+/+) or discordant (DNP+/-) 
for diabetic nephropathy and probands and sibs both without diabetic 
nephropathy (DNP-/-) 
Sib pain 
Number 
M/b 
Age yean (range) 
Diabetes duration 
years (range) 
Age at onset of 
diabetes years 
(range) 
HbA,
c
 % 
AER μξ/τπίη (range) 
Cholesterol mmollhter 
Creatinine цліоі/інег 
Systolic BP mm Hg 
Diastolic BP mm Hg 
DNP+/+ 
5 
10 
4/6 
33 ±4» 
(27-39) 
25 ± 6 
(15-35) 
9 ± 5 ' 
(2-19) 
8 6 * 0 7 
373 ± 491' 
(31-1378) 
6 5 * 1 5 
113 ±42" 
133 ± 15 
82 ± 9 " 
DNP+/-
4 
9 
6/3 
42 ± 5 
(32-50) 
24 ± 7 
(17-39) 
18 ± 7 
(4-33) 
9 2 * 1 3 
199 ± 302 
(4-907) 
6 1 * 0 8 
8 4 * 11 
142 ± 19 
79 ± 10 
DNP-/-
7 
15 
6/9 
4 6 ± 9 
(32-61) 
27 ± 9 
(18-^ (4) 
19 ± 10 
(17-39) 
88 ± 1 1 
7 ± 3 
(2-12) 
58 ± 0 7 
82 * 12 
133 ± 12 
75 ± 6 
Data are given as mean ± SD, ranges are given in parenthesis 
• P < 0 O 0 l 
" Ρ < 0 05 
NaLiCT and familial diabetes 
To study whether an elevated NaLiCT clustered with familial 
occurrence of DNP 16 probands with long standing (>15 years) 
type 1 diabetes mellitus who had at least one sib also with type 
I diabetes mellitus for more than 15 years could be selected 
The eight probands with DNP had nine sibs with diabetes, of 
whom five had DNP, in contrast to only one out of nine sibs of 
the eight probands without DNP This increased prevalence of 
DNP in sibs of probands with DNP indicates a trend towards 
familial clustering of DNP, which however, was not statistically 
significant Table 3 shows the clinical and metabolic data of the 
patients studied Three groups of siblings were formed one 
with probands and sibs concordant for the presence of nephrop­
athy (DNP+/+), a second group with probands and sibs con­
cordant for absence of nephropathy ( D N P - / - ) and a group 
with probands and sibs discordant for nephropathy ( D N P + / - ) 
Age at onset of diabetes was significantly lower in the DNP+/+ 
group Diabetes duration was the same in all groups Diastolic 
blood pressure and serum creatinine were also significantly 
increased in the DNP+/+ group The correlation between 
NaLiCT in probands and sibs was not significant (r
s
 = 0 48, Ρ 
= 0 06), which confirms the weak genetic basis of NaLiCT 
NaLiCT did not differ between DNP+/+ (median 307, range 
217 to 428 μπιοί liter cells ' hr"') and D N P - / - (median 
279, range 189 to 442), but was significantly increased in 
D N P + / - (median 468, range 310 to 649, Ρ < 0 02, Fig 6) The 
two highest NaLiCT levels in this group come from a sister and 
brother with and without nephropathy, respectively In two 
DNP+/+ families and three D N P - / - families a positive history 
of parental hypertension was present In four families the 
history of parental hypertension was not clear (three in the 
D N P - / - and one in the DNP+/+) These data do not permit a 
conclusion whether hypertension was more prevalent in parents 
of sibs with DNP 
Discussion 
As already mentioned, it is at present not known which 
factors determine the development of nephropathy in Type 1 
(insulin-dependent) diabetes mellitus Although metabolic con­
trol is certainly an important factor [3, 4], it is generally 
accepted that other factors are also involved Recently, the 
predisposition to essential hypertension [8, 10, 11] was put 
forward as an important risk factor This was based on the 
presence of an increased prevalence of two indicators for a 
genetic predisposition to essential hypertension in patients with 
DNP a) hypertension in non-diabetic parents and b) an in­
creased NaLiCT As indicated in Ί able 4 this increased activity 
of NaLiCT was initially reported in patients with overt DNP 
[10, II] and subsequently also m patients with incipient DNP 
[12] Furthermore, it was found that normoalbuminunc diabetic 
patients with an increased NaLiCT had evidence for glomerular 
hyperfiltration [13] This led to the conclusion that an increased 
NaLiCT might be useful as an early predictor of nephropathy in 
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Table 4. Review of the literature on sodium-lithium countertransport in patients with diabetic nephropathy (DNP+). without nephropathy 
(DNP-), non-diabetic renal disease (RD) and in healthy controls 
400 
1 
2 
3 
4 
5 
6 
Author 
[refi 
Krolewskiet al [10] 
Mangili et al [111 
Jones et al [12] 
Carretal [13] 
Jensen et al [17] 
Elving et al (this 
study) 
Loading 
procedure 
LiCl 
L i d 
liCI 
LiCI 
LiHCO, 
LiHCOj 
DNP+ 
Mean ±. SD 
or median 
(range) 
510 ± 229 
(210-1400) 
550 * 190 
(180-880) 
430 
(190-750) 
ND 
480 
(60-1200) 
314 
(162-676) 
%> 400" 
60 
87 
55 
— 
71 
28 
D N P -
Mean ± SD 
or median 
(range) 
180 ± 162 
(20-780) 
330 ± 160 
(100-680) 
290 
(110-600) 
330 
(130-590) 
410 
(120-750) 
325 
(189-627) 
% > 
400 
38 
15 
17 
33 
53 
26 
RD 
Mean t SD 
or median 
(range) 
ND 
310 ± 140 
(120-580) 
ND 
N D 
N D 
300 
(142-655) 
27 
24 
Controls 
Mean ± SD 
or median 
(range) 
N D 
2 8 0 * ·> 
(120-410) 
ND 
240 
(20-390) 
310 
(180-730) 
244 
(134-390) 
%> 400 
-
) 
— 
0 
25 
0 
'% patients with NaLiCT > 400 /¿mol liter cells"1 hr 
type I diabetes Several mechanisms have been proposed to 
explain the association between predisposition to essential 
hypertension and DNP [10-12] It has been hypothesized that 
predisposition to essential hypertension is related to genetically 
determined abnormalities in renal hemodynamics [26-28] 
These derangements in combination with diabetes-associated 
alterations in renal hemodynamics, together with poor meta-
bolic control, could then lead to the development of DNP The 
findings of Carr et al [13] are compatible with this contention, 
because they could identify within a group of normoalbuminunc 
type 1 diabetes a subgroup of patients with hyperfiltration, by 
means of an increased NaLiCT A second explanation that has 
been raised for the association between DNP and elevated 
NaLiCT is that the NaLiCT activity is at least functionally 
related to the sodium-hydrogen antiport [29—31] The activity of 
the Na*/H+ antiporter is responsible for the proximal tubular 
sodium-reabsorption and regulation of cell pH, cell volume and 
vascular tone [30, 31] If an increased NaLiCT reflects an 
elevated activity of the Na + /H + antiporter, it may be associated 
with increased renal sodium retention, leading to an expanded 
extracellular volume [32] and increased vascular tone This idea 
is consistent with the finding of sodium retention in some 
patients with diabetes [33, 34] Irrespective of the responsible 
mechanism, an increased systemic arterial pressure can lead to 
an increased intraglomerular pressure because most diabetic pa-
tients show, dependent of their actual metabolic control, a preglo-
merular vasodilation which facilitates the transmission of systemic 
hypertension to the glomerular capillaries This glomerular hyper-
tension aggravates the glomerular alterations secondary to diabe-
tes, and may thereby lead to the full clinical picture of DNP A 
third explanation that has been advocated is that an increased 
NaLiCT is a marker for an increased peripheral insulin resistance 
[35], which itself is associated with hyperhpidemia, hypertension 
and increased cardiovascular mortality [36] Furthermore, an 
increased NaLiCT is associated with higher levels of cholesterol 
and VLDL-tnglycendes and with lower levels of HDL-cholesterol 
[37-39] This more atherogenic lipoprotein profile may be a 
permissive factor for the development of DNP 
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The enthusiasm about the initial idea that an increased 
NaLiCT might be useful to identify patients at nsk for the 
development of DNP has been tempered by more recent 
findings Our study does not confirm the findings of the initial 
reports [10-13] We found no differences in NaLiCT between 
patients with or without DNP, and with non-diabetic patients 
with other renal diseases, although patients with diabetes 
mellitus had higher NaLiCT values than healthy control sub­
jects Since the majority of the patients in the initial studies had 
overt DNP and hypertension, we analyzed whether patients 
with hypertension or overt DNP had higher NaLiCT activity 
This was found not to be the case After we had finished our 
studies [15, 16] results were published by English and Danish 
investigators on the relation between a genetic predisposition to 
hypertension and the occurrence of DNP [17,40) In contrast to 
earlier observations [8] no difference was found in blood 
pressure of parents of diabetic patients with DNP, compared to 
parents of patients without DNP In both studies a significant, 
although weak, correlation was found between NaLiCT in 
parents and children, in agreement with the presence of genetic 
determinants in NaLiCT However, the results of NaLiCT 
measurements in these two studies were quite different In the 
study of Walker, Tanq and Viberti [40] patients with and 
without DNP showed a clear difference in NaLiCT, whereas 
Jensen et al [17] could not find a difference in this respect, either 
when patients with or without DNP, or when parents of diabetic 
patients with or without DNP were compared In the latter 
study, all patients had a higher activity of NaLiCT than healthy 
controls Our study as well as the studies of Jensen et al [17] and 
Gall et al [41] (in type 2 diabetic patients) do not confirm that an 
increased NaLiCT is a genetic risk marker for the development 
of DNP This is further substantiated by our finding in familial 
DNP, in which sib pairs concordant for the presence of DNP 
had the same magnitude of NaLiCT as sib pairs concordant for 
the absence of DNP So, even in patients in whom the occur 
rence of DNP is clearly genetically determined, NaLiCT cannot 
be used as a marker for DNP 
Theoretically these differences in results might be due to 
differences in methodology of NaLiCT measurement Several 
methods are used to measure NaLiCT, which vary especially 
for the procedure used to load the erythrocytes with lithium, 
that is a) loading with 150 тм LiCl [9, 11-13], b) loading with 
10 тм LiCl and nystatin [10] or c) loading with 150 тм LiHCO, 
[this study, 17, 41] The disadvantage of loading the erythro­
cytes with LiCl is that it takes three hours before the intracel­
lular lithium concentration is above 5 mmol liter cells'' (Fig 
1), at which concentration the NaLiCT is saturated [20] By 
adding nystatin to the incubation medium, the lithium influx is 
enhanced, because nystatin disturbs the integrity of the cell 
membrane and thereby increases the permeability for ions It is 
not known whether this rather drastic procedure might have an 
effect on the function of the delicate transmembrane transport 
ers We therefore chose LiHCO, as loading medium, as orig­
inally described by Ibsen et al [20] Using these conditions 
lithium is transported into the cell via anion exchange [24] This 
is a much faster process than exchange diffusion, which takes 
place during loading with LiCl A second difference between 
our method and those applied by others [10-13] is that the 
sodium independent efflux is measured in a KCl medium instead 
of a MgClj medium as originally described by Canessa et al [9] 
Previous studies by Ibsen et al [20] have shown that this 
sodium-independent spontaneous lithium efflux is identical in 
KCl, MgCI, and choline chloride medium In the first four 
studies listed in Table 4, showing that the NaLiCT was elevated 
in DNP, LiCl was used as loading medium, whereas in the last 
two studies, in which LiHCO, was used, no differences be­
tween patients with and without DNP were found This might 
suggest that the outcome of these studies is influenced by the 
method used to measure NaLiCT Several observations, how­
ever, indicate that both methods are equally reliable First, our 
value for NaLiCT in normal controls is comparable to that 
reported in the literature (Table 4) [22] Second, both loading 
procedures achieve an intracellular lithium concentration above 
the critical value at which the countertransport is saturated [20] 
The final proof that differences in methodology are not respon 
sible for the observed differences in results, comes from our 
observation that the NaLiCT measured after both loading 
procedures is identical (Table 1, Fig 4) 
We cannot offer a clear explanation for the differences in 
results If one analyzes the different studies with regard to the 
proportion of patients who have a NaLiCT above the upper 
limit of normal controls, that is, 400 μιηοΐ liter cells-' hr ' 
(Table 4), one finds identical values in patients with non-
diabetic renal diseases (studies 2 and 6) and in patients without 
DNP (studies 1 to 4 and 6) except for study 5 In the last study, 
however, the median value for the NaLiCT is rather high in all 
groups, and a considerable proportion of the normal controls 
(25%) has a NaLiCT above 400 ^mol liter cells ' hr"' This 
discrepancy might be explained by a difference in time of blood 
sampling In the Danish study, blood was collected in the 
afternoon It was recently reported that NaLiCT has a diurnal 
rhythm, the activity increasing during the day [42] The major 
difference for the proportion of patients with a NaLiCT > 400 
μπιοί liter cells" ' hr ' in the various studies listed in Table 
4, is observed in patients with diabetic nephropathy It is known 
that NaLiCT can be influenced by several exogenous factors 
such as oral contraceptives, hypokalemia [43], pregnancy [44], 
thyroid hormones [45], factors that influence the intracellular 
calcium concentration [46], exercise [47], lead [48], prednisone 
[49], and most importantly, lipid profiles [38, 39] Recently, it 
was shown that LDL-apheresis induces an acute change in 
NaLiCT [50] Although it has been claimed that impaired 
kidney function can increase NaLiCT [51, 52], others could not 
confirm these data [53, 54] Since the NaLiCT in our group of 
patients with non diabetic renal disease was comparable to that 
in patients without DNP, irrespective of a much higher serum 
creatinine in the first group, impaired kidney function can be 
excluded as an important factor influencing NaLiCT Differ­
ences in lipid profiles might be an explanation for the differ­
ences observed with regard to NaLiCT in DNP It is known that 
serum lipid profiles [38 39], as well as the lipid composition of 
the cell membrane [55] influence NaLiCT The importance of 
this is reflected by a recent study of Jones et al [12], who 
concluded that in microalbuminunc diabetic patients, NaLiCT 
is related to total and VLDL triglycerides independent of 
HbA|C, AER, insulin dose and body mass index They did not 
analyze whether Nal iCT was still elevated in microalbuminunc 
patients when differences in the lipid profile were taken into 
account It is known that even in microalbuminunc patients the 
lipid profiles are disturbed [56] In most [10, II, 13, this study]. 
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ТаЫе 5. Influence of low sodium diet (3 g NaCI/day) and high 
sodium diet (12 g NaCl/day) on unnary sodium excretion (U N a V) 
fractional sodium excretion ( F E N a ) fractional lithium excretion 
( F E L | ) and sodium-lithium countertransport (NaLiCT) in 10 normal 
controls 
Low salt High salt 
27 ± 15 
0 28 ± 0 17 
25 0 ± 5 5 
257 ± 55 
245 ± 41" 
1 06 ± 0 31* 
32 5 ± 14 5" 
243 ± 38 
U N , V mmoll24 hr 
F E N , % 
F E , , % 
NaLiCT μτηοΙ liter 
cells ' hr' 
Data are given as mean : 
" . P < 0 0 l 
b u t n o t all s t u d i e s [12, 17] o n t h e r e l a t i o n b e t w e e n N a L i C T a n d 
D N P n o c o r r e l a t i o n w a s found b e t w e e n M A P a n d / o r anti­
h y p e r t e n s i v e t r e a t m e n t a n d t h e m a g n i t u d e of t h e N a L i C T By 
c o n t r a s t this c o r r e l a t i o n is in g e n e r a l p r e s e n t in p a t i e n t s with 
e s s e n t i a l h y p e r t e n s i o n [57, 58] T h i s di f ference is r e m a r k a b l e 
a n d again ra i ses t h e poss ibi l i ty t h a t t h e i n c r e a s e in N a L i C T in 
D N P f o u n d b y s o m e i n v e s t i g a t o r s is s e c o n d a r y t o n o n - g e n e t i c , 
e x o g e n o u s f a c t o r s U n f o r t u n a t e l y , o u r s t u d i e s w e r e n o t de­
s igned t o s tudy t h e p o t e n t i a l effect of e x o g e n o u s f a c t o r s on 
N a L i C l , t h e r e f o r e w e c a n n o t e v a l u a t e a p o s s i b l e c o n t r i b u t i o n 
of t h e v a r i o u s m e n t i o n e d f a c t o r s on t h e m a g n i t u d e of the 
N a L i C T in o u r p a t i e n t s 
After t h e finding that t h e N a L i C T w a s e l e v a t e d in D N P , the 
h y p o t h e s i s h a s b e e n put forth that this w a s a n i n d i c a t o r for an 
i n c r e a s e d act iv i ty of t h e s o d i u m - p r o t o n e x c h a n g e r in t h e renal 
p r o x i m a l t u b u l e I n e s s e n t i a l h y p e r t e n s i o n a n i n v e r s e corre la­
t i o n w a s d e s c r i b e d b e t w e e n red cell N a L i C T a n d f ract ional 
l i thium e x c r e t i o n ( F E L | ) [32], a n i n d i c a t o r for p r o x i m a l t u b u l a r 
s o d i u m r e a b s o r p t i o n [59] In v i t r o s t u d i e s , h o w e v e r , h a v e 
s h o w n t h a t b o t h c a t i o n t r a n s p o r t s y s t e m s s h o w a differential 
sens i t iv i ty t o a m i l o n d e , t h e N a + / H + a n t i p o r t c r be ing sens i t ive 
in c o n t r a s t t o N a L i C T [60, 61) W e a n a l y z e d t h e re lat ion 
b e t w e e n N a L i C T a n d F E L , b y m e a s u r i n g b o t h p a r a m e t e r s in 
h e a l t h y v o l u n t e e r s after high a n d low d i e t a r y salt i n t a k e [62] A s 
e x p e c t e d t h e F E L l w a s c l e a r l y inf luenced by t h e a m o u n t of 
d i e t a r y salt i n t a k e ( T a b l e 5), but t h e N a L i C T w a s n o t influ­
e n c e d D u r i n g high a n d low salt i n t a k e b o t h , w e found n o 
c o r r e l a t i o n b e t w e e n N a L i C T a n d F E [ „ whi le F E t , w a s signif­
icant ly c o r r e l a t e d wi th t h e f ract ional s o d i u m e x c r e t i o n u n d e r 
b o t h diet r e g i m e n s ( r
s
 = 0 6 5 , Ρ < 0 05) T h i s conf i rms ear l ier 
s t u d i e s in w h i c h n o r e l a t i o n w a s f o u n d b e t w e e n N a L i C T a n d 
p r o x i m a l t u b u l a r s o d i u m h a n d l i n g [29, 6 3 , 64] T h e s e in v i t ro 
a n d in vivo findings d o n o t s u p p o r t t h e h y p o t h e s i s t h a t N a L i C T 
is funct ional ly r e l a t e d t o p r o x i m a l t u b u l a r N a + / H + e x c h a n g e 
T h i s is fur ther s u b s t a n t i a t e d b y t h e v e r y r e c e n t finding t h a t 
N a L i C T is n o t l inked t o t h e N a * / H + a n t i p o r t e r g e n e [65] 
In c o n c l u s i o n , N a L i C T is i n c r e a s e d in p a t i e n t s w i t h t y p e 1 
d i a b e t e s mel l i tus , p r o b a b l y d u e t o e x o g e n o u s f a c t o r s It c a n n o t 
be u s e d , h o w e v e r , t o d e t e c t p a t i e n t s a t r i sk for t h e d e v e l o p m e n t 
of d i a b e t i c n e p h r o p a t h y . 
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A Comparison of the Hypotensive Effects 
of Captopril and Atenolol in the Treatment 
of Hypertension in Diabetic Patients 
L. D. EJving, MD, E. de Nobel, MD, H. ƒ. ƒ. van Lier, MSc, and Th. Thien, MD 
In a double-blind, randomized, cross-over study in 23 diabetic patients, insulin treated 
(N = 11) or noninsulin treated (N = 12), with mild to moderate hypertension, the hypo­
tensive effects of Captopril and atenolol were compared Five patients had overt diabetic 
nephropathy All patients received 50 mg twice daily of either drug Treatment periods 
lasted 6 weeks and were preceded and separated by a placebo period Two patients 
dropped out, one because of intermittent claudication during atenolol, one with cardiac 
arrhythmia during placebo Blood pressure was reduced /rom 165 ± 5/96 ± 1 to 154 
± 5/89 ± 2 mmHg (mean ± SEM Ρ < 0 01) during Captopril and from 171 ± 5/98 ± 1 to 
159 ± 6/89 ± 2 mmHg (Ρ < О 01) during atenolol These antihypertensive effects are not 
significantly different There was a wide inter- and intraindividual variation in hypo­
tensive response to both drugs, which may have important consequences for treatment 
strategies No consistent differences between insulin and noninsulin treated patients 
were seen Parameters of glycémie control did not change during any therapy, neither in 
insulin treated nor in non-insulin treated patients Albuminuria and renal /unction did 
not change During Captopril treatment one patient complained of a non-productive 
cough Two patients experienced a severe hypoglycemic reaction during atenolol No 
other major side-effects were seen In conclusion, this study showed equal hypotensive 
e/fectivity of 100 mg Captopril and 100 mg atenolol daily in hypertensive diabetics, 
without evident effect on glycémie control 
Hypertension and diabetes mellitus are often seen in combination. ' Lowering of arterial blood 
pressure slows the deterioration of renal function in 
diabetic nephropathy2 and may also reduce cardio-
vascular mortality,3 Effective treatment of hyper-
tension with regular drugs in diabetics is limited by 
interference with glycémie control (thiazides), or 
with the symptoms of hypoglycemia (beta-adreno-
ceptor antagonists) or with baroreceptor regulation 
(alpha-adrenoceptor antagonists and postganglionic 
neuronblockers).4"6 Therefore the angiotensin-con-
verting enzyme (ACE) inhibitors, e.g Captopril, may 
be an alternative, if also for diabetic patients the 
reported good tolerance7 can be confirmed. In this 
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dress tor reprints L D Elving, Department of Medicine, University 
Hospital, Geert Grooteplein Zuid β, 6525 GA Nijmegen, The Nether­
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double-blind study we compared the hypotensive 
efficacy of the ACE-inhibitor Captopril with a /8,-se-
lective adrenoceptor antagonist, atenolol, with spe­
cial attention to changes in diabetes control, renal 
function, proteinuria and to side-effects. 
SUBJECTS AND METHODS 
Patients with diabetes mellitus, insulin treated or 
noninsulin treated, with mild to moderate hyper­
tension were selected from the outpatient clinic. 
Excluded from the study were women with child-
bearing potential, pat ients with impaired renal 
function (creatinine clearance > 60 ml/min), ortho­
static hypotension, angina pectoris, congestive heart 
failure, chronic respiratory disease, documented 
renal artery stenosis, collagen disease, proliferative 
diabetic retinopathy and patients using nonsteroidal 
antiinflammatory drugs, Cimetidine or allopurinol. 
Twenty three patients (11 insulin treated) were able 
and willing to join the study. Twelve patients had 
previously used antihypertensive drugs, seven ei-
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ther a beta-adrenoceptor antagonist (/3-blocker) or 
thiazide diuretic, and five the combination. All pa­
tients gave oral informed consent; the hospital ethi­
cal committee approved the protocol. 
The study was designed as a double blind, ran­
domized, cross-over trial. All antihypertensive 
treatment was discontinued. The patients had unre­
stricted salt intake. After a wash-out period of at 
least six weeks patients were randomly assigned to 
initial treatment with Captopril (С) or atenolol (A). 
The study comprised four periods, i.e. a placebo pe­
riod of 4-6 weeks, an initial treatment period of 6 
weeks, a second placebo period of 4-6 weeks and a 
second period of 6 weeks with the alternative treat­
ment. These periods were considered to be long 
enough to warrant a stable level of blood pressure to 
be reached. Since Captopril and atenolol tablets do 
not look alike, each patient took two tablets twice 
daily during the entire study, in order to preserve 
the double blindness: either Captopril + placebo-
atenolol or atenolol + placebo-captopril or two times 
. two placebo tablets. The dosage of both drugs was 50 
mg twice daily. Before the start of the study each 
patient received a test dose of 25 mg Captopril during 
blood pressure monitoring because of the possibility 
of first-dose hypotension.8 
Patients visited the outpatient clinic every two 
weeks at least 1 hour after ingestion of the last dose. 
Blood pressure was always measured by the same 
observer (L.E.) with a random zero sphygmomano 
meter (Hawksley), after 5 min rest in the supine posi­
tion and immediately after standing up (mean of two 
readings each time). Phase V of the Korotkoff sounds 
was considered as the diastolic blood pressure. Mean 
arterial pressure (MAP) was calculated as the sum of 
the diastolic blood pressure and one third of the 
pulse pressure. Blood pressure was also at each visit 
measured with the Arteriosonde Roche (noninva­
sive automatic blood pressure monitor) during 20 
minutes supine rest at 2 minute intervals. Except for 
the first two and the last one, all readings of one visit 
were averaged. Blood samples were drawn for deter­
mination of creatinine, glucose and a complete blood 
count, using routine analytical methods. HbAl was 
measured with a microcolumn method (Isolab, nor­
mal value 5.3-7.7%). Twenty four hours urine was 
collected the day before each control visit for mea­
surement of glucose, creatinine, albumin, and was 
tested for ketones. Albumin concentrations in urine 
were measured by a modified laser nephelometric 
method (detection limit 0.5 mg/L).9 To assess patient 
compliance, at the end of each period the remaining 
tablets were counted and plasma renin activity 
(PRA) was determined.10 After each period all pa­
tients filled in a questionnaire concerning adverse 
effects. Patients were withdrawn from the study 
when severe adverse reactions appeared. All data 
were calculated as the means of the values mea­
sured at the last two visits of each period. Values are 
given as mean ± SEM unless indicated otherwise. 
Data from each treatment period, for each patient 
separately, were compared with the preceding pla­
cebo period. Statistical analysis comprised Wilcoxon 
matched pairs (signed-ranks) test and rank sum test, 
and the test proposed by Koch." 
RESULTS 
Two patients did not complete the study. One pa­
tient (a 68-year-old woman) dropped out because of 
disabling complaints of intermittent claudication 
during the second treatment period when she was 
on A. The other patient (a 65-year-old woman) was 
withdrawn because of paroxysmal supraventricular 
tachycardia during placebo after the first treatment 
period (with C). Thus twenty one patients could be 
evaluated. Their major characteristics are listed in 
Table I. There were no significant differences be­
tween insulin treated and non-insulin treated pa­
tients in natriuresis, renal function, pre-treatment 
PRA and blood pressure. After analysis had shown 
that the antihypertensive effects were not different, 
data of insulin treated and noninsulin treated pa­
tients were taken together. There were no signifi­
cant carry-over effects: blood pressure at the end of 
the first placebo period was not significantly differ­
ent from that at the end of the second placebo period 
and there were no timé related or sequence effects. 
Mean supine blood pressure measured by random 
zero meter fell from 165 ± 5/96 ± 1 to 154 ± 5/89 ± 2 
mmHg (Ρ < 0.01) during Captopril and from 171 
± 5/98 ± 1 to 159 ± 6/89 ± 2 mmHg (Ρ < 0.01) during 
atenolol. Measured by arteriosonde mean supine 
blood pressure fell from 160 ± 5/96 ± 2 to 150 
± 5/90 ± 2 mmHg during Captopril and from 167 
± 5/100 ± 2 to 154 ± 6/88 ± 2 mmHg during A. The 
effects on supine and erect blood pressure and heart 
rate are' shown in Figure 1. The readings done by 
arteriosonde and randomzero correlated well 
(Spearman correlation coefficients 0.92 and 0.78 for 
systolic and diastolic pressure). Figure 2 shows the 
individual changes of MAP. Mean decrease of MAP 
during С was 7.4 ± 1.4% and during A 7.3 ± 1.8%. 
There was, however, a considerable intra- and in­
terindividual variation in hypotensive effectivity of 
the drugs. A diastolic blood pressure below 90 
mmHg, with a fall of at least 5% was reached in 12 
patients during С and in 10 patients during A. The 
hypotensive effects were not related to pre-treat­
ment PRA. Type of diabetes nor gender had signifi­
cant influence on change in blood pressure. 
As is shown in Table II, no significant effect of 
either drug was seen on variables for glycémie con-
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TABLE I 
Clinical Characteristics of the Patients Studied. Values Are Given as Mean ± SD (range) 
or as Number of Patients 
Total Iniulln Treated Non-lniulln Treated 
number 
sex (M/F) 
age (yrs) 
known duration of diabetes (yrs) 
known duration of hypertension (yrs) 
Quetelet index 
Endogenous creatinine clearance 
(ml/min) 
Bloodpressure before study (mmHg) 
supine 
erect 
PRA (ng/ml/hr) 
Natriuresis (mmol/24hr) 
21 
8/13 
49 ± 15 
12 ± 9 
12 ± 13 
25.9 ± 4.7 
102 ± 21 
171 ± 22/100 ± 
169 ± 22/105 ± 
1.53 ± 1.04 
177 ± 60 
6 
10 
11 
6/5 
42 ± 16 
15 ± 10 
7 ± 9 
24.0 ± 4.7 
98 ± 2 3 
169 ± 25/100 ± 6 
165 + 2 6 / 1 0 6 + 11 
1.35 ± 0 . 8 9 
159 ± 43 
10 
2/8 
57 ± 11 
9 ± 6 
19 ± 14 
25.0 ± 3.9 
106 ± 2 0 
174 ± 20/100 ± 6 
173 ± 16/104 ± 9 
1.74 ± 1.18 
198 ± 74 
Quetelet index is defined as body weight divided by length1 PRA plasma renin activity (9). 
trol or renal function. Positive urine ketone tests 
were seen occasionally in two insulin requiring pa­
tients independently from therapy with C, A or P. In 
one patient on diet alone, a positive test was found 
once during C. Two severe hypoglycemic episodes 
with coma were seen during A. Both patients were 
known for having hypoclycemic episodes, but coma 
had never occurred before. Two male patients no­
ticed cold hands and feet during A and as already 
mentioned, one patient left the study because of in­
termittent claudication. One female patient com­
plained of a nonproductive cough starting during С 
and immediately resolving afterwards. The ques-
tionaire filled in by each patient yielded no further 
signs of side-effects i.e. no symptoms which were not 
already present during the placebo periods. There 
were no changes in hematological tests. 
Tablet counts suggested a consumption of 88 
± 11% for С and 90 ± 11% for A (NS). Four patients 
had tablet a consumption less than 80%. During A 
pulse rate decreased in all but one patient, the mean 
going from 80 ± 2 to 66 ± 2 beats/min (P < 0.01). 
During C, pulse rate remained unchanged (80 ± 2 
beats/min). 
Baseline PRA before the first dose of Captopril was 
1.53 ± 1.04 (SD) ng/ml/hr in the whole group, 
which was not significantly different from baseline 
values in a control group of 69 patients with essen­
tial hypertension without diabetes (2.07 ± 2.74 
ng/ml/hr). PRA rose in all patients during chronic 
treatment with C, from 1.45 ± 0.24 to 4.43 ± 0.65 
ng/ml/hr (P < 0.01). During A, PRA fell in 19 out of 
the 21 patients, from 1.38 ± 0.23 to 0.61 ± 0.13 
ng/ml/hr (P < 0.01). 
DISCUSSION 
ACE-inhibitors are quickly gaining a place in the 
treatment of hypertension. This study demonstrates 
that in patients with diabetes mellitus the ACE-in-
Blood pressurelrmnHg ) 
ISO η 
Heart rate (bom ) 
ЮО-і 
placebo Captopril 
Figure 1. Blood pressure and heart raie fmean ± SEM) during 
treatment with Captopril and atenolol and the preceding placebo 
periods, hatched bars: random zero supine; black bars: arterio-
sonde supine; white bars; random zero erect; open circles; heart 
rate supine; closed circles: heart rate erect. 
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Figure 2 Relative changes of mean arterial pressure (MAP) in 
individual patients (numbered 1 to 23) during therapy with Capto-
pril and alenoioJ Patients 6 and 14 have dropped out Biood pres-
sure measured by random zero meter Note the wide inter- as weìì 
as intra individual variations 
hibitor Captopril has a hypotensive effect similar to 
that of atenolol, when both are used in a total daily 
dose of 100 mg. We have chosen a cross-over model 
with a sufficiently long wash out period. Negative 
consequences of this design (i.e. carry-over effects, 
time- and sequence-related effects) could not be 
demonstrated. Blood pressure was measured with 
objective methods, using a random zero meter (2 
readings) and an automatic recorder (Arteriosonde; 
В readings). This rules out possible observer bias. 
The dose of the drug under investigation, Captopril, 
is as actually recommended, 50 mg twice daily. For 
practical reasons atenolol was not given once daily 
but also given in two doses of 50 mg. Compliance 
with both drugs was acceptable and similar. The 
reduction of blood pressure during Captopril (11/7 
mmHg) or atenolol (12/9 mmHg) was similar. Re­
spectively 12 and 10 patients reached a diastolic 
blood pressure below 90 mmHg. 
In our diabetic patients PRA was normal, which is 
in agreement with data from other authors.12 ' 3 As a 
sign of good compliance PRA rose during therapy 
with Captopril in all patients. 
Variables of glycémie control did not change in 
our patients during treatment with either drug. In a 
long term study in nondiabetics no diabetogenic ef-
fect of Captopril was found.14 Evidence on hypogly-
cemic episodes during Captopril in patients with 
diabetes has been conflicting.13 '8 We did not find a 
significant increase in the occurrence of symptom-
atic or biochemical hypoglycemia during either С or 
A, as compared with placebo. The two episodes of 
unconsciousness, however, which occurred during 
atenolol in patients who earlier tolerated hypoglyce­
mic reactions well, might be regarded as illustra­
tions of the well documented masking of the warn­
ing symptoms of hypoglycemia during beta-adreno-
ceptor blockade.6 Higher doses of Captopril (over 300 
mg daily) may cause false-positive urine ketone 
tests, interfering with assessment of diabetic con­
trol.14 We have not observed this phenomenon, ex-
TABLE II 
Variables of Metabolic Control, Renal Function and PRA During The Treatment Periods and The Preceding 
Plasma-glucose 
(mmol/l) 
HbAl (%) 
Glucosuria (g/24hr) 
Creatinine Clearance 
(ml/mm) 
Albuminuria 
(mg/24hr) 
(N = 9) 
PRA (ng/ml/hr) 
Placebo Periods Values 
Placebo 
13.3 ± 1.0 
10.2 ± 0.5 
22(0-111) 
101 ± 10 
579 
(58-1242) 
1.45 ± 0.24 
are Mean ± SEM or Median (Range). 
Captopril 
Therapy Placebo 
12 6 ± 1 . 0 11.5 ± 0 8 
10 0 ± 0 . 5 9.9 ± 0 4 
17(0-64) 18 (0-93) 
100 ± 10 98 ± 8 
534 643 
(18-1912) (43-2314) 
4 43 ± 0.65· 1.38 ± 0.23 
Atenolol 
Therapy 
11.3 ± 0 . 9 
10.3 ± 0.4 
24 (2-80) 
100 ± 9 
573 
(20-1878) 
0.61 ± 0 . 1 3 * 
• P < 0 01 
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cept in one patient treated with diet alone. As to 
other side-effects, the nonproductive cough in one 
patient was clearly related to the use of Captopril and 
is recognized as a side-effect of all currently avail­
able ACE-inhibitors.20 Other side-effects such as 
rash, disturbance of taste or neutropenia21 were not 
seen. The intermittent claudication and the cold 
hands and feet may be considered as related to the 
0-blocker. 
We found no significant change in macro- or mi­
croalbuminuria. Early reports on aggravation of pro­
teinuria during Captopril have led to a prudent atti­
tude towards patients with pre-existing renal dis­
ease, such as diabetic nephropathy21 a Since then, 
however, the opposite phenomenon, a substantial 
reduction of the (heavy) proteinuria in 9 patients 
with diabetic nephropathy was reported.23 This has 
been confirmed in other studies, describing a reduc­
tion of the albumin excretion rate during treatment 
with ACE-inhibitors.24 2 5 
In half our patients the therapeutic goal (diastolic 
pressure below 90 mmHg) was not achieved with 
either drug alone. The obvious next step in these 
sub)ects is the addition of a diuretic.26 It is important 
to notice the wide variations of the blood pressure 
responses to the two drugs (Figure 2) Therefore, in 
patients who do not respond to one drug, replace­
ment of this drug should be considered rather than 
the addition of a second drug 
In conclusion this short study shows that Captopril 
and atenolol are equally effective and safe as anti­
hypertensive drugs in diabetic patients with normal 
or near-normal renal function. Long-term studies, 
however, are needed to confirm this conclusion. 
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Captopril Acutely Lowers Albuminuria in Normotensive Patients 
With Diabetic Nephropathy 
L.D. Elving, MD, J.F.M. Wetzeis, MD, PhD, E. de Nobel, MD, PhD, A.J. Hoitsma, MD, PhD, 
and J.H.M. Berden, MD, PhD 
• Angiotensin-Converting enzyme (ACE) inhibitors decrease albuminuria in patients with diabetic nephropathy. To 
study the change in albuminuria in relation to changes in systemic and renal hemodynamics, nine normotensive 
patients with type 1 (insulin-dependent) diabètes mellitus and persistent proteinuria were given a single oral dose of 
25 mg of the ACE inhibitor Captopril. Blood pressure, glomerular filtration rate (GFR), effective renal plasma flow 
(ERPF), and albumin eicrebon rate (AER) were measured in two periods of 40 minutes before and in four periods of 
40 minutes after administration of Captopril. A constant water diuresis was maintained. Blood pressure did not decrease 
significantly (130/79 ± 4/3 ν 124/74 ± 4/Э mm Hg; mean ± SEM), median AER decreased from 403 (interquartile range 
[IQR], 812) мд/rnin lo 333 (707) дд/mín (Ρ < 0.01). GFR did not change (123 ± 13 ν 117 ± 14 mL/min), but ERPF 
increased significantly from 609 ± 56 to 714 ± 55 mL/mln (P < 0.01). Consequently, the filtration fraction (FF; quotient 
of GFR and ERPF) decreased from 0.20 ± 0.014 to 0.17 ± 0.014 (P < 0.01). A strong correlation was found between 
the decrease of AER and the decrease of FF (r. = 0.75; Ρ < 0.02). No correlation was found between the decrease in 
AER and changes In GFR or blood pressure. In the normotensive patient with diabetic nephropathy, Captopril causes 
an acute reduction of AER, which is probably mediated by a lowering of the intraglomeruiar pressure. 
© 1992 by the National Kidney Foundation, Inc. 
INDEX WORDS: Diabetes mellitus; diabetic nephropathy; albuminuria; anglotensln-converting enzyme Inhibitors; glo­
merular filtration rate; effective renal plasma flow; filtration fraction. 
IN THE EARLY STAGES of their disease, patients with insulin-dependent diabetes mel­
litus demonstrate an increased glomerular filtra­
tion rate (GFR), which probably reflects an in­
creased intraglomeruiar capillary pressure.' This 
"intrarenal hypertension" could be an important 
factor in the development and progression of di­
abetic nephropathy.2 Studies in diabetic rats have 
demonstrated that angiotensin-converting en­
zyme (ACE) inhibition reduces intraglomeruiar 
capillary pressure through vasodilation of the ef­
ferent arteriole, decreases albuminuria, and re­
tards progression of renal insufficiency.3 In dia­
betic nephropathy, ACE inhibitors may be more 
effective than the conventional antihypertensive 
drugs, because they selectively lower intraglo­
meruiar pressure.4 In hypertensive and normo­
tensive diabetic patients with overt diabetic ne­
phropathy, ACE inhibitors indeed have been 
proven effective in decreasing albuminuria and 
reducing the rate of deterioration of renal func­
tion.5,6 These beneficial effects may be explained 
by lowering of the systemic blood pressure. How­
ever, Mathiesen et al7 recently showed that in 
incipient diabetic nephropathy, ACE inhibition 
reduced microalbuminuria and prevented pro­
gression to overt diabetic nephropathy without 
any effect on systemic blood pressure. To eluci­
date the relationship between changes in protein­
uria and changes in systemic and renal hemo­
dynamics, we studied the acute effects of Captopril 
on albuminuria in normotensive diabetic pa­
tients. 
PATIENTS AND METHODS 
Patients 
Patients were selected for the study when the following cri­
teria were fulfilled (I) proteinuria г 0 5 g/24 h on at least 
three consecuuvc occasions; (2) normal blood pressure (<140/ 
90 mm Hg) without antihypertensive medication; (3) endog­
enous creatinine clearance greater than 80 mL/min/1.73 m1; 
and (4) no medication other than insulin All patients gave 
informed consent and the study protocol was approved by 
the local ethical committee. 
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ТаЫе 1. Clinical Characteristics of the Patients 
Patient 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Sex/ 
Age 
M/47 
F/25 
F/41 
F/34 
M/30 
M/26 
M/50 
M/38 
F/20 
Diabetes 
Duration 
(yr) 
40 
20 
33 
32 
15 
12 
26 
20 
16 
HbA,„ 
<%) 
8.4 
8.0 
8.8 
8.1 
8.3 
7.4 
11.1 
6.8 
9.5 
Blood 
Pressure 
(mm Hg) 
140/78 
120/74 
125/70 
130/80 
135/80 
128/80 
122/60 
138/80 
134/58 
ECC 
(тІ т і п / и З т 3 ) 
100 
150 
81 
118 
98 
122 
183 
139 
140 
Proteinuria 
(g/24h) 
3.5 
1.8 
0.9 
1.0 
1.6 
1.2 
4.0 
1.0 
0.6 
Retinopathy 
Ρ 
Ρ 
Ρ 
Ρ 
Ρ 
Β 
Ρ 
Β 
Ρ 
Abbreviations: НЬА,
С
, hemoglobin A1c; ECC. endogenous creatinine clearance; P, proliferative; B, background. 
Methods 
All measurements were determined between 9:00 AM and 
4:00 PM. Patients had their regular breakfast at home with an 
adjusted dose of short-acting insulin only. Coffee was not al­
lowed. Thereafter no food or beverages other than water were 
permitted. During the entire study, patients were in the supine 
position and allowed to stand or sit only for voiding. Blood 
glucose levels were kept constant with an intravenous infusion 
of glucose (5% solution; SO to 100 mL/h) and insulin (Actrapid 
HM, Novo Nordisk, Copenhagen, Denmark; 0 to 2.5 IU/h). 
To attain water diuresis, patients drank 1,000 mL of tap water 
between 9:00 and 9:30 AM, and subsequently 250 mL every 
30 minutes. GFR and effective renal plasma flow (ERPF) 
were measured by a continuous infusion technique using ln-
ulin (Inutest, polyfructosan, Laevosan, Linz, Austria) and p-
aminohippurate. Urine and blood samples were collected at 
40-minute intervals. After an equilibration period of 90 min­
utes, clearances were measured during six consecutive periods 
of 40 minutes each. The mean of the first two periods was 
taken as the basal value. Thereafter, Captopril was administered 
orally in a dose of 25 mg, with subsequent measurements of 
clearances during four periods of 40 minutes. Glucose, inulin, 
/>-aminohippurate, and creatinine were measured with routine 
analytical methods. Albumin concentration in the urine was 
measured with laser immunonephelometry (detection limit, 
0.5 mg/L). The interassay coefficient of variation of the method 
is 3% for high (>70 pg/mL) and 10% for low albumin con­
centrations.8 Blood pressure was measured every 5 minutes 
with an automatic recorder (Arteriosonde, Roche, Basle, 
Switzerland). Heart rate was calculated from a simultaneously 
recorded electrocardiogram. Filtration fraction (FF) was cal­
culated as the quotient of GFR and ERPF. Mean arterial blood 
pressure (MAP) was calculated as the diastolic pressure plus 
one third of the pulse pressure. 
Statistical Analysis 
Data are given as the mean ± SEM, except for albumin 
excretion rate (AER), which is expressed as median and in­
terquartile range (IQR), because of skewed distribution. Wil-
coxon's nonparametric test for paired comparisons was used. 
For each parameter, the results during the four clearance pe­
riods after Captopril were separately compared with the basai 
value. Bonferroni's adjustment for multiple comparisons was 
applied, determining statistical significance at Ρ < 0.01.' Cor­
relations were analyzed as Spearman's correlation coefficienL 
RESULTS 
Nine patients with insulin-dependent (type 1) 
diabetes mellitus were studied. The clinical char­
acteristics of these patients are shown in Table 1. 
Blood glucose levels did not change significantly 
during the study. Mean glucose before Captopril 
was 8.9 ± 1.2 mmol/L (160 ± 22 mg/100 mL) 
and after Captopril 6.5 ± 0.3 mmol/L (117 ± 5 
mg/100 mL). Urinary flow was constant during 
all 40-min periods; the mean flow was 11.1 ± 0.8 
mL/min. After the administration of 25 mg Cap­
topril, AER decreased in all patients. The median 
AER decreased from 403 (IQR, 812) Mg/min to 
333 (IQR, 707) /ig/min (ƒ> < 0.01). The maxi­
mum decrease in individual patients was seen 80 
to 160 minutes after administration of Captopril, 
and it ranged from -3% to -33% (median, 
-21%). Figure 1 shows the mean percentual de­
crease of albuminuria during the four measure­
ment periods. Figure 2 shows the maximum per­
centual decrease in albuminuria of each 
individual. Blood pressure and heart rate, as 
shown in Fig 3, did not change significantly. Fig­
ure 4 illustrates the effects of Captopril on ERPF, 
GFR, and FF. GFR decreased slightly, but not 
significantly, from 123 ± 13 to 116 ± 13 mL/ 
min, with a greatest mean decrease of 6.3% 
± 2.4% at 120 minutes after the ingestion of Cap­
topril. ERPF showed a significant increase from 
609 ± 56 to 714 ± 55 mL/min (P < 0.01). The 
greatest mean increase was 18.4% ± 2.4%, at 80 
74 
C h t n g · in AER (%> 
τ Γ 
120 160 (min) 
Fig 1. Percentual decrease ol AER in the four con­
secutive measurement periods alter Captopril. Values 
are given as the mean ± SEM. 'Ρ < 0.01. 
minutes. As a consequence, FF decreased from 
0.20 ± 0.014 to 0.17 ± 0.014 (P < 0.01), with a 
greatest mean decrease of 16.9% ± 2.4%. Frac­
tional albumin excretion (AER corrected for 
GFR) also decreased significantly by 12.2% 
± 3.1%. AER showed the greatest mean decrease 
between 120 and 160 minutes. This decrease 
correlated strongly with the decrease in FF (Fig 
5) (r
s
 = 0.75; Ρ < 0.02) and with the increase in 
ERPF (r
s
 = -0.75; Ρ < 0.02). However, there 
was no correlation between the decrease in AER 
and the decrease in GFR (r
s
 = 0.50; Ρ = 0.17) or 
the decrease in MAP (r
s
 = 0.62; Ρ = 0.08). 
DISCUSSION 
This study demonstrates that a single oral dose 
of Captopril acutely reduces albuminuria in nor-
motensive patients with diabetic nephropathy. 
Blood pressure did not change; therefore, this re­
duction in albuminuria is probably mediated by 
a lowering of intraglomerular pressure, as re­
flected by the reduction of the FF. 
An increased intraglomerular capillary pres­
sure might be an important factor in the devel­
opment and progression of diabetic nephropa­
thy.2 Since the course of overt diabetic 
nephropathy can not be influenced by strict met­
abolic control10 other than pancreas transplan­
tation," attention has been focused on treatment 
modalities that reduce intraglomerular pressure. 
1 2 3 4 G 6 7 6 9 
Patient nr. 
Fig 2. Maximum percentual changes In AER in indi­
vidual patients. 
In animal models, reduction of intraglomerular 
pressure (by restriction of protein intake or ACE 
inhibition) decreases proteinuria and retards renal 
insufficiency.312 Theoretically, a reduction of in­
traglomerular pressure can be attained by a de­
crease in systemic blood pressure or a reduction 
of efferent glomerular arteriolar resistance. A de­
crease in proteinuria after ACE inhibition, with-
Blood pressure (mm Hg ) 
120-
100-
ΘΟ- I 
60-" 
Heart rate 
70-
I 1 I 1 
40 80 120 160 
time (min) 
Fig Э. Blood pressure and heart rate before and dur­
ing the four measurement periods after Captopril. Π, 
Blood pressure before Captopril administration. Values 
are given as the mean ± SEM. 
75 
ERPF ( m l / m m ) 
7 0 0 
600-
500 
GFR (ml/mm) 
200-
100-
0 
FF 
0 20-
0 15 
J 
4 0 8 0 120 160 (min) 
Fig 4. ERPF, GFR, and filtration FF before and during 
the (our measurement periods after Captopril Values 
are given as the mean ± SEM. 'Ρ < 0.01. 
fpoterisin II in patients during chronic ACE in­
hibition counteracts the hemodynamic changes 
induced by ACE inhibition, but does not reverse 
the antiproteinunc effect " It is therefore likely 
that the antiproteinunc effect of chronic ACE in­
hibition is not only exerted via hemodynamic 
changes. 
Treatment of hypertension with conventional 
therapy in patients with diabetic nephropathy 
also decreases proteinuria and slows the progres­
sion of renal insufficiency '6 However, in animal 
studies, enalapnl compared with conventional 
antihypertensive therapy was more effective in 
this respect, despite a similar reduction of sys­
temic blood pressure with both treatment mo­
dalities4 A recent Inai in nondiabetic patients 
with proteinuria due to various renal diseases 
showed that enalapnl lowered proteinuna more 
effectively than atenolol after 16 weeks of treat­
ment Enalapnl induced a significantly greater 
decrease in FF than atenolol, despite a similar 
effect on systemic blood pressure " Also, in di­
abetic nephropathy, it was suggested that the ef­
ficacy of ACE inhibition in protection of kidney 
function is better than that of ^-blockade Treat­
ment for 2 years with enalapnl resulted in a lesser 
decline in GFR and in a greater reduction of al-
buminuna than metoprololιβ Unfortunately, 
blood pressure control was not the same with 
both treatments in this study 
out a decrease of systemic blood pressure, has 
been observed in both overt and incipient ne­
phropathy 7 '3 In this latter study, a 9% decrease 
of albuminuna. after 4-year treatment with cap-
topnl, was seen without change in systemic blood 
pressure Unfortunately, FF was not measured 
Our results demonstrate that the reduction of 
albuminuna after administration of captopnl is 
mediated by a reduction of the FF and occurs 
without changes in GFR or systemic blood pres­
sure Since FF probably reflects lntraglomerular 
capillary pressure, the acute effects of captopnl 
seem predominantly mediated by a decrease of 
lntraglomerular capillary pressure by efferent va­
sodilation As recently reviewed, the reduction 
in lntraglomerular pressure may lead to structural 
changes in the glomerular basement membrane 
by reducing the number of large nonselective 
pores, thereby ameliorating proteinuna '4 This is 
supported by the observation that infusion of an-
change in AER ita) -
0 -
-10-
R..0 7S 
p < 0 0 2 
Τ • 1βΟ min 
О 10 20 
chanq· in FF ( ъ ) 
Fig S. Correlation between the percentaial change of 
FF and the porcentual change of AER during the laat 
measurement period (120 to 160 minutes) after the ad­
ministration of captopnl. 
76 
In summary, our results indicate a positive ef­
fect of ACE inhibition on proteinuria in patients 
with diabetic nephropathy and normal blood 
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Captopril and atenolol are equally effective in retarding 
progression of diabetic nephropathy 
Results of a 2-year prospective, randomized study 
L. D. Elving1, J. F. M. Wetzels2, H. J. J. van Lier3, E.de Nobel', J. H. M. Berden2 
1
 Department of Mediane Division of General Internal Medicine University Hospital Nijmegen, Nijmegen, The Netherlands 
2
 Department of Medicine Division of Nephrology University Hospital Nijmegen Nijmegen, The Netherlands 
1
 Department of Medical Statistics, University of Nijmegen Nijmegen, The Netherlands 
Summary The progression of diabetic nephropathy can 
be positively influenced by maintaining a low blood 
pressure level This has been shown in studies with con­
ventional antihypertensive treatment as well as with 
ACE inhibitors Whether the latter group of drugs is 
more effective remains to be proven and was the aim of 
our study In a prospective randomized study we com­
pared the effects of ACE inhibition and /^-blockade on 
retarding progression of renal function in IDDM pa­
tients with an early stage of overt diabetic nephropathy 
Twenty-nine patients were studied for 2 years, 15 were 
randomized for treatment with Captopril and 14 for 
atenolol Every 6 weeks blood pressure and urinary al­
bumin and total protein excretion were measured GFR 
was measured every 6 months as 5lCr-EDTAclearance 
Baseline values for blood pressure, renal function and 
albuminuria were identical in the two groups The effect 
of both drugs on blood pressure was not significantly dif­
ferent In the captopril-treated patients MAP before 
During the 1980's it became clear that antihypertensive 
treatment attenuates deterioration of renal function in 
patients with diabetic nephropathy [1, 2] It has been 
suggested that intraglomerular hypertension caused by 
Received 28 September 1993 
and in revised form 29 December 1993 
Corresponding author Dr L D Elving Department of Medi 
cine, Division of General Internal Medicine, University Hospi­
tal Nijmegen PO Box 9101 6500 HB Nijmegen, The Nether 
lands 
Abbreviations IDDM, insulin dependent diabetes mellitus, 
ACE, angiotensin converting enzyme, ECC, endogenous creati­
nine clearance, MAP mean arterial pressure, GFR, glomerular 
filtration rate 
andafter2yearswasllO±3(SEM)andlOO±2mmHg, 
respectively and in the atenolol-treated patients 105 ± 2 
vs 101 ± 2 mm Hg Both drugs reduced albuminuria and 
total proteinuria to the same extent With Captopril al­
buminuria decreased from 1549(989-2399) to 851 
(537-1380) mg/24 h and proteinuria from 2 5 (1 6-3 8) 
to 1 2 (0 8-1 8) g/24 h With atenolol albuminuria de­
creased from 933 (603-1445) to 676 (437-1047) mg/ 
24 h and proteinuria from 15(10-2 4) to 0 9(0 Ο­
Ι 5) g/24 h The rate of decline of GFR was similar with 
both treatments, on Captopril - 4 9 ± 2 1 and on ateno­
lol - 3 7 ± 1 6 ml min ' year ' No major side effects 
with either drug were observed We conclude that, in 
this 2-year study, Captopril and atenolol are equally ef­
fective in retarding progression of diabetic nephro­
pathy [Diabetologie (1994) 37 604-609] 
Keywords IDDM, diabetic nephropathy, glomerular 
filtration rate, albuminuria, Captopril, atenolol 
vasodilation of the afferent arteriole contributes to the 
pathogenesis of diabetic glomerular sclerosis [3] 
Hence, antihypertensive drugs that can reduce ìntra-
glomerular pressure, may be of special benefit in the 
treatment of patients with diabetic nephropathy 
Therefore, ACE inhibitors, which decrease the ìntra-
glomerular capillary pressure by blocking the effect of 
angiotensin II on the efferent arteriole, might be supe-
rior to other antihypertensive drugs Indeed, in pa-
tients with severe diabetic nephropathy addition of 
Captopril to the antihypertensive regimen, reduced 
proteinuna without further effect on blood pressure 
[4] In proteinuric diabetic patients with normal blood 
pressure and normal renal function, we found that Cap-
topril acutely lowered albuminuria without lowering 
blood pressure [5] These studies suggest a specific ìn-
81 
traglomerular effect of ACE inhibitors in patients with 
diabetic nephropathy Whether long-term treatment of 
overt diabetic nephropathy with ACE inhibitors is su-
perior to other antihypertensive drugs remains to be 
proven We have performed a prospective, ran-
domized, controlled study comparing the effects of 
ACE inhibition with ^-blocker therapy on the decline 
of GFR and on albuminuria in patients with an early 
stage of overt diabetic nephropathy 
Patients and methods 
Patients 
From a population of 530 IDDM patients who regularly visited 
the out-patient diabetic clinic ot the University Hospital 
Nijmegen between April 1988 and April 1990, 73 patients with 
signs of overt diabetic nephropathy were selected IDDM was 
defined as age at onset of diabetes before 10 years and start of in-
sulin treatment within 1 year of diagnosis Overt diabetic ne-
phropathy was defined as albuminuria greater than 300 mg/24 h 
in at least three unne samples, in the absence of urinary tract in 
fection Other types of renal disease were excluded on the basis 
of medical history, duration of diabetes of more than 10 years 
and the presence of diabetic retinopathy Exclusion criteria for 
entry to the study were age below 18 or above 60 years, preg-
nancy or wish to become pregnant in the near future, FCC less 
than 30 ml/mm, use of two or more antihypertensive drugs co 
ronary heart disease or congestive heart failure, chronic obstruc-
tive pulmonary disease, regular use of non-steroidal anti-inflam-
matory drugs or proven non-compliance The study protocol was 
approved by the local ethical committee and all patients gave 
written informed consent 
Study design 
All previous antihypertensive medication was stopped for at 
least 6 weeks before entrv into the study Thereafter, baseline la-
boratory parameters were determined Patients were allocated 
for treatment with either Captopril or atenolol with the stan-
dardized variance method [6], balancing for the following fac-
tors age, sex, duration of diabetes, blood pressure, proteinuria, 
ECC, HbA|C and smoking Captopril was started at a dose of 
25 mg twice daily and increased to 50 mg twice daily Atenolol 
was started at a dose of 50 mg once daily and increased to 100 mg 
once daily All patients received the maximal dosage except 
when ECC was less than 50 ml/min or when supine systolic blood 
pressure dropped below 110 mm Hg When on two consecutive 
visits MAP was above 110 mm Hg, chlortahdone 25 mg once 
daily, was added to the medication If necessary, this dose was in-
creased to 50 mg once daily All the patients were studied for 
2 years During this period they continued their usual diet with-
out salt restriction Patients visited the out-patient clinic every 
6 weeks MAP was measured with an automatic recorder (Dina-
map, Criticón Ine, Tampa, Fla , USA), ten recordings during 
20 nun in the supine position Thereafter blood pressure was 
measured with a sphygmomanometer two tunes in the supine 
position and two times after 1 mm standing Every 6 weeks a 
24-h unne sample was analysed for creatinine, albumin, total 
protein and sodium and a blood sample was tested for sodium, 
potassium, creatinine and HbAlc Every 3 months plasma reran 
activity, total and HDL-cholesterol, albumin and haemoglobin 
levels were measured Before the start of the treatment and at 
6-month intervals GFR was measured 
Measurements 
Urinary albumin concentration was measured by laser lmmu-
nonephelometry as previously described [7] (interassay vari-
ation 3%) HbA|C was measured by HPLC (normal less than 
6 2%) Plasma renin activity was measured by radioimmunoas-
say [8] Other laboratory parameters were measured using 
standard techniques GFR was calculated from the plasma dis-
appearance curve after a single ι ν injection of 100 цСі MCr-
EDTA [9] Plasma samples were obtained after 180,200,220 and 
240 mm The coefficient of vanation of repeated measurements 
in patients with stable renal function is 5 % All GFR measure­
ments were performed in the morning under normoglycaemic 
conditions (glucose level 3 5-8mmol/l) Patients took their usual 
morning insulin before breakfast and received ι ν insulin and 
glucose if necessary to obtain and maintain a normal, stable 
blood glucose level The glucose level was measured every 
30 mm during the procedure (Reflolux 3M, Boehnnger Mann­
heim Mannheim, Germany) 
Statistical analysis 
For comparison of the two treatments a distribution-free test for 
curve analysis was applied [10] Within each treatment group 
comparisons were made using Wilcoxon's signed rank test The 
rate of change in GFR (ml min 'year ') was calculated by li­
near regression analysis on all GFR values in each subject 
Correlations were calculated as Spearman correlation coeffi­
cients Values are given as means with SEM Albuminuria and 
total proteinuria are given as geometric means (antilog 95 % 
confidence interval of the logarithms) Ρ values of 0 05 or less 
were considered significant 
Results 
Of the 73 patients with diabetic nephropathy, 30 pa­
tients fulfilled the entrance criteria and all agreed to 
participate in the study Twenty-nine patients com­
pleted the 2-year study protocol One patient (female, 
aged 49 years, no 22) who was randomized for treat­
ment with atenolol experienced severe headache dur­
ing the first 2 weeks of treatment. After cessation of 
atenolol the headache immediately resolved and re­
turned upon re-challenge Thus, she was excluded from 
further study The two treatment groups were well 
matched for the balancing factors Fifteen patients 
(12 males/3 females) received Captopril, the mean age 
was 37 ± 2 years and duration of diabetes was 
26+ 2 years. Fourteen patients (11 males/3 females) 
received atenolol, the age of these patients was 
39 ± 3 years and duration of diabetes was 26 ± 2 years. 
All the patients had signs of retinopathy. Eleven pa­
tients had hypertension (defined as blood pressure 
above 140/90 mmHg) before start of the study Five 
had been treated with antihypertensive drugs pre­
viously, either Captopril (4) or enalapnl (1). Of these 
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ТаЫе 1. Effects of 2-year antihypertensive treatment with Captopril or atenolol on haemodynamic and metabolic parameters and 
renal function 
MAP (mmHg) 
Heart rate (beats/min) 
GFR (ml/min) 
Creatinine (umol/1) 
Total protein excretion (g/24 h) 
Albumin excretion (mg/24 h) 
Sodium excretion (mmol/24 h) 
Plasma renin activity (nmol/l/h) 
Albumin (g/l) 
Cholesterol (mmol/1) 
HDL-cholesterol (mmol/1) 
Haemoglobin (mmol/1) 
Captopril (л = 15) 
Baseline 
110±3 
7 6 ± 2 
9 5 ± 6 
9 8 ± 8 
25 
(1 6-3 8) 
1549 
(989-2399) 
170 ±14 
1 0 5 ± 0 1 7 
42 ±1 
6 1 ± 0 3 
1 5 ± 0 1 
9 0 ± 0 3 
After 
2 years 
100 ±2' 
77 ± 2 
84 ± 6 ' 
109 ±12 
12 ' 
(0 8-1 8) 
851" 
(537-1380) 
168 ±13 
5 53 ± 1 16' 
42 ±1 
6 0 ± 0 3 
1 4 ± 0 1 
8 1 ± 0 4 " 
Atenolol (n = 14) 
Baseline 
105 ± 2 
77 ± 3 
97 ± 9 
105 ±10 
15 
(10 2 4) 
933 
(603-1445) 
153 ±18 
091 ± 0 1 3 
42 ±1 
5 6 ± 0 3 
1 3 ± 0 1 
8 8 ± 0 3 
After 
2 years 
101 ±2" 
65 ± 2 ' 
89 ±9" 
118 ±14" 
09» 
(06-15) 
676' 
(437-1047) 
160 ±13 
0 61 ± 0 1 0 
42 ± 1 
5 7 ± 0 3 
1 2 ± 0 1 " 
8 8 ± 0 3 
Results after 2 years are the mean of all values measured during 
the last 6 months of the study 
Results are given as mean ± SEM except for albumin excretion 
and total protein excretion which are given as geometric means 
(antilog 95 % confidence intervals of the logarithms) 
*p<00l "p<005vsbaseline 
Table 2. Changes in albuminuria (ΔΑ№ %) and rates of change 
inGFR(AGFR ml min ' year ') in patients with diabetic ne­
phropathy who were treated for 2 years with Captopril or aleno 
lol 
Captopril 
Patient 
no 
1 
7 
8 
9 
11 
12 
13 
15 
17 
20 
23 
24 
26 
29 
30 
1 
ДАІЬ 
+ 291 
- 6 2 
- 6 6 
+ 101 
- 5 
- 6 9 
-51 
+ 44 
- 6 9 
- 6 2 
- 8 0 
- 8 4 
-59 
- 2 3 
+ 14 
AGFR 
- 5 8 
- 2 2 
- 5 9 
- 1 1 1 
- 1 8 9 
- 1 1 0 
- 1 0 4 
- 1 2 8 
+ 3 4 
- 4 5 
- 8 4 
- 1 3 
+ 13 4 
+ 4 8 
- 1 5 
Atenolol 
Patient 
no 
2 
3 
4 
5 
6 
10 
14 
16 
18 
19 
21 
25 
27 
28 
ДАІЬ 
- 3 4 
- 1 5 
- 6 2 
- 1 2 
- 2 6 
+ 5 
- 1 7 
- 3 6 
- 9 
- 2 0 
- 3 7 
- 1 
- 6 9 
- 5 
AGFR 
- 1 0 2 
- 4 8 
- 7 1 
- 7 2 
+ 112 
- 1 2 8 
+ 0 1 
+ 12 
- 6 2 
- 3 7 
- 0 7 
- 1 7 
- 0 5 
- 8 6 
Patient no 22 was excluded (see text results) 
five patients, four were randomized for Captopril treat­
ment and one for atenolol 
The effects of both therapeutic regimens on haemo­
dynamic parameters and renal function are shown in 
Table 1 Baselinevalueswerenotsignificantlydifferent 
The daily dose of Captopril was 91 ± 2 mgand of atenolol 
94 ± 2 mg Blood pressure was lowered to the same level 
in both treatment groups During the first 6 months 
MAP decreased with Captopril from 110 + 3 to 102 ± 
2 mm Hg (p < 0 01) and with atenolol from 105 ± 2 to 
101 ± 2 mm Hg (p < 0 05) Blood pressure remained at a 
stable level thereafter (Fig 1) After 24 months the per-
centual change of MAP was - 8 8 ± 1 9% with Captopril 
and — 4 1 ± 1 6% with atenolol The effect of both drugs 
on standing blood pressure was similar baseline and 2-
year values were 138/90 and 128/83 with Captopril, and 
135/90 and 128/85 mmHg with atenolol Chlortahdone 
had to be given to two patients in the atenolol group and 
to six in the Captopril group 
Renal function, as measured by GFR, did not differ 
between the two groups before treatment In both 
groups GFR decreased significantly and to the same 
extent (Fig land Table 1) The mean rates of decline of 
GFR were - 4 9 ± 2 1 m l mm"1 year ' and - 3 7 ± 
1 6 ml mm " ' year ~l in the Captopril- and atenolol-
treated patients, respectively The rates of change in 
GFR in the individual patients are shown m Table 2 
The greatest decline in GFR occurred dunng the first 
6 months Calculated from 6 months onwards, the de­
cline in GFR was - 3 8±2 3and - 1 8 ± 2 2ml min - 1 
year ' in the Captopril- and atenolol-treated patients, 
respectively (NS) 
Urinary total protein and albumin excretion in the 
two groups were not significantly different at baseline 
A significant reduction of proteinuria and albuminuria 
with both drugs was seen (Table 1 and Fig 1) The 
relative change in albuminuria for the individual pa­
tients is shown m Table 2 The changes in albuminuria 
paralleled the change in MAP in both treatment 
groups The greatest reduction occurred dunng the 
first 6 months After 24 months the median change m 
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F¡g.2. Correlation between relative change m albuminuna and the 
relative change in MAP after 2 years treatment with Captopril ( · ) or 
atenolol ( О ) Spearman correlation coefficient |>,) = 0 48 (p < 0 01 ) for 
all patients For captopnl r, - 0 53 (p < 0 05) and for atenolol r, = 0 15 
(NS) 
albuminuria was -59% (range -84/+ 291) and -
18% (-69/+ 5) with captopnl and atenolol, respec­
tively (NS) For all patients together the relative 
change in albuminuria after 2 years was significantly 
correlated with the relative change in MAP (r, = 0 48, 
ρ < 0 01, Fig 2) Analysis for each treatment group re­
vealed a significant correlation in the captopnl-treated 
patients (r
s
 = 0 53, ρ < 0 05) but not in the atenolol-
treated patients (л, = 0 15, NS) 
Curve analysis for MAP, albuminuria and GFR over 
the 2-year study period did not show significant dif­
ferences between the two treatments 
Neither treatment regimen had a significant effect 
on glycaemic control Mean HbAi
c
 during the entire 
period was 8 6 ± 0 4 % in the captopnl-treated patients 
and 8 9 ± 0 3 % in the patients treated with atenolol 
The effects of both treatments on other metabolic pa­
rameters are shown in Table 1 Notably, haemoglobin 
concentration was significantly lowered during the 
treatment with captopnl 
In all the patients treated with Captopril a rise in 
plasma renin activity was seen In all the patients on 
atenolol heart rate was lowered These observations 
suggest good compliance with drug treatment No 
major side effects of either drug were seen during the 
study period During the 24 months two patients, one 
on captopnl (no 12) and one on atenolol (no 28), suf­
fered from myocardial infarction, after 16 and 
23 months treatment, respectively Since the thera­
peutic regimen was not changed, except for the addi­
tion of acenocoumarol, with no change in blood pres­
sure, these two patients completed the study 
Although overall albuminuria decreased, an in­
crease was observed in five patients On atenolol albu­
minuria increased 5 % in one patient (no 10) In four 
patients (nos 1,9,15 and 30) on captopnl an increase in 
albuminuria was seen of 291,101,44 and 14%, respec­
tively To determine whether these patients influenced 
the outcome of the study the data of these five patients 
were excluded Re-analysis indicated that captopnl de­
creased blood pressure and albuminuna to a greater 
extent than atenolol (ΔΜΑΡ - 10 6 ± 1 7 vs -
5 2 ± 1 3 % ( p < 0 05) and Aalbuminuna - 6 2 % ( -
84/ - 5) and - 20 % ( - 69/ -1) (p < 0 01) for captopnl 
and atenolol, respectively) However, the rate of de­
cline of GFR was still the same in both groups ( -
3 7 ± 2 1 v s - 2 9 ± 1 5 m l mm 'year ' (NS)) 
Discussion 
Our study demonstrates that ACE inhibition and ß-
blockade are equally effective in retarding progression 
of diabetic nephropathy Both drugs were well-tol-
erated and no major changes in metabolic parameters 
were observed During captopnl treatment a decrease 
in the haemoglobin concentration was noted as has 
been observed previously [11] 
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Experimental studies in rats have demonstrated that 
progression of renal disease is correlated with in­
creased intraglomerular pressure [3] In humans, mtra-
glomerular pressure cannot be assessed directly, but it 
may be reflected in proteinuria Furthermore, pro­
teinuria is correlated with the progression of renal 
failure [12, 13] In our patients Captopril clearly de­
creased protein excretion, which is in agreement with 
previous studies [14-16], but atenolol also reduced pro­
teinuria to the same extent Our data thus suggest that 
ACE inhibitors and ^-blockers have equal antipro-
teinunc effects Results of other studies comparing the 
antiproteinunc effects of ACE inhibitors and ^-block­
ers in patients with diabetic and non-diabetic renal dis­
ease are equivocal [17-21] An explanation for the 
seemingly contradictory results of these studies might 
be provided by the recent study of Weidmann et al [22] 
From their meta-analysis on the anti-protemunc ef­
fects of antihypertensive drugs it becomes clear that 
ACE inhibition is superior to /J-blockade in studies in 
which minimal reduction of blood pressure is achieved, 
whereas the differences become less clear at higher de­
grees of blood pressure reduction 
Recently, the question has been raised, whether uri­
nary protein excretion should be used as a solid end 
point for studies designed to evaluate the effects of die­
tary or drug intervention on progression of renal dis­
ease [23] I he decrease in GFR over time, and ultimate 
progression to end-stage renal disease are more valid 
end points Our study demonstrates equal rates of de­
cline of GFR in both treatment groups This conclusion 
is still valid when the data are analysed after exclusion 
of the five patients with an increase in proteinuria The 
decline in GFR in our study is clearly slower than 
10 ml mm"1 year"1, the value generally observed in 
untreated patients with overt diabetic nephropathy [15, 
24] Furthermore, from our data it is evident that GFR 
decreased predominantly in the first 6 months, which is 
probably related to the fall in blood pressure There­
fore, it can be expected that the rates of decline will be 
even slower at longer follow-up This became apparent 
from 6 months onwards Although we did not find a sig­
nificant difference between decline of GFR in either 
treatment group, we cannot exclude that such a dif­
ference might become apparent when patients are 
studied over a more prolonged period of time From 
our data it can be calculated that the chance that Capto­
pril is 50 % better than atenolol in retarding deteriora­
tion of renal function is 4 8 % 
Bjorck et al [17] conducted a study very similar to 
ours They concluded that enalapnl was more effective 
than metoprolol in retarding progressive diabetic ne­
phropathy However, their results are open for discus­
sion First, blood pressure reduction was less in meto-
prolol-treated patients Moreover, in their analysis of 
the decline of GFR over time, data were included from 
patients who were followed-up for less than 1 year As 
noted before, in the early treatment period a relatively 
large decrease in GFR is observed This decrease is 
probably related to the abrupt decrease in blood pres­
sure, and is probably not a reflection of ongoing renal 
damage If the patients with a follow-up of less than 
1 year are excluded from their study, the differences in 
the rates of decline of GFR between enalapnl and 
metoprolol treatment are no longer significant This 
conclusion is substantiated by the observation by 
Bjorck et al that the decline of GFR from 6 months on­
wards is similar in the two treatment groups The re­
sults of our study are in line with those of uncontrolled 
studies [1,2,15,25-27] on antihypertensive treatment 
in diabetic nephropathy, in which no differences in ef­
fects of the various treatment modalities on change in 
GFR were found In conclusion, our study suggests that 
treatment with Captopril or atenolol is equally effective 
in retarding deterioration of renal function in IDDM 
patients with an early stage of nephropathy It remains 
to be determined whether treatment over a longer peri­
od of time will lead to a different result At present the 
data indicate that it is not the type of treatment but the 
treatment itself which is most important in changing 
the natural history of diabetic nephropathy 
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CHAPTER IX 
Progression of diabetic retinopathy during 2-year 
antihypertensive treatment with Captopril or atenolol is 
similar and related to changes in albuminuria 
L.D. Elving, M.A.D. Tilanus, J.F.M.Wetzels, 
F. Hendrikse, J.H.M. Berden 
Submitted 
Abstract 
The progression of diabetic retinopathy during antihypertensive treatment with Captopril 
or atenolol was investigated in a prospective randomized study Twenty-seven IDDM 
patients, with diabetic retinopathy and persistent proteinuria, participated. Fourteen 
received Captopril treatment and 13 were treated with atenolol Every six months all 
patients were seen by the ophthalmologist. At baseline and after two years of treatment a 
fluorescein angiogram (FAG) was made. Laser photocoagulation treatment was performed 
during the study when appropriate A scoring system for progression of retinopathy was 
developed, in which decrease of visual acuity, deterioration of the retinopathy on FAG 
and the intensity of photocoagulation treatment were scored (maximal score = 5) The 
severity of retinopathy did not differ between the two groups at baseline. The progres-
sion-score did not differ between the Captopril or atenolol treated patients (1 5 + 0.3 vs. 
1.2 ± 0.4). The progression of retinopathy correlated with the change in albuminuria 
after 2 year treatment (r„=0 46,p<0.02) and with the duration of diabetes (rs=-0.53, 
p < 0 001). No significant correlations were found between progression of retinopathy and 
HbAu, blood pressure (either systolic or diastolic) and change of GFR, neither at baseline 
nor after two years. When the patients were divided into fast (score >1) and slow 
(score <1) progressors, the slow progressors (n = 18) had a more pronounced decrease in 
albuminuria and a longer diabetes duration. 
In conclusion: Captopril and atenolol do not have different effects on the progression of 
retinopathy. Furthermore this study indicates that progression of retinopathy during an-
tihypertensive treatment is related to the effect of this treatment on albuminuria. 
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Introduction 
Diabetic retinopathy is the most frequent complication of diabetes mellitus and still the 
worlds leading cause of blindness in adults. After 15 years of diabetes about 98% of 
IDDM patients have some form of retinopathy which is in 25% a proliferative retinopa-
thy. This percentage increases to 67% after 30 years of diabetes1. Diabetic nephropathy 
develops in about 30% of IDDM patients2. A strong association exists between prolifera-
tive retinopathy and nephropathy and in fact the diagnosis of diabetic nephropathy should 
be questioned if retinopathy is absent3. The most important risk factors for retinopathy are 
the duration of diabetes and poor metabolic control4 \ Moreover, microalbuminuria has 
been found to be a strong predictor for the development of proliferative retinopathy67. 
There is debate as to whether high blood pressure is an independent risk factor for the 
development and progression of diabetic retinopathy. Klein et al.8 found that the level of 
systolic blood pressure was related to the development of retinopathy, whereas the level 
of diastolic blood pressure was related to the progression These relations could only be 
demonstrated in patients with age at diagnosis of diabetes below 30 years and taking 
insulin. The association between diastolic blood pressure and retinopathy was also found 
by Chase et al9. Norgaard and coworkers demonstrated that hypertension alone is not 
associated with retinopathy but that diabetic nephropathy, with or without hypertension is 
associated with the most advanced forms of retinopathy10. 
Early initiation of antihypertensive treatment attenuates the progression of diabetic 
nephropathy11 n It has been suggested that the use of ACE-inhibitors might be superior in 
this respect". To our knowledge no studies have addressed the role of antihypertensive 
treatment on the natural course of diabetic retinopathy. 
During the past years we performed a study in which the effects of Captopril and atenolol 
on the progression of diabetic nephropathy were compared14. In the same group of 
patients we have also studied the effects of the two treatment regimens on the progression 
of retinopathy. 
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Patients and methods. 
Patients 
Details about the selection of the patients and the study design have been published 
previously14. Briefly, patients were eligible for the study if they had IDDM, defined as 
age of onset of diabetes before 30 years of age and start of insulin treatment within 1 year 
of diagnosis. All had overt diabetic nephropathy, defined as albuminuria greater than 300 
mg/24 h in at least three 24 h urine samples. Other types of renal disease were excluded 
on the basis of medical history, duration of diabetes of more than 10 years and the 
presence of diabetic retinopathy The study protocol was approved by the hospital ethical 
committee and all patients gave written informed consent 
Study protocol 
Previously used antihypertensive medication was stopped for at least 6 weeks before the 
start of the study After determination of baseline parameters, patients were randomly 
allocated for treatment with either Captopril or atenolol All patients were studied for 2 
years The patients were seen at the outpatient diabetic clinic every 6 weeks for measure-
ment of mean arterial blood pressure (MAP) with an automatic recorder (Dinamap, 
Criticón Inc., Tampa, Fionda), 10 recordings during 20 minutes. Thereafter blood 
pressure was measured with a normal sphygmomanometer twice in the supine position 
Also every 6 weeks a 24 h urine sample was analyzed for creatinine and albumin Blood 
samples were taken tor measurement of creatinine and HbA,c Every 3 months plasma 
renin activity was measured Every 6 months glomerular filtration rate (GFR) was 
measured, using a single shot method with 51Cr-EDTA14. 
The status of retinopathy was evaluated at entry and every 6 months by ophthalmologic^ 
examination with assessment of the best corrected visual acuity (Snellen) and by fundus-
copy through dilated pupils Before and at the end of the 2-year study the eyes were also 
examined by fluorescein angiography (FAG) Angiography was performed after intrave-
nous injection of 5 ml of 10% sodium-fluorescein solution Photographs were taken in a 
standardized fashion using a Topcon TRC retinal camera All FAG's that were made 
before the start of the study and after 2 years were evaluated. A careful description of the 
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fundus was given based on the FAG. Retinopathy was described as non-proliferative 
(NP), pre-proliferative (PP), proliferative (P) or involuted (Inv), according to the defini-
tions given in Table 1. 
Table 1. Definitions of the 4 stages of retinopathy that were used during this study. 
Diagnosis was made by fluorescein angiography. 
Non-Proliferative (NP) capillary dilatation 
capillary occlusion 
venous dilatation 
microaneurysms 
hemorrhages 
hard exudates 
Pre-proliferative (PP) cotton wool spots 
non-perfused areas 
retinal haemorrhages in all quadrants 
venous beading in 2 or more quadrants 
intraretinal microvascular abnormalities (IRMA) 
Proliferative (P) neovascularization 
diffuse leakage 
vitreous or preretinal hemorrhage 
Involuted (Inv) retinopathy in regression after panretinal laser 
coagulation treatment or vitrectomy 
Focal and/or panretinal laser coagulation treatment was carried out using the Dye Laser, 
wavelength 577 nm, (Coherent, Palo Alto, California) in case of proliferative retinopathy 
or when at least one sign of pre-proliferative retinopathy was present. The ophthalmolo-
gist was unaware of the type of antihypertensive treatment. We quantitated the progres-
sion of retinopathy using a scoring system which takes into account changes in visual 
acuity, alterations on the FAG and the intensity of the laser treatment needed during the 
study (Table 2). The maximal score in a single patient could be 10 points, 5 for each eye. 
The mean progression in each patient was calculated as the average of the scores for each 
eye. When, however, only one eye could be evaluated, the mean progression score was 
considered to be the same as the progression score for that eye. This seemed justified 
since the correlation coefficient between the progression scores of the right and the left 
eye was 0.83 (p<0.0001). Slow progression was defined as a mean progression score of 
less or equal to 1, fast progression as a mean progression score of more than 1. 
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Table 2. Retinopathy progression score. 
Parameter Score 
Decrease of visual acuity 1 
Deterioration of retinopathy on FAG 1 
Laser therapy during the study: None 0 
Mild scatter ( < 1000 bums) 1 
Full scatter (1000-2000 burns) 2 
Vitrectomy with endolaser or more 3 
than full scatter 
(> 2000 burns) 
FAG=Fluorescein angiography 
Statistical analysis 
Data are given as means ± SEM or as medians and range in case of skewed distribution. 
For comparisons Mann-Whitney test for unpaired comparisons was used. All FAG's at 
the start of the study and after 2 year were separately ranked according to severity of 
retinopathy by two ophthalmologists who were not aware of the type of antihypertensive 
treatment the patients were receiving. For this ranking only the worst eye of each patient 
was taken, except when only one eye was évaluable. This made it possible to perform a 
rank sum test to determine whether the severity of retinopathy was different between the 
two treatment groups either at the start or at the end of the 2 year. 
For correlations Spearman's correlation coefficient was applied. Statistical significance 
was determined at ρ < 0.05. 
For an approximate power of >80% it was estimated that fourteen patients in each group 
were needed to detect a difference of 1.5 in the progression-score, which we regarded as 
clinically significant. 
Results 
Twenty-nine patients with IDDM and an early form of overt diabetic nephropathy were 
treated with either Captopril (η = 15) or atenolol (n=14), during 2 years, to study the 
effects of these drug regimens on parameters of progression of diabetic nephropathy. The 
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results of this treatment on the renal parameters have been published14. Two patients did 
not participate in the retinopathy study, since one female treated with Captopril was 
functionally blind on both eyes and the other patient, also female, treated with atenolol, 
did not wish to participate because she was controlled at an ophthalmology clinic outside 
our hospital and she did not want to change. The latter woman was panretinally treated 
for proliferative retinopathy in the past. During the study her retinopathy was stable and 
she did not need additional treatment. The course of retinopathy could therefore be 
evaluated in 27 patients, with a mean age of 38.5 + 10.4 yr and a mean duration of 
diabetes of 25.9+6.5 yr. Of both the Captopril and atenolol treated patients 3 patients 
were blind in one eye. Therefore of the Captopril treated patients 25 eyes were évaluable 
and of the atenolol treated patients 23 eyes. The visual acuity, FAG appearance, the 
intensity of laser treatment before and during the study, and the progression score of all 
patients are shown in Table ЗА for the Captopril treated patients and in Table 3B for the 
atenolol treated patients. The progression score is similar in the 2 groups, 1.5 ± 0.3 and 
1.2 + 0.4 for the Captopril and atenolol treated patients respectively, indicating that the 
type of treatment, Captopril or atenolol, did not influence the course of retinopathy. 
Further evidence that atenolol and Captopril have similar effects on the progression of 
retinopathy can be derived from the ranking scores of the FAG's that were made at the 
beginning and at the end of the study. The sum of rank-scores at baseline was 185 and 
193 for the Captopril and atenolol treated patients respectively, which is not significantly 
different. The sum of rank-scores at the end of the 2 year study was 210 and 168 
respectively, which is also not significantly different. Thus there was no difference 
between the two groups concerning the severity of retinopathy, neither at baseline nor 
after 2 years. Therefore in the subsequent analyses the results of the two treatment groups 
were taken together. The progression of retinopathy correlated with the change in al­
buminuria (r5=0.46;p<0.02) and with the duration of diabetes (rs=-0.53;p< 0.001). No 
significant correlations were found with HbAlc, MAP, decline of GFR, plasma renin 
activity, neither for the baseline nor for the 2-year results nor for the relative changes of 
these parameters during treatment. The group was divided into fast (score > 1, η =9) and 
slow progressors (score < 1 , η = 18). Ranking of all baseline FAG's showed a tendency 
toward more advanced retinopathy before the study in the fast progressors (sum of rank-
scores 162 vs. 216, p=0.07). 
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In Table 4 the most important parameters of the slow and fast progressors are shown. As 
expected the change in albuminuria and the duration of diabetes were significantly dif-
ferent between the slow and fast progressors. Fast progressors are characterized by a 
shorter duration of diabetes and the absence of a reduction in albuminuria during 
antihypertensive treatment. Four of the 5 patients with an increase in albuminuria showed 
a fast progression of retinopathy (Fig.l). 
Table 4. Characteristics of the patients when divided into slow (progression score < 1) 
and fast progressors (progression score > 1). 
Slow progressors Fast progressors 
Number (M/F) 
Age (yr) 
Duration of diabetes mellitus (yr) 
Change in albuminuria (%) 
Decline in GFR (ml/min/yr) 
HbAlc (%) during study 
Blood Pressure at start (mmHg) 
Blood Pressure after 2 yr 
Plasma renin activity (nmol/l/h) 
at baseline 
after 2 year 
Diuretic added (n) 
Smokers (n) 
Given are means ± SEM or median (range), GFR = glomerular filtration rate 
'p<0 .01 
Discussion 
14/4 
40 + 2 
28 ± 1 
-42 (-80/+5) 
-4.7 ± 1.2 
8.7 ± 0.3 
143±4/88±2 
139±4/84±1 
1.10+0.15 
3.70+1.11 
5 
11 
9/0 
35 ± 3 
2 1 + 2 * 
-5 (-59/+291) * 
-4.0 ± 3.5 
8.4 + 0.4 
139+6/88+3 
135+4/85+3 
0.71+0.12 
2.28+0.66 
3 
4 
We have studied the effects of two antihypertensive drugs, Captopril and atenolol, on the 
progression of diabetic retinopathy in patients with IDDM. During the past decade the 
prognosis of patients with diabetic nephropathy has improved considerably due to a better 
antihypertensive treatment.15"17. It has been suggested that the use of ACE-inhibitors 
would be more advantageous for the treatment of diabetic nephropathy18·". Studies on the 
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effect of antihypertensive treatment on the course of diabetic retinopathy are scarce. It has 
been demonstrated that the progression of retinopathy is related to the level of blood 
pressure". This relation is not unexpected in view of the impaired autoregulation of the 
retinal blood flow that has been shown in patients with IDDM20. Such an impairment of 
renal autoregulation will lead to a direct transmission of systemic blood pressure to the 
p<0.01 
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Fig 1. Change in albuminuria (%) after 2 year treatment with Captopril (A) or atenolol 
( · ) in patients showing fast or slow progression of retinopathy. The line indicates the 
median change in albuminuria. 
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retinal capillary vessels which can lead to structural damage Indeed an increased blood 
flow in the retinal vessels has been demonstrated21 Lowering of systemic blood pressure 
can then be expected to attenuate progression of retinopathy Based on the finding of 
receptors for angiotensin II in human retinal vessels22 and the fact that angiotensin II can 
stimulate angiogenesis one could speculate that ACE-inhibitors might offer benefits over 
other antihypertensive drugs. 
During the past years we have conducted a prospective, randomized study to compare the 
effects of the ACE-inhibitor captopnl and the ß-blocker atenolol on the progression of 
diabetic nephropathy in IDDM patients with overt proteinuria14 This study allowed us 
also to address the question whether progression of retinopathy is differently influenced 
by these drugs Progression of retinopathy was evaluated using a scoring system which 
took into account visual acuity, changes in FAG appearance and the need for laser 
treatment. We had to develop this scoring system because the existing scoring systems 
could not be used in these patients with advanced retinopathy. Our results clearly demon-
strate that the progression of diabetic retinopathy is similar in both groups. This does, 
however, not allow us to draw conclusions on the effects of antihypertensive treatment 
per se on the progression of retinopathy To evaluate such an effect it would be necessary 
to include placebo-treated patients in the study However, with the current knowledge it is 
no longer justified to withhold antihypertensive treatment to patients with IDDM and 
manifest nephropathy We found no evidence that the use of an ACE-inhibitor provided a 
greater protection against progression of diabetic retinopathy. Two studies have reported a 
decrease of permeability of the blood-retinal barrier during 7 and 18 months treatment 
with Captopril2324 This effect could not be reproduced in an acute experiment in which 
blood pressure was adequately lowered but no effect on retinal permeability was seen25 
This suggests that the observed decrease in permeability in the long-term study is due to 
structural changes of the retinal vessels rather than to changes in hydrostatic forces. 
During the above mentioned studies2324 retinopathy did not show any progression as 
determined by visual acuity, fundoscopy and FAG The results of these studies are 
difficult to compare with our study since we did not measure retinal permeability and our 
patients had more advanced stages of retinopathy Jackson et al26 conducted an un-
controlled study in 10 patients with micro- or macroalbuminuna who were treated with 
captopnl. They found an improvement of retinopathy in 4 patients (40%) In untreated 
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patients (n=231) of the same clinic an improvement was seen in 14%, suggesting a 
beneficial effect of the Captopril treatment We saw an improvement of retinopathy in 
only three (11%) patients (nos 2, 12 and 17), two of which were treated with Captopril. 
In the Wisconsin retinopathy study spontaneous improvement of retinopathy was seen in 
7% over a 4-year period27. 
When analyzing all our patients as one group we made two possibly important obser­
vations. First, we observed that progression of retinopathy was correlated with changes in 
albuminuria during antihypertensive treatment This observation is in line with the 
observations of Chavers et al.2e and underscores the likelihood that both nephropathy and 
retinopathy share similar pathogenetic mechanisms Secondly, the progression was 
negatively correlated with the duration of diabetes. Also in the Wisconsin retinopathy 
study27 the progression rate was faster in patients with a duration of diabetes of less than 
15 years. 
In conclusion, we could not demonstrate a difference in progression of retinopathy during 
treatment with Captopril or atenolol. However, an unfavorable effect of antihypertensive 
treatment on albuminuria may be indicative for a more rapid progression of retinopathy. 
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Introduction 
The life expectancy of patients with diabetes mellitus is strongly influenced by the presen-
ce or absence of diabetic nephropathy. In diabetic patients with proteinuria the relative 
mortality is about 40 times higher than in diabetic patients without proteinuria'. In elderly 
patients this is mainly due to cardiovascular causes, while in patients below 35 years 
mortality is related to renal insufficiency2. 
In patients with Type 1 (insulin-dependent) diabetes the onset of diabetic nephropathy is 
heralded by measurable urinary losses of albumin (>300 mg/24h). After this stage renal 
function invariably deteriorates, independently of metabolic control and end stage renal 
disease is reached on average 10 years after the onset of proteinuria3·4. Hypertension is 
one of the main features of diabetic nephropathy and present in most if not all patients. 
During the last decade it has become evident that an elevated blood pressure is the major 
determinant for the deterioration of the renal function5 and subsequent studies have 
provided evidence that the prognosis of diabetic nephropathy can be greatly improved by 
adequate treatment of the hypertension6. In this review we will discuss various aspects of 
antihypertensive treatment in diabetic patients and focus particularly on treatment of 
hypertension in patients with type 1 diabetes mellitus with nephropathy. 
The relation between hypertension and diabetic nephropathy. 
Clinical or overt diabetic nephropathy can be diagnosed when persistent albuminuria (> 
300 mg/24 h) develops in a patient with a diabetes duration of more than 10 years, 
without clinical or laboratory evidence for other kidney or urinary tract diseases. This 
phase of clinical diabetic nephropathy is invariably preceded by a phase of microalbumin-
uria defined as an urinary albumin excretion of 30-300 mg/24h. In general, diabetic 
nephropathy is associated with retinopathy, as illustrated by the study of Parving et al7 
who found some form of retinopathy in 99% of 180 diabetic patients with proteinuria. 
The prevalence of hypertension (> 160/95 mmHg) in this study was 65%. In patients with 
end stage renal failure due to diabetic nephropathy the prevalence of hypertension is 
almost 100%e. In a Danish study9 hypertension was not more prevalent in patients with 
normal urinary albumin excretion than in a matched control population (± 4%). 
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However, when microalbuminuria was present it increased to ± 25%, and in patients 
with clinical diabetic nephropathy the prevalence further increased to ± 80%. It is still a 
matter of debate whether hypertension is the cause or the consequence of diabetic 
nephropathy. Mathiesen et al.10 demonstrated in a prospective study that the development 
of microalbuminuria preceded the onset of clinical hypertension. This finding was confir-
med by Chase et al" who found in a longitudinal prospective study that the rise in blood 
pressure to values above the 90th centile for age occurred about a year after the develop-
ment of microalbuminuria. However, recently Mathiesen demonstreated that an increase 
of blood pressure within the normal range, already occurred before the onset of micro-
albuminuria12. After onset of microalbuminuria blood pressure rapidly increases, promp-
ting the need for antihypertensive therapy in 46% of the microalbuminuric patients12. 
A genetic basis for diabetic nephropathy has been suggested. Seaquist et al.13 found that 
the incidence of diabetic nephropathy was five times higher in diabetic siblings of pro-
bands with diabetic nephropathy than in diabetic siblings of probands without diabetic 
nephropathy. We also found a tendency towards familial clustering14. Of 8 probands with 
diabetic nephropathy, 5 out of 9 diabetic siblings also had diabetic nephropathy, whereas 
from 8 probands without diabetic nephropathy only 1 out of 9 diabetic siblings had 
diabetic nephropathy. A familial predisposition to hypertension may be the explanation for 
this observation. In non-diabetic parents of diabetics with diabetic nephropathy a higher 
blood pressure was measured compared to parents of patients without diabetic nephropa-
thy15. This was however, not confirmed by Jensen at al16, who found nearly identical 
blood pressure levels in parents of patients with or without diabetic nephropathy. Two 
groups of investigators simultaneously reported increased levels of sodium-lithium 
countertransport (a genetic marker for essential hypertension) in patients with diabetic 
nephropathy compared to patients without complications and non-diabetic patients with 
other renal diseases1718. This finding supported the hypothesis that a genetic predisposition 
to essential hypertension predisposes to the development of diabetic nephropathy. But, in 
other studies this could not be confirmed1416. Methodological aspects related to the mea-
surement of sodium-lithium countertransport may be responsible for the discrepancies 
between the various analyses". Recent studies have shown a clear difference of kinetic 
parameters (Km and Vmax) of the sodium-lithium countertransport activity between 
patients with and without diabetic nephropathy20. Thus, measurement of these parameters 
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may be more discriminating. Prospective studies validating the increased sodium-lithium 
countertransport, or its kinetic parameters, as a risk marker for the development of 
diabetic nephropathy are warranted. 
Blood pressure in relation to progression of diabetic nephropathy 
Histologically diabetic nephropathy is characterized by glomerulosclerosis. This diabetic 
glomerulosclerosis is probably the ultimate result of an increased intraglomerular capillary 
pressure caused by afferent vasodilation21-22. If transmission of the systemic blood 
pressure to the glomerulus is prevented, diabetic glomerulosclerosis can be attenuated. 
The classical observation by Berkman et al.23 is a clear illustration for this point. At 
autopsy of a diabetic patient with hypertension due to unilateral renal artery stenosis, they 
found in the kidney with the patent artery clear signs of diabetic nephropathy, whereas in 
the kidney with the stenotic artery no signs of diabetic glomerulosclerosis were seen. 
In patients with overt diabetic nephropathy glomerular filtration rate (GFR) decreases 
linearly over time24. The rate of decline however, is quite variable, and mainly determi-
ned by the systemic blood pressure5. Mogensen25 found a correlation between the decline 
in GFR and the level of diastolic blood pressure. During a longitudinal study with a 
follow-up of 3.5 years Walker et al26 found that a systolic blood pressure above 140 
mmHg was associated with a more rapid decline in renal function. It seems therefore 
justified to initiate antihypertensive treatment at least at a level of 140/90 mm Hg. There 
are even arguments that treatment should be started earlier, since it has been shown even 
for diastolic blood pressures below 90 mm Hg that there exists a linear relationship 
between the decline in GFR and diastolic blood pressure27. 
Treatment of hypertension retards progression of diabetic nephropathy. 
Apart from the possibly favourable effects on cardiovascular complications, the most 
important goal of antihypertensive treatment in patients with diabetic nephropathy is to 
retard the decline in renal function. The first uncontrolled studies, published about a 
decade ago28,29, showed that adequate blood pressure control reduced the rate of decline of 
GFR from ± 10 ml/min/yr to ± 5 ml/min/yr. These beneficial effects of antihypertensive 
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treatment have been confirmed in a number of controlled and uncontrolled studies30"35. 
Probably as a result of a more adequate treatment of hypertension, the prognosis of 
patients with diabetic nephropathy has greatly improved. During a 10 year follow-up of 
45 patients with an onset of diabetic nephropathy between 1974 and 1978 the cumulative 
death rate was 18%, while in earlier cohorts this exceeded 50%6 (Fig. 1). The same 
favourable effect was found by Mathiesen et. al.36 who compared two cohorts of patients 
with diabetic nephropathy. In patients within the first cohort, with onset of diabetic 
nephropathy between 1959 and 1973, antihypertensive treatment was started only when 
diastolic blood pressure rose to levels above 110 mm Hg, as was the usual practice in 
those days. Patients belonging to the second cohort, with onset of diabetic nephropathy 
between 1979 and 1983, received antihypertensive treatment when diastolic blood 
pressure exceeded 95 mm Hg. In the first cohort the probability of 8 year-renal survival 
was 48%, while in the second cohort this had increased to 87%. 
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Fig.l. Death from diabetic nephropathy in insulin-dependent diabetic patients who did not 
receive antihypertensive therapy (Δ,η =45; D,n=360; 0,π=76) compared with those who 
recieved adequate antihypertensive treatment ( · ,η=45) . (Reprinted with permission6) 
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From these data it is evident that antihypertensive treatment retards the progression of 
renal failure in IDDM patients with overt diabetic nephropathy. Recent data suggest that 
initiation of antihypertensive treatment at an earlier stage may be warranted. Treatment of 
patients with microalbuminuria delayed the development of overt proteinuria37,38. However 
it remains to be proven that this delay in the development of macroproteinuria reflects 
prolonged preservation of renal function. 
b there a rationale for the use of a specific class of anti-hypertensive drugs? 
ƒ. Experimental studies. 
Not all antihypertensive agents may be equally effective in preventing or retarding 
progression of diabetic renal disease. Based on the assumption that diabetic glomeru-
losclerosis is the result of an increased intraglomerular pressure most studies have 
focussed on angiotensin converting enzyme inhibitors. These drugs inhibit the production 
of angiotensin II and thereby decrease efferent glomerular vascular tone leading to a 
decrease of the intraglomerular pressure. In Munich-Wistar rats with streptozotocine-
induced diabetes, treatment with enalapril during 14 months indeed prevented the increase 
in intraglomerular pressure, reduced albuminuria, and limited the development of 
glomerular injury39. Since systemic blood pressure was significantly lower in the enala-
pril-treated rats, it was not clear whether the observed effect could be attributed to any 
specific intrarenal effects of enalapril. Therefore, in consecutive studies several classes of 
antihypertensive agents have been compared to angiotensin converting enzyme inhibitors. 
In the above-mentioned model Captopril was compared to triple therapy consisting of 
reserpine, hydralazine and hydrochlorothiazide''0. After 6-10 weeks of treatment no 
difference was found between the two treatments groups. After 70 weeks, however, 
Captopril significantly reduced the severity of focal glomerulosclerosis, despite equal 
blood glucose and systemic blood pressure levels. In a study comparing the angiotensin 
converting enzyme inhibitor fosinopril with the calcium entry blocker nifedipine, 
fosinopril limited the development of albuminuria and glomerular injury, whereas 
nifedipine did not have any effect on intraglomerular pressure or on glomerular injury41. 
In other experimental studies the superiority of angiotensin converting enzyme inhibitors 
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could not be confirmed. O'Brien et al. compared the effects of the angiotensin converting 
enzyme inhibitor Perindopril with the above-mentioned triple therapy in Sprague-Dawley 
rats with streptozotocine-induced diabetes42. In this normotensive model both treatment 
modalities reduced blood pressure and albuminuria to the same extent. However, neither 
treatment had any effect on glomerular basement membrane thickening, mesangial expan-
sion and glomerular hypertrophy. In spontaneously hypertensive rats with streptozotocine-
induced diabetes equal effects of enalapril and the combination of metoprolol and hydral-
azine were observed43. Both treatment modalities significantly reduced albuminuria and 
glomerular structural abnormalities. In the same rat model, triple therapy consisting of 
hydralazine, reserpine and hydrochlorothiazide, also reduced albuminuria to the same 
extent as Perindopril44. Although the equivocal results of experimental studies can not be 
explained easily, there are major differences in these studies with regard to the used rat 
strain, the experimental model and duration of therapy. It is not clear which model best 
reflects human diabetic nephropathy. Therefore the available animal data do not provide a 
clear rationale for the choice of a specific class of antihypertensive drugs in the treatment 
of human diabetic nephropathy. 
2. Human studies 
The early studies, indicating a beneficial effect of antihypertensive treatment on the 
course of diabetic nephropathy, were published a decade ago. Since then a large number 
of studies on this subject have been performed. Before addressing these studies it is 
important to consider some of the pitfalls involved in the evaluation of studies on the 
effects of antihypertensive treatment in diabetic nephropathy. Although changes in GFR 
correlate with changes in proteinuria25, and changes in albuminuria during the first year of 
treatment predict the subsequent rate of decline in GFR45 one should realize that a 
reduction of proteinuria is not equivalent to protection of renal function. The choice of 
proper study end points was a topic on a meeting organized by the US Food and Drug 
Administration in September 1991 as discussed by Mogensen46. The postponement or pre-
vention of end stage renal disease is the main objective of treatment. The reduction of the 
rate of decline in GFR (expressed as ml/min/yr) is therefore a solid end point of a study, 
provided the study lasts for at least 2-3 years. The effects of different drugs on proteinu-
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ria can merely be used as a secondary end point in short-term clinical trials with the 
perspective of long-term follow-up. The various studies also differ with respect to patient 
characteristics (severity of renal failure and hypertension), duration of treatment and the 
used methods for measurement of blood pressure and GFR. Blood pressure is not always 
measured in the same position. Supine blood pressure, mean of supine and standing, and 
sitting blood pressures have been used. This makes it difficult to compare the studies with 
respect to the efficacy of blood pressure reduction. Especially since patients with diabetic 
nephropathy very often suffer from autonomic neuropathy with concomittant orthostatic 
hypotension the use of sitting or standing blood pressure levels may be misleading. Renal 
function is often measured as serum creatinine level or endogenous creatinine clearance. 
Although both can be used in daily clinical practice, in studies comparing different 
antihypertensive therapies GFR should be measured as renal clearance of a radio-isotope 
(51Cr-EDTA or 13lI-thalamate) or inulin. 
A number of investigators have studied the effects of various antihypertensive drugs on 
proteinuria in patients with IDDM and diabetic nephropathy. In uncontrolled studies28,29 
the combination of a ß-blocker and a diuretic lowered blood pressure and reduced 
proteinuria. Treatment with angiotensin converting enzyme inhibitors consistently resulted 
in a decrease of proteinuria3002. We have observed an acute decrease of proteinuria after 
administration of 25 mg of Captopril47. Blood pressure did not fall, which suggests that 
the lowering of proteinuria might be attributed to a specific intrarenal effect of Captopril. 
Results of controlled trials comparing the antiproteinuric effect of angiotensin converting 
enzyme inhibitors and ß-blockers are equivocal. Enalapril reduced proteinuria more 
effectively than metoprolol in the study by Björck et al.33. We recently completed a 
randomized trial comparing Captopril and atenolol in IDDM patients with an early stage 
of overt diabetic nephropathy35. Both treatment modalities reduced blood pressure and 
albuminuria to the same extent. 
The effects of calcium entry blockers on proteinuria have only been evaluated in short-
term studies. Both verapamil and diltiazem lower proteinuria48, whereas the use of a 
dihydropyridine calcium entry blocker, nifedipine, has been associated with increased 
proteinuria4950. It is unclear whether the reported differences indicate differences between 
the various classes of calcium entry blockers or are related to the pre-existing level of 
blood pressure, as was suggested by Gansevoort et al.51. 
I l l 
Recently, two meta-analyses were published of studies on the antiproteinunc effects of 
different antihypertensive drugs in diabetic nephropathy52 53. These meta-analyses included 
studies using ß-blockers, angiotensin converting enzyme inhibitors and calcium entry 
blockers in patients with type 1 or type 2 diabetes at different stages of diabetic nephro-
pathy. Overall, all treatment modalities lowered blood pressure to the same extent by 10 
to 15%. Angiotensin converting enzyme inhibitors consistently decreased proteinuria by 
an average of 52%, ß-blockers lowered proteinuria by 17% and calcium entry blockers 
(excluding nifedipine) by 23%. Weidmann et al.52 found a positive correlation between 
the mean percentual changes in proteinuna and the mean percentual changes in systemic 
blood pressure for both angiotensin converting enzyme inhibitors and ß-blockers (Fig 2). 
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Fig.2. Relative changes in albuminuria or proteinuna in relation to blood pressure 
changes in diabetic patients on different antihypertensive drugs. DN = nifedipine, 
(reprinted with permission52) 
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The slope of the regression lines is clearly different, angiotensin converting enzyme 
inhibitors reduced proteinuria even without lowering blood pressure, whereas a decrease 
of proteinuria during ß-blockade only occurred at a blood pressure decrease of over 5 %. 
Kasiske et al.53 came to a similar conclusion, reduction of proteinuria during angiotensin 
converting enzyme inhibitors being independent of changes in mean arterial pressure, 
whereas with the other drugs the change in proteinuria could entirely be attributed to 
decreases in systemic blood pressure. These data might explain the differences in outcome 
of various studies. When comparing angiotensin converting enzyme inhibitors with ß-
blockers, differences in anti-proteinuric efficacy are to be expected in studies in which a 
limited decrease in blood pressure occurs, whereas no differences might be apparent in 
case of a blood pressure reduction of over 10%. 
As discussed previously, proteinuria is not a solid end point for a study on the beneficial 
effects of antihypertensive drugs in diabetic nephropathy. Unfortunately, only a limited 
number of long-term studies have assessed the effects of antihypertensive treatment on the 
progression of diabetic nephropathy. In uncontrolled studies both ß-blockers and angioten-
sin converting enzyme inhibitors seemed effective in attenuating the rate of decline of 
GFR from ± 10 ml/min/yr to ± 4 ml/min/yr (Table). Controlled comparisons of a ß-
blocker with an angiotensin converting enzyme inhibitors have yielded equivocal results. 
Enalapril was more effective in preserving renal function than metoprolol in the study of 
Björck et al33. However, blood pressure reduction was less with metoprolol and the supine 
diastolic blood pressure was significantly lower in the enalapril treated patients. The 
overall decrease in mean blood pressure on metoprolol resulted from a decrease in 
standing blood pressure only. Moreover, in their analysis of the decline of GFR over 
time, Björck et al included data from patients who were followed for less then one year. 
If the patients with a follow-up of less than one year are excluded from their study, the 
differences in the rates of decline of GFR between enalapril and metoprolol treatment are 
no longer significant. 
We have recently finished a randomized study in patients with type 1 diabetes and clinical 
diabetic nephropathy in which, over a 2-year period, the effects of Captopril (η = 15) and 
atenolol (n = 14) on progression of diabetic nephropathy were compared35. The median 
change in albuminuria was -18% with atenolol and -59% with Captopril, which was not 
significantly different. The decline in GFR was -4.9 ml/min/yr with Captopril and -3.7 
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ml/min/yr with atenolol. As can be seen in Fig.3, we also observed a predominant 
decrease of GFR in the first 6 months of treatment (probably related to the decrease in 
blood pressure). 
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Fig.3. Cumulative decline of GFR during 2 year treatment of with Captopril (solid line 
η = 15) or atenolol (broken line η =14) in patients with clinical diabetic nephropathy. Data 
derived from reference 36. 
When we analyzed the data from 6 months onwards an even slower rate of decline was 
observed (-3.8 vs. -1.8 ml/min/yr). It can therefore be expected that the rates of decline 
will be even slower at longer follow-up. This is demonstrated by Parving et al.w in a 10-
year follow-up of 9 patients with severe diabetic nephropathy. The rate of decline in GFR 
is significantly smaller during the last 6 years of follow-up compared to the first 3 years 
as is shown in Fig.4. 
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Fig.4. Average course of mean arterial blood pressure, GFR and albuminuria before (O) 
and during ( · ) long-term effective antihypertensive treatment of nine insulin-dependent 
diabetic patients with diabetic nephropathy, (reprinted with permission54) 
The recent study of Lewis et al.34 has attracted much attention and is being regarded as a 
clear indication for the superiority of angiotensin converting enzyme inhibitors in patients 
with diabetic nephropathy. In this multicenter study, conducted in 409 patients with 
diabetic nephropathy, 207 patients received Captopril and 202 received placebo. Both 
Captopril and placebo were added to ongoing antihypertensive medication, and in the 
respective groups maximally 46% and 53% of the patients received a ß-blocker and up to 
87% and 93% a diuretic. 
The major end-points of this study were a doubling of serum creatinine or the combined 
end point of death, dialysis or transplantation. The mean duration of the study was 3 
years. Adding Captopril resulted in a reduction of the risk of a doubling of the serum 
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Creatinine by 48% and in reaching the combined endpoints of death, dialysis or transplan-
tation by 50%. However, the effects of Captopril were only significant in the subgroup of 
102 patients with disturbed renal function (serum creatinine > 133 /xmol/1) at the start of 
the study . Furthermore, blood pressure in the captopril-treated patients on average was 
lower both in patients with and without renal insufficiency. Despite the adequate treatment 
of hypertension in the captopril-treated patients as well as in the control-group the rate of 
decline of GFR was very high in both groups,-9 and -13 ml/min/yr respectively. This is 
much higher than the rate of decline observed in European studies (see Table 1.). In our 
opinion the results of Lewis et al. indicate that Captopril is more effective than placebo in 
delaying deterioration of renal function in patients with diabetic nephropathy. But a 
proper comparison with other antihypertensive drugs cannot be made and in view of the 
lower blood pressure during Captopril treatment, even no definite argument for a specific 
intrarenal effect of the angiotensin converting enzyme inhibitor can be made. 
In conclusion adequate blood pressure control is of utmost importance to retard progres-
sion of diabetic nephropathy. At present there are no data to support a preferential choice 
of one of the major classes of antihypertensive agents. 
3. Adverse effects 
The requirements for antihypertensive therapy are that it should be effective, safe, well 
tolerated and simple. If the efficacy of the various classes of antihypertensive drugs is 
comparable, the choice for a certain treatment modality could be governed by the profile 
of side-effects in diabetic patients. The current first line-drugs are cardio-selective ß-
blockers, angiotensin converting enzyme inhibitors and calcium entry blockers. Especially 
in diabetic patients ß-blockers have a number of disadvantages. First, they induce a more 
atherogenic lipid profile, although the clinical significance remains to be elucidated55. 
Second, a major disadvantage of these drugs is that they can blunt thesymptoms of 
hypoglycemia like palpitations and tremor. Although there is no total unawareness of 
hypoglycemic symptoms, the glucose level at which the patients experience symptoms of 
hypoglycemia is lower56. This can lead to potentially dangerous situations. The patients 
have to be informed about this risk. Finally ß-blockers may aggravate or induce im-
potence especially in patients who have a certain degree of autonomic neuropathy. A 
117 
positive effect of ß-blockers is that they may offer some cardioprotection, which can be of 
advantage in this patient population with a high incidence of macrovascular disease. 
Thusfar there is no evidence that angiotensin converting enzyme inhibitors have an 
adverse effect on lipid metabolism. Moreover because of their more consistent anti-
proteinuric effect they may actually decrease cholesterol levels in patients with a nephrotic 
syndrome. Angiotensin converting enzyme inhibitors also do not interfere with symptoms 
evoked by hypoglycemia. However, other side-effects may limit their use. Angiotensin 
converting enzyme inhibitors may induce hyperkalemia, especially in patients with a more 
advanced renal failure. This necessitates frequent monitoring of the serum potassium 
levels, and angiotensin converting enzyme inhibitors should never be combined with a 
potassium sparing diuretic. In 10-15% of the patients cough develops which often makes 
it necessary to discontinue the drug. Furthermore it is important to realize that angiotensin 
converting enzyme inhibitors cannot be used in pregnancy. 
Like with angiotensin converting enzyme inhibitors there are no indications that calcium 
entry blockers have an adverse effect on lipid profiles or perception of hypoglycemia. 
Because of their vasodilating properties they may induce palpitations or flushing. A 
common side-effect of these drugs is edema formation, which is rather unexpected in 
view of the natriuretic effects of these drugs. Although there are no formal data to prove 
this, we have the impression that edema formation is more pronounced in diabetic 
patients, maybe a logical consequence of their enhanced vascular permeability. 
Since very often blood pressure cannot be controlled with only one drug, diuretics are 
regularly added to the therapeutic regimen, especially if the patient develops edema. In 
type 1 diabetics diuretics do not have a negative effect on glucose control. Like with ß-
blockers an effect of diuretics on lipid metabolism has been reported, but this also does 
not seem to be of great clinical significance55. Recently, it was reported that diuretics 
increase cardiovascular mortality57. Whether this forms a contra-indication for its use in 
diabetic nephropathy remains to be determined since this observation comes from a 
retrospective analysis in which the diuretic- and the non-diuretic treated patients may not 
have been comparable with regard to preexisting vascular disease. However, the results 
warrant a careful monitoring of patients treated with diuretics. 
Based on these profiles of side-effects there are arguments to favour the choice of 
angiotensin converting enzyme inhibitors as the first-choice treatment especially in 
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patients who do not have an advanced stage of renal insufficiency. One should realize 
however that antihypertensive treatment needs to be tailored to the specific problems in 
the individual patient. If a second drug needs to be added, a ß-blocker or a calcium entry 
blocker can be considered. In case of edema a diuretic would be preferable. 
Conclusion 
In patients with diabetic nephropathy hypertension may be an early feature which may 
occur already during the phase of microalbuminuria. In patients with clinical diabetic 
nephropathy an adequate lowering of blood pressure is effective in retarding the progres-
sion of diabetic nephropathy. Treatment should be initiated at least at a blood pressure 
level of 140/90 mm Hg, although there is some evidence that treatment of a rise in blood 
pressure within the normal range may be beneficial. The optimal level to which blood 
pressure should be lowered is not known. A target level could be a stable blood pressure 
below 135/85 mm Hg. 
The ideal drug for treatment of hypertension does not exist. Based on an analysis of 
effectiveness and side-effects we would prefer at this moment angiotensin converting 
enzyme inhibitors as the drug of first choice. 
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CHAPTER XI 
Summary 

Summary 
Approximately 30% of patients insulin-dependent diabetes mellitus develop diabetic 
nephropathy, a condition associated with a high morbidity and mortality Diabetic 
nephropathy rarely becomes manifest within 15 years after onset of diabetes. The course 
of diabetic nephropathy is characterized by an initial onset of proteinuria, followed by an 
increase in blood pressure, mostly to hypertensive levels, a decrease in glomerular 
filtration rate (GFR) and ultimately the development of end-stage renal disease. Before the 
regular use of early antihypertensive treatment 50% of the patients with nephropathy died 
within 7 years after onset of proteinuna. Over the past decade our knowledge about 
diabetic nephropathy has greatly increased. 
In chapter II an overview is given of the current ideas about the pathogenesis and risk 
factors for development of diabetic nephropathy. Hyperglycemia, hemodynamic changes 
with an increased intraglomerular pressure, biochemical changes such as a decrease in 
heparansulfate m the glomerular basement membrane (GBM) and genetic factors such as 
essential hypertension have all been implicated in the development of diabetic nephropa-
thy. It has been demonstrated that the urinary excretion of albumin is slightly increased 
above baseline (microalbuminuria) in the period before diabetic nephropathy becomes 
clinically manifest The phase in which microalbuminuria is present is called the period of 
incipient nephropathy Microalbuminuria thus far has proven to be the most sensitive nsk 
factor identifying patients at nsk for the development of diabetic nephropathy. These 
observations emphasized the need for a laboratory method to measure these small amounts 
of albumin in the unne as a part of the routine care for patients with diabetes mellitus. 
In chapter III we descnbe the method we developed for the measurement of microalbu-
minuria. Urinary albumin is complexed by antibodies against albumin and quantified by 
measuring changes in light scatter This so-called laser immunonephelometry is a simple, 
sensitive and inexpensive method The detection limit of this method, 1 mg/L, is 
sufficient for routine use The inter-assay variation was 3% and 10% in respectively the 
high and low concentration ranges. Since unne samples are often stored for longer 
periods before analysis, we have investigated whether prolonged frozen storage has an 
influence on the measured albumin concentration of unne samples. For this purpose unne 
samples from 73 diabetic patients were divided into four ahquots and stored for 2 weeks 
125 
at 4°C and -20°C and for 2 and 6 months at -20°C. Albumin concentrations in the 
samples stored for 2 and 6 months were significantly different when compared to the 
samples stored for 2 weeks at 4°C. The reason for this difference in concentration has not 
become clear but may be due to entrapment of albumin in precipitates. 
It has been suggested that alterations in GBM permeability might already occur in patients 
with diabetes mellitus before the phase of microalbuminuria. Such alterations in GBM 
permeability might become apparent by performing a provocation test. We have studied 
the effects of a individualized submaximal exercise test on albumin and IgG excretion in 
24 insulin-dependent diabetic patients with a normal albumin excretion at rest. The results 
are given in chapter IV. In 8 (33%) patients exercise-induced albuminuria exceeded the 
highest value found in the controls. In these patients urinary IgG excretion also increased, 
but to a lesser degree. As a result the ratio of urinary IgG/urinary albumin excretion 
decreased. We suppose that the increased albuminuria during exercise might be indicative 
of existing changes in GBM permeability characteristics. The preferential loss of albumin 
over IgG is compatible with a decrease in GBM negative charge. To determine if the 
results of the exercise test predict future development of microalbuminuria the patients 
were screened again after 5 years for the presence of microalbuminuria or hypertension. 
However, only one patient had developed microalbuminuria. Therefore, we cannot draw 
definite conclusions on the usefulness of the exercise test. 
As already mentioned genetic factors such as a predisposition to essential hypertension 
may contribute to the development of diabetic nephropathy. An increased erythrocyte 
sodium-lithium countertransport (NaLiCT) has been found in patients with essential 
hypertension and their relatives and has since been regarded as a risk marker for the 
development of essential hypertension. An increased NaLiCT was indeed found in patients 
with diabetic nephropathy. These observations prompted us to study erythrocyte NaLiCT 
in more detail (chapter V). We have used LiHC03 to load erythrocytes with lithium. 
NaLiCT was measured in patients with diabetic nephropathy, in diabetic patients without 
nephropathy, in non-diabetic patients with various renal diseases and in healthy controls. 
We found a significantly increased level of NaLiCT in the diabetic patients compared to 
non-diabetic patients with other renal diseases or to the controls. No difference however 
was seen between the diabetic patients with or without nephropathy. Next we studied 
whether an elevated NaLiCT clusters with the familial occurrence of diabetic nephropa-
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thy. Sixteen probands with diabetes duration of more than 15 years could be selected. The 
8 probands with diabetic nephropathy had 9 sibs with diabetes mellitus of whom 5 had 
diabetic nephropathy, in contrast to only one of the 9 sibs of the 8 probands without 
nephropathy. These data are in agreement with the well-known familial clustering of 
diabetic nephropathy. NaLiCT measured in the families concordant for the presence of 
diabetic nephropathy was not different from NaLiCT in families concordant for the 
absence of diabetic nephropathy. In our opinion therefore NaLiCT can not be used as a 
marker for diabetic nephropathy. 
Over the past decade antihypertensive treatment has improved the prognosis of patients 
with diabetic nephropathy. No firm data existed on the possible advantages of certain 
classes of antihypertensive drugs. We first studied the effects of Captopril and atenolol on 
blood pressure in hypertensive diabetic patients (chapter VI). The study was designed as 
a double-blind, randomized, cross-over study. Twenty-three diabetic patients (both 
insulin- and non-insulin-dependent) were studied during two periods of 6 weeks, with a 6-
week placebo period before and in-between. The dose used of both drugs was 50 mg. 
twice daily. The antihypertensive efficacy of both drugs was similar. Neither drug 
influenced metabolic control. 
The acute effects of 25 mg Captopril on renal hemodynamics and albuminuria were stu-
died in 9 normotensive insulin-dependent diabetic patients with macroalbuminuria 
(chapter VII). A decrease in albuminuria was seen in all patients. A strong correlation 
was found between the decrease in filtration fraction and the decrease in albuminuria after 
Captopril. Blood pressure did not change. We therefore concluded that the acute reduction 
in albuminuria caused by Captopril is mediated by lowering of the intra-glomerular 
pressure. 
This observation was the basis for a long-term study comparing the effects of Captopril 
and atenolol on albuminuria and the progression of renal disease. The results of this study 
are presented in chapter VIII. The study was carried out for 2 years. Twenty-nine 
insulin-dependent diabetic patients, with overt nephropathy, were randomized for 
treatment with Captopril (n=15) or atenolol (n = 14). The dose of both drugs was 100 mg 
daily. In order to obtain good blood pressure control chlortalidone had to be added to 6 
and 2 patients of each group respectively. Blood pressure and albuminuria were measured 
every 6 weeks. GFR was measured every 6 months. Albuminuria was reduced to the 
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same extent with Captopril as with atenolol The rate of decline of GFR was similar in 
both treatment groups and was -4 9 and -3 7 ml/min/yr, which is clearly different from 
non-treated patients who show a decline of GFR of about 10 ml/min/yr We therefore 
concluded that Captopril and atenolol are equally effective in retarding progression of 
diabetic nephropathy In these patients we also studied the effects of both treatments on 
the progression of diabetic retinopathy (chapter IX) Since these patients almost all 
suffered from severe forms of retinopathy it was not possible to apply the commonly used 
scoring system We have therefore developed a simplified scoring system for the 
progression of retinopathy in which the need for and the extent of laser therapy was an 
important determinant Using this scoring system, we observed no difference in progres-
sion of retinopathy between Captopril or atenolol treated patients An interesting finding 
was that patients with the lesser response of albuminuria on antihypertensive treatment 
showed the fastest progression of retinopathy This confirms the close association between 
diabetic retinopathy and nephropathy 
In chapter X an overview is given about the treatment of hypertension in patients with 
diabetic nephropathy, particularly focussing on patients with insulin-dependent diabetes 
mellitus The different treatment modalities are discussed 
We conclude that diabetic nephropathy is the most severe complication of diabetes 
mellitus with a serious impact on life expectancy Early identification of complication is 
very important, which is possible by the measurement of microalbuminuria An increase 
in blood pressure, although within the normal range, is often already present in micro-
albuminunc patients Blood pressure reduction has greatly improved the prognosis of 
patients with diabetic nephropathy From our studies on antihypertensive treatment we 
conclude that adequate blood pressure control is the major determinant for the protection 
of renal function Based on our studies angiotensin-converting enzyme inhibitors did not 
have a greater beneficial effect than ß-blockers in patients with overt diabetic nephro-
pathy 
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CHAPTER XII 
Samenvatting 

Samenvatting 
Diabetische nefropathie is de meest levensbedreigende complicatie van diabetes mellitus. 
Van alle patiënten met van insuline afhankelijke (type 1) diabetes mellitus zal ongeveer 
30% diabetische nefropathie ontwikkelen. De symptomen van diabetische nefropathie 
worden zelden waargenomen voordat de diabetes 15 jaar heeft bestaan. Proteinurie is het 
eerste symptoom, gevolgd door hypertensie en uiteindelijk achteruitgang van de nier-
functie tot terminale nierinsufficiëntie. Voordat het gebruikelijk werd de hypertensie bij 
deze patiënten in een vroeg stadium te behandelen overleed de helft van deze patiënten 
binnen 7 jaren na het vaststellen van de Proteinurie. Onze kennis over deze complicatie 
van diabetes mellitus is gedurende de laatste tien jaren sterk verbeterd. 
In hoofdstuk II van dit proefschrift wordt een overzicht gegeven van de huidige opvattin-
gen over het ontstaan en de risicofactoren van diabetische nefropathie. Hyperglycémie, 
hemodynamische veranderingen welke leiden tot een verhoogde intraglomerulaire druk, 
biochemische veranderingen van de glomerulaire basaal membraan zoals een vermindering 
van heparan sulfaat en genetische factoren zoals aanleg voor essentiële hypertensie 
worden allemaal genoemd als potentiële oorzaken voor het ontwikkelen van nefropathie. 
In de periode voordat diabetische nefropathie klinisch manifest wordt, kan een lichte 
verhoging in albumine uitscheiding worden gemeten. Deze zogeheten microalbuminurie is 
kenmerkend voor de fase van beginnende ("incipient") nefropathie. Deze observatie leidde 
er toe dat de bepaling van microalbuminurie een belangrijk onderdeel werd van de zorg 
voor de patiënten met diabetes mellitus. 
In hoofdstuk ΙΠ wordt de methode beschreven die wij in ons ziekenhuis hebben ontwik­
keld voor de bepaling van de microalbuminurie. De albumine in de urine wordt neergesla­
gen met antistoffen tegen albumine en gekwantificeerd door de verstrooiing van licht te 
meten. Deze methode wordt genoemd laser-immunonephelometrie en is eenvoudig, gevoe­
lig en goedkoop. Concentraties tot 1 mg/l kunnen nog nauwkeurig worden gemeten, wat 
voor klinische toepassing van de methode voldoende is. De inter-assay variatie van de 
bepaling is 3% en 10% voor respectievelijk de hoge en lage concentraties. Bij weten­
schappelijk onderzoek worden urinemonsters soms gedurende lange tijd ingevroren om 
vervolgens tegelijk geanalyseerd te worden. We hebben gekeken in hoeverre het bewaren 
van de monsters van invloed was op de gemeten albumine concentratie. Urinemonsters 
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van 73 diabetes patiënten werden verdeeld over 4 buisjes die als volgt werden bewaard: 
gedurende 2 weken bij 4°C en -20°C en gedurende 2 en 6 maanden bij -20°C. Na 2 en 6 
maanden bewaren werd significant lagere albumine concentratie gemeten dan na 2 weken 
bewaren bij 4°C. Het is vooralsnog niet duidelijk wat hiervoor precies de verklaring is, 
maar mogelijk wordt albumine opgenomen in neerslagen die zich in de urine vormen 
tijdens het bewaren. 
Veranderingen in de permeabiliteit van de glomerulaire basaal membraan liggen mogelijk 
ten grondslag aan het ontstaan van microalbuminurie. Door een provocatietest kunnen 
deze veranderingen misschien duidelijk worden. We hebben daartoe de effecten bestu-
deerd van submaximale inspanning, op een individueel vastgesteld niveau, op de albumine 
en IgG uitscheiding bij patiënten zonder microalbuminurie. De resultaten hiervan worden 
weergegeven in hoofdstuk IV. Bij 8 (33%) patiënten werd een meer dan normale 
albumine uitscheiding na inspanning vastgesteld. Bij deze patiënten was ook de uitschei-
ding van IgG verhoogd, zij het in mindere mate. Het quotiënt van de concentraties van 
IgG en albumine in de urine daalde. Mogelijk is dus de verhoogde albuminurie tijdens 
inspanning een aanwijzing voor reeds bestaande veranderingen in glomerulaire basaal-
membraan. De waarneming dat er meer albumine dan IgG wordt uitgescheiden past in de 
hypothese dat sprake zou kunnen zijn van verlies van negatieve lading van de glomeru-
laire basaalmembraan. Vijf jaar na de inspanningsproef werd bij de deelnemers aan deze 
studie nog eens de bloeddruk gemeten en de albuminurie bepaald. Slechts 1 patiënt had 
microalbuminurie gekregen bij deze follow-up. Het is dan ook niet mogelijk om aan de 
inspanningstest conclusies te verbinden met betrekking tot het ontwikkelen van manifeste 
nefropathie. 
Zoals al genoemd lijken ook genetische factoren bij te dragen tot het ontstaan van 
diabetische nefropathie. De aanleg voor essentiële hypertensie zou zo'n factor kunnen 
zijn. Een verhoging van het natrium-lithium countertransport (NaLiCT) in rode bloedcel-
len wordt gezien bij patiënten met essentiële hypertensie en bij hun familieleden. Dit 
verhoogde NaLiCT wordt daarom wel gezien als teken van een verhoogd risico voor het 
krijgen van een te hoge bloeddruk. Ook bij patiënten met diabetische nefropathie werd 
een verhoogd NaLiCT gevonden. In hoofdstuk V worden de resultaten beschreven van 
onze studies van het NaLiCT bij diabetes patiënten met en zonder nefropathie, bij 
patiënten met andere nierziekten en bij gezonde controles. Het bleek dat de patiënten met 
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diabetes mellitus een significant hoger NaLiCT hadden dan de met-diabetes patiënten met 
andere nierziekten en dan de gezonde controles We zagen geen verschil tussen de 
diabetespatiënten met en zonder nefropathie De familiaire clustering van nefropathie, die 
door anderen was gevonden kon door ons worden bevestigd. Acht diabetespatiënten met 
nefropathie hadden 9 broers of zusters die ook diabetes mellitus hadden Daarvan hadden 
5 ook diabetische nefropathie Van de 8 geselecteerde probandi zonder nefropathie werd 
maar in 1 geval nefropathie vastgesteld bij een broer of zus De hoogte van het NaLiCT 
verschilde echter niet tussen de families met en zonder nefropathie We konden geen 
significante correlatie aantonen voor de hoogte van het NaLiCT tussen broers of zusters 
die beide gedurende tenminste 15 jaar diabetes hadden 
De behandeling van diabetische nefropathie is gedurende de laatste jaren sterk verbeterd 
vooral door een betere en eerdere behandeling van de verhoogde bloeddruk Het is daarbij 
echter niet duidelijk of er bepaalde antihypertensieve medicijnen zijn die betere resultaten 
geven dan andere We zijn begonnen met het bestuderen van de effecten van Captopril en 
atenolol op de bloeddruk bij type 1 en 2 diabeten met hypertensie (hoofdstuk VI) Het 
betrof een gerandomiseerd, dubbel-blind, placebo gecontroleerd onderzoek, waarin 23 
patiënten gedurende 2 perioden van 6 weken, gescheiden door een placebo-penode, 
werden behandeld met Captopril of atenolol Van beide middelen werd 2 maal daags 50 
mg voorgeschreven Het effect op de bloeddruk van beide middelen was gelijk Er werd 
geen nadelig effect gezien op de metabole controle 
De acute effecten van Captopril op de renale hemodynamiek en albuminurie werden 
bestudeerd bij 9 diabetes patiënten met macroalbuminune en een normale bloeddruk 
(hoofdstuk VII) Bij alle patiënten werd een daling van de albuminurie waargenomen na 
Captopril De bloeddruk veranderde niet Er was een sterke correlatie tussen de daling van 
de albuminurie en de afname in filtratie fractie Hieruit kan worden geconcludeerd dat de 
afname in albuminurie veroorzaakt wordt door een vermindering van de ïntraglomerulaire 
capillaire druk 
Deze observatie was de basis voor een lange termijn studie naar de effecten van Captopril 
en atenolol op de progressie van diabetische nefropathie De resultaten van dit onderzoek 
worden gepresenteerd in hoofdstuk VIII De studie duurde 2 jaar voor iedere patient 
Negenentwintig type 1 diabetes patiënten met manifeste nefropathie werden geran-
domiseerd voor behandeling met Captopril (η = 15) of atenolol (η =14). De dosering van 
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beide middelen was 100 mg. per dag. Wegens onvoldoende bloeddrukdaling moest 
hieraan chloortalidon worden toegevoegd bij respectievelijk 6 en 2 patiënten.Bloeddruk en 
albuminurie werden elke 6 weken gemeten. De nierfunctie (GFR) werd elk half jaar 
gemeten. Met zowel Captopril als atenolol werd een afname van de albuminurie gezien, 
deze afname was niet significant verschillend. De daling van de GFR was -4,9 ml/min/jr 
met Captopril en -3,7 ml/min/jr met atenolol. Dit is eveneens niet significant verschillend. 
Wel is het duidelijk beter dan de spontane afname van de GFR bij patiënten met diabeti-
sche nefropathie van ±10 ml/min/jr. We concluderen dan ook dat Captopril en atenolol 
even effectief zijn waar het gaat om remming van de progressie van nefropathie. Bij deze 
zelfde groep patiënten is ook gekeken naar het effect van deze middelen op de progressie 
van retinopathie (hoofdstuk IX). Vrijwel alle patiënten hadden reeds een zeer ernstige 
retinopathie en moesten ook tijdens deze 2 jaren laserbehandelingen ondergaan. Om de 
progressie van retinopathie te beoordelen hebben we een scorings-systeem ontwikkeld 
waarin vooral ook de mate van laser behandeling werd meebeoordeeld. We vonden geen 
verschil in progressie van de retinopathie tussen met Captopril of met atenolol behandelde 
patiënten. Interessant is de gevonden correlatie tussen de verandering in albuminurie 
tijdens de behandeling en de progressie van de retinopathie. Dit bevestigt de nauwe 
associatie tussen diabetische nefropathie en retinopathie. 
In hoofdstuk X wordt een overzicht gegeven van de huidige inzichten over de hypertensie 
behandeling bij de diabetes patiënt met nefropathie. Hierbij wordt speciaal uitgegaan van 
de patiënt met type 1 diabetes mellitus. 
Geconcludeerd kan worden dat diabetische nefropathie de meest ernstige complicatie van 
diabetes mellitus is en zeer bepalend voor de levensverwachting van de diabetes patiënt. 
Vroege opsporing van nefropathie, mogelijk door de bepaling van microalbuminurie, is 
heel belangrijk. Een verhoogde bloeddruk, ook binnen het normale gebied, wordt vaak al 
gezien bij patiënten met microalbuminurie. Verlaging van de bloeddruk heeft de prognose 
van de diabetespatiënt met nefropathie sterk verbeterd. Op basis van onze studies kan 
worden geconcludeerd dat Captopril en atenolol even effectief zijn ten aanzien van de 
bescherming van de nierfunctie bij de patiënt met een manifeste nefropathie. 
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gen, Marja Hesseis en Annemarie School voor alle NaLiCT bepalingen en Bea Kohler 
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STELLINGEN 
1. De levensverwachting van patiënten met type 1 diabetes mellitus wordt vooral 
bepaald door de aanwezigheid van nefropathie. 
2. Voor de bepaling van microalbuminurie dient urine niet langer dan 2 weken te 
worden bewaard bij 4°C. 
dit proefschrift 
3. De bepaling van het natrium-lithium countertransport in erythrocyten bij een vaste 
natrium concentratie in het efflux-medium is niet van waarde voor het identificeren 
van diabetespatiënten met een grotere kans op het ontstaan van nefropathie. 
dit proefschrift 
4. Bij patiënten met een manifeste diabetische nefropathie hebben ACE-remmers en 
ß-blokkers een gelijkwaardig beschermend effect op de achteruitgang van de 
nierfunctie. 
dit proefschrift 
5. De progressie van diabetische retinopathie tijdens bloeddrukverlagende therapie is 
gecorreleerd aan de progressie van de nefropathie. 
dit proefschrift 
6. Gezien de hoge mate van spontane regressie van microalbuminurie, dient de defi-
nitie voor beginnende (incipient) diabetische nefropathie te worden veranderd in 
"stijging van microalbuminurie gemeten over een periode van tenminste 1 jaar". 
7. Voor patiënten met manifeste diabetische nefropathie is normotensie belangrijker 
dan normoglycemic 
8. Bij diabetes patiënten waarbij Proteinurie wordt gevonden dient, indien er bij 
funduscopie geen tekenen zijn van diabetische retinopathie, een fluorescentie 
angiogram te worden gemaakt. 
9. De beste peer reviewers hebben een lage academische rang en zijn jonger dan 40. 
Science 1993;262:25-26 
10. Scepsis is een gezonde ziekte waaraan helaas maar weinig medici lijden. 
11. Voor veel postdoc subsidies is de maximum leeftijd voor toekenning 40 jaar. 
Voor vrouwen zou deze leeftijdsgrens dienen te worden verhoogd met tenminste 
één jaar per gebaard kind. 
12. What thou wilt thou rather shall enforce it with a smile, than hew to 't with thy 
sword. 
Shakespeare 
4 december 1995 Lammy Elving 
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